Ongoing and Future Research Directions

doi:10.1017/9781108632591.030

Part V - Ongoing and Future Research Directions

Published online by Cambridge University Press: 13 July 2020

Edited by

Steve Sussman

Show author details

Steve Sussman: Affiliation:
University of Southern California

Book contents

Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Type: Chapter
Information: The Cambridge Handbook of Substance and Behavioral Addictions , pp. 295 - 425

DOI: https://doi.org/10.1017/9781108632591.030 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Andrews, C., Abraham, A., Grogan, C. M., et al. (2015). Despite resources from the ACA, Most states do little to help addiction treatment programs implement health care reform. Health Affairs (Millwood), 5, 828–835.CrossRef Google Scholar

Barh, D., García-Solano, M. E., Tiwari, S., et al. (2017). BARHL1 is downregulated in Alzheimer’s disease and may regulate cognitive functions through ESR1 and multiple pathways. Genes (Basel), 10, 245.Google Scholar

Baron, D., Blum, K., Chen, A., Gold, M. & Badgaiyan, R. D. (2018). Conceptualizing addiction from an osteopathic perspective:Dopamine homeostasis. Journal of the American Osteopathic Association, 118, 115–118.Google Scholar

Barratt, D. T., Coller, J. K. & Somogyi, A. A. (2006). Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments. American Journal of Medical Genetics Part B Neuropsychiatric Genetics, 141, 323–331.Google Scholar

Berridge, K. C. & Robinson, T. E. (2016). Liking, wanting, and the incentive-sensitization theory of addiction. American Psychologist Journal, 71, 670–679.CrossRef Google Scholar PubMed

Bershad, A. K., Miller, M. A., Norman, G. J. & de Wit, H. (2018). Effects of opioid- and non-opioid analgesics on responses to psychosocial stress in humans. Hormones and Behavior, 102, 41–47.Google Scholar

Blum, K. (2017). Reward Deficiency Syndrome. The Sage Encyclopedia of Abnormal Clinical Psychology, Wenzel, A. (Ed.). Pennsylvania: Sage Publications.Google Scholar

Blum, K. & Baron, D. (2019). Opioid substitution therapy: Achieving harm reduction while searching for a prophylactic solution. Current Pharmaceutical Biotechnology, 20, 180–182.CrossRef Google Scholar PubMed

Blum, K., Badgaiyan, R. D., Braverman, E. R., et al. (2016a). Hypothesizing that, a pro-dopamine regulator (KB220Z) should optimize, but not hyper-activate the activity of Trace Amine-Associated Receptor 1 (TAAR-1) and induce anti-craving of psychostimulants in the long-term. Journal of Reward Deficiency Syndrome Addiction Science, 2, 14–21.Google Scholar

Blum, K., Chen, A. L., Chen, T. J., et al. (2008a). Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long-term treatment of reward deficiency syndrome (RDS): A commentary. Theoretical Biology Medical Modelling, 12(5), 24.Google Scholar

Blum, K., Chen, T. J., Meshkin, B., et al. (2007a) Genotrim, a DNA-customized nutrigenomic product, targets genetic factors of obesity: Hypothesizing a dopamine-glucose correlation demonstrating reward deficiency syndrome (RDS). Medical Hypotheses, 68, 844–852.CrossRef Google Scholar PubMed

Blum, K., Chen, A. L., Oscar-Berman, M., et al. (2011). Generational association studies of dopaminergic genes in reward deficiency syndrome (RDS) subjects: Selecting appropriate phenotypes for reward dependence behaviors. International Journal of Environmental Research and Public Health, 8, 4425–4459.CrossRef Google Scholar PubMed

Blum, K., Chen, A. L. C., Thanos, P. K., et al. (2018a). Genetic addiction risk score (GARS) ™, a predictor of vulnerability to opioid dependence. Frontiers in Bioscience (Elite Edition), 10, 175–196.Google Scholar

Blum, K., Chen, T. J., Meshkin, B., et al. (2007b). Genotrim, a DNA-customized nutrigenomic product, targets genetic factors of obesity: Hypothesizing a dopamine-glucose correlation demonstrating reward deficiency syndrome (RDS). Medical Hypotheses, 68, 844–852.Google Scholar

Blum, K., Chen, T. J., Morse, S., et al. (2010). Overcoming qEEG abnormalities and reward gene deficits during protracted abstinence in male psychostimulant and polydrug abusers utilizing putative dopamine D2 agonist therapy: Part 2. Postgraduate Medical Journal, 122, 214–226.Google Scholar

Blum, K., Chen, T. J. H., Chen, A. L. C., et al. (2008b). Dopamine D2 receptor Taq A1 allele predicts treatment compliance of LG839 in a subset analysis of pilot study in the Netherlands. Gene Therapy & Molecular Biology, 12, 129–140.Google Scholar

Blum, K., Febo, M. & Badgaiyan, R. D. (2016b). Fifty years in the development of a glutaminergic-dopaminergic optimization complex (KB220) to balance brain reward circuitry in Reward Deficiency Syndrome: A pictorial. Austin Addiction Sciences, 1, 1006.Google Scholar PubMed

Blum, K., Febo, M., Badgaiyan, R. D., et al. (2017a). Common neurogenetic diagnosis and meso-limbic manipulation of hypodopaminergic function in Reward Deficiency Syndrome (RDS): Changing the recovery landscape. Current Neuropharmacology, 15, 184–194.Google Scholar

Blum, K., Febo, M., Fried, L., et al. (2017b). Hypothesizing that neuropharmacological and neuroimaging studies of glutaminergic-dopaminergic optimization complex (KB220Z) are associated with “dopamine homeostasis” in Reward Deficiency Syndrome (RDS). Substance Use and Misuse, 52, 535–547.CrossRef Google Scholar PubMed

Blum, K., Febo, M., McLaughlin, T., et al. (2014a). Hatching the behavioral addiction egg: Reward Deficiency Solution System (RDSS)™ as a function of dopaminergic neurogenetics and brain functional connectivity linking all addictions under a common rubric. Journal of Behavioral Addictions, 3, 149–156.Google Scholar

Blum, K., Febo, M., Thanos, P. K., et al. (2015a). Clinically combating Reward Deficiency Syndrome (RDS) with dopamine agonist therapy as a paradigm shift: Dopamine for dinner? Molecular Neurobiology, 52, 1862–1869.CrossRef Google Scholar PubMed

Blum, K., Gardner, E., Oscar-Berman, M. & Gold, M. (2012). “Liking” and “wanting” linked to Reward Deficiency Syndrome (RDS): Hypothesizing differential responsivity in brain reward circuitry. Current Pharmaceutical Design, 18, 113–118.Google Scholar

Blum, K., Han, D., Hauser, M., et al. (2013a). Neurogenetic impairments of brain reward circuitry links to Reward Deficiency Syndrome (RDS) as evidenced by Genetic Addiction Risk Score (GARS): A case study. The Institute of Integrative Omics and Applied Biotechnology Journal, 4, 4–9.Google Scholar

Blum, K., Han, D., Modestino, E. J., et al. (2018b). A systematic, intensive statistical investigation of data from the Comprehensive Analysis of Reported Drugs (CARD) for compliance and illicit opioid abstinence in substance addiction treatment with buprenorphine/naloxone. Substance Use and Misuse, 53, 220–229.Google Scholar

Blum, K., Han, D., Femino, J., et al. (2014b). Systematic evaluation of “compliance” to prescribed treatment medications and “abstinence” from psychoactive drug abuse in chemical dependence programs: Data from the comprehensive analysis of reported drugs. PLoS ONE, 9, e104275.Google Scholar

Blum, K., Jacobs, W., Modestino, E. J., et al. (2018c). Insurance companies fighting the peer review empire without any validity: The case for addiction and pain modalities in the face of an American drug epidemic. SEJ Surgery and Pain, 1, 1–11.Google Scholar

Blum, K., Liu, Y., Wang, W., et al. (2015b). rsfMRI effects of KB220Z™ on neural pathways in reward circuitry of abstinent genotyped heroin addicts. Postgraduate Medical Journal, 127, 232–241.Google Scholar

Blum, K., Lott, L. Siwicki, D., et al. (2018d). Genetic Addiction Risk Score (GARS) as a predictor of substance use disorder: Identifying predisposition not diagnosis. Current Trends in Medical Diagnostic Methods, 1, 1–3.Google Scholar

Blum, K., Madigan, M. A., Fried, L., et al. (2017c). Coupling Genetic Addiction Risk Score (GARS) and pro dopamine regulation (KB220) to combat substance use disorder (SUD). Global Journal of Addiction and Rehabilitation Medicine, 1.Google Scholar

Blum, K., Modestino, E. J., Gondre-Lewis, M., et al. (2018e). The benefits of Genetic Addiction Risk Score (GARS™) testing in Substance Use Disorder (SUD). International Journal of Genomics and Data Mining, 1, 115.Google Scholar

Blum, K., Modestino, E. J., Gondré-Lewis, M. C., et al. (2017d). Global opioid epidemic: Doomed to fail without genetically based precision addiction medicine (PAMTM): Lessons learned from America. Journal of Laboratory and Precision Medicine (Bangalore), 2, 17–22.Google Scholar

Blum, K., Modestino, J. E., Gondre Lewis, C. M., et al. (2018f). Pro-dopamine regulator (KB220) a fifty year sojourn to combat Reward Deficiency Syndrome (RDS): Evidence based bibliography (annotated). CPQ Journal of Neurology and Psychology, 1.Google Scholar

Blum, K., Modestino, E. J., Lott, L., et al. (2018g). Introducing “Precision Addiction Management (PAM^®)” as an adjunctive genetic guided therapy for abusable drugs in America. Open Access Journal of Psychology and Behavioral Science, 1, 1–4.Google Scholar

Blum, K., Modestino, E. J., Neary, J., et al. (2018h). Promoting Precision Addiction Management (PAM) to combat the global opioid crisis. Biomedical Journal of Scientific and Technical Research, 2, 1–4.CrossRef Google Scholar PubMed

Blum, K., Noble, E. P., Sheridan, P. J., et al. (1990). Allelic association of human dopamine D2 receptor gene in alcoholism. The Journal of American Medical Association, 263(15), 2055–2060.Google Scholar

Blum, K., Oscar-Berman, M., Demetrovics, Z., Barh, D. & Gold, M. S. (2014c). Genetic Addiction Risk Score (GARS): Molecular neurogenetic evidence for predisposition to Reward Deficiency Syndrome (RDS). Molecular Neurobiology, 50, 765–796.CrossRef Google Scholar PubMed

Blum, K., Oscar-Berman, M., Femino, J., et al. (2013b). Withdrawal from buprenorphine/naloxone and maintenance with a natural dopaminergic agonist: A cautionary note. Journal of Addiction Research and Therapy, 4.Google Scholar

Blum, K., Thompson, B., Demotrovics, Z., et al. (2015c). The molecular neurobiology of twelve steps program & fellowship: Connecting the dots for recovery. Journal of Reward Deficiency Syndrome, 1, 46–64.Google Scholar

Blum, K., Wood, R. C., Braverman, E. P., Chen, T. J. H. & Sheridan, P. J. (1995). D2 dopamine receptor gene as a predictor of compulsive disease: Bayes’ theorem. Functional Neurology, 10, 37–44.Google Scholar

Bousman, C., Maruf, A. A. & Müller, D. J. (2019). Towards the integration of pharmacogenetics in psychiatry: a minimum, evidence-based genetic testing panel. Current Opinion in Psychiatry, 32, 7–15.CrossRef Google Scholar PubMed

Casey, B. J., Craddock, N., Cuthbert, B. N., Hyman, S. E., Lee, F. S. & Ressler, K. J. (2013). DSM-5 and RDoC: progress in psychiatry research? Nature reviews. Neuroscience, 14, 810–814.Google Scholar

Chen, A. L., Blum, K., Chen, T. J., et al. (2012). Correlation of the Taq1 dopamine D2 receptor gene and percent body fat in obese and screened control subjects: a preliminary report. Food and Function, 3, 40–48.CrossRef Google Scholar PubMed

Chen, A. L., Chen, T. J., Waite, R. L., et al. (2009). Hypothesizing that brain reward circuitry genes are genetic antecedents of pain sensitivity and critical diagnostic and pharmacogenomic treatment targets for chronic pain conditions. Medical Hypotheses, 72, 14–22.CrossRef Google Scholar PubMed

Chen, D., Liu, F., Shang, Q., et al. (2011). Association between polymorphisms of DRD2 and DRD4 and opioid dependence: evidence from the current studies. American Journal of Medical Genetics, 156, 661–670.Google Scholar

Chen, T. J., Blum, K., Mathews, D., et al. (2005). Are dopaminergic genes involved in a predisposition to pathological aggression? Hypothesizing the importance of “super normal controls” in psychiatricgenetic research of complex behavioral disorders. Medical Hypotheses, 65, 703–707.Google Scholar

Comings, D. E., MacMurray, J., Johnson, P., Dietz, G. & Muhleman, D. (1995). Dopamine D2 receptor gene (DRD2) haplotypes and the defense style questionnaire in substance abuse, Tourette syndrome, and controls. Biological Psychiatry, 37, 798–805.Google Scholar

Corrigan, P. W., Schomerus, G., Shuman, V., et al. (2017). Developing a research agenda for reducing the stigma of addictions, part II: lessons from the mental health stigma literature. American Journal on Addictions, 1, 67–74.Google Scholar

Dahlgren, A., Wargelius, H. L., Berglund, K. J., et al. (2011). Do alcohol-dependent individuals with DRD2 A1 allele have an increased risk of relapse? Alcohol and Alcoholism, 46, 509–513.Google Scholar

Dunn, K E. & Strain, E. C. (2013). Pretreatment alcohol drinking goals are associated with treatment outcomes. Alcoholism: Clinical and Experimental Research, 37, 1745–1752.Google Scholar

Elston, S. F., Blum, K., DeLallo, L. & Briggs, A. H. (1982). Ethanol intoxication as a function of genotype dependent responses in three inbred mice strains. Pharmacology Biochemistry and Behavior, 16, 13–15.Google Scholar

Erickson, C. (2007). The Science of Addiction. New York: W. W. Norton & Co.Google Scholar

Febo, M., Blum, K., Badgaiyan, R. D., et al. (2017a). Enhanced functional connectivity and volume between cognitive and reward centers of naïve rodent brain produced by pro-dopaminergic agent KB220Z. PLoS ONE, 12, e0174774.Google Scholar

Febo, M., Blum, K., Badgaiyan, R. D., et al. (2017b). Dopamine homeostasis: brain functional connectivity in reward deficiency syndrome. Frontiers Bioscience (Landmark Edition), 22, 669–691.Google Scholar

Florence, C. S., Zhou, C., Luo, F. & Xu, L. (2016). The economic burden of prescription opioid overdose, abuse, and dependence in the United States. Medical Care, 54, 901–906.Google Scholar

Gardner, E. L. (2011). Addiction and brain reward and antireward pathways. Advances in Psychosomatic Medicine, 30, 22–60.Google Scholar

Gelernter, J., O'Malley, S., Risch, N., et al. (1991). No association between an allele at the D2 dopamine receptor gene (DRD2) and alcoholism. The Journal of American Medical Association, 266, 1801–1807.Google Scholar

Gerra, G., Somaini, L., Leonardi, C., et al. (2014). Association between gene variants and response to buprenorphine maintenance treatment. Psychiatry Research, 215, 202–207.Google Scholar

Gold, M. S., Blum, K., Febo, M., et al. (2018). Molecular role of dopamine in anhedonia linked to reward deficiency syndrome (RDS) and anti-reward systems. Frontiers in Bioscience (Scholar Edition), 10, 309–325.Google Scholar PubMed

Gressler, L. E., Martin, B. C., Hudson, T. J. & Painter, J. T. (2018) Relationship between concomitant benzodiazepine-opioid use and adverse outcomes among US veterans. Pain, 159, 451–459.Google Scholar

Hill, E., Han, D., Dumouchel, P., et al. (2013). Long term Suboxone™ emotional reactivity as measured by automatic detection in speech. PLoS ONE, 8, e69043.Google Scholar

Hyman, S. E. (2007). Can neuroscience be integrated into the DSM-V? Nature Reviews Neuroscience, 8(9), 725–732.Google Scholar

Johnson, M. I., Paley, C. A., Howe, T. E. & Sluka, K. A. (2015). Transcutaneous electrical nerve stimulation for acute pain. Cochrane Database Systematic Review, CD006142.Google Scholar

Joseph, Z., Victor, K. & Rimona, D. (2011). “Ego-dystonic” delusions as a predictor of dangerous behavior. Psychiatric Quaterly, 82, 113–120.Google Scholar

Kandel, D. & Kandel, E. (2015). The Gateway Hypothesis of substance abuse: developmental, biological and societal perspectives. Acta Paediatrica, 104, 130–137.CrossRef Google Scholar PubMed

Krebs, E. E., Gravely, A., Nugent, S., et al. (2018). Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: The SPACE randomized clinical trial. The Journal of American Medical Association, 319, 872–882.Google Scholar

Loth, E., Carvalho, F. & Schumann, G. (2011). The contribution of imaging genetics to the development of predictive markers for addictions. Trends in Cognitive Sciences, 15, 436–446.Google Scholar

Lötsch, J., Skarke, C., Liefhold, J. & Geisslinger, G. (2004). Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clinical Pharmacokinetics, 43, 983–1013.Google Scholar

Makhinson, M. & Gomez-Makhinson, J. (2014). A successful treatment of buprenorphine withdrawal with the dopamine receptor agonist pramipexole. The American Journal on Addictions, 23, 475–477.Google Scholar

Matthews, S., Dwyer, R. & Snoek, A. (2017). Stigma and self-stigma in addiction. Journal of Bioethical Inquiry, 14, 275–286.Google Scholar

Moeller, S. J., Parvaz, M. A., Shumay, E., et al. (2013). Gene x abstinence effects on drug cue reactivity in addiction: multimodal evidence. Journal of Neuroscience, 33, 10027–10036.Google Scholar

Mogil, J. S. & Wilson, S. G. (1997). Nociceptive and morphine antinociceptive sensitivity of 129 and C57BL/6 inbred mouse strains: implications for transgenic knock-out studies. European Journal of Pain, 1, 293–297.Google Scholar

Palmer, R. H., Brick, L., Nugent, N. R., et al. (2015). Examining the role of common genetic variants on alcohol, tobacco, cannabis and illicit drug dependence: genetics of vulnerability to drug dependence. Addiction, 110, 530–537.Google Scholar

Pergolizzi, J. V. Jr, LeQuang, J. A., Taylor, R. Jr. & Raffa, R. B. (2018) Going beyond prescription pain relievers to understand the opioid epidemic: the role of illicit fentanyl, new psychoactive substances, and street heroin. Postgraduate Medicine Journal, 130, 1–8.Google Scholar

Raheb, G., Khaleghi, E., Moghanibashi-Mansourieh, A., Farhoudian, A. & Teymouri, R. (2016). Effectiveness of social work intervention with a systematic approach to improve general health in opioid addicts in addiction treatment centers. Psychology Research and Behavior Management, 9, 309–315.Google Scholar

Reilly, M. T., Noronha, A., Goldman, D. & Koob, G. F. (2017). Genetic studies of alcohol dependence in the context of the addiction cycle. Neuropharmacology, 122, 3–21.Google Scholar

Ritchie, T. & Noble, E. P. (1996). (3H) naloxone binding in the human brain: alcoholism and the TaqI A D2 dopamine receptor polymorphism. Brain Research, 718, 193–197.Google Scholar

Rudd, R. A., Seth, P., David, F. & Scholl, L. (2016). Increases in drug and opioid-involved overdose deaths – United States, 2010–2015.Morbidity and Mortality Weekly Report, 65, 1445–1452.Google Scholar

Salling, M. C. & Martinez, D. (2016). Brain stimulation in addiction. Neuropsychopharmacology, 41, 2798–2809.Google Scholar

Schoenthaler, S. J., Blum, K., Fried, L., et al. (2017). The effects of residential dual diagnosis treatment on alcohol abuse. Journal of Systems and Integrative Neuroscience, 3.CrossRef Google Scholar PubMed

Schreiber, A. L. (2014). Challenging pain syndromes. Physical Medicine and Rehabilitation Clinics of North America, 2, xv–xvi.Google Scholar

Severino, A. L., Shadfar, A., Hakimian, J. K., et al. (2018). Pain therapy guided by purpose and perspective in light of the opioid epidemic. Frontiers in Psychiatry, 9, 119.Google Scholar

Simpatico, T. A. (2015). Vermont responds to its opioid crisis. Preventive Medicine, 80, 10–11.Google Scholar

Smith, D. E. (2012). The process addictions and the new ASAM definition of addiction. Journal of Psychoactive Drugs, 44, 1–4.CrossRef Google Scholar PubMed

Smith, S. R., Deshpande, B. R., Collins, J. E., Katz, J. N. & Losina, E. (2016). Comparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review. Osteoarthritis Cartilage, 24, 962–972.Google Scholar

Stamer, U. M. & Stüber, F. (2007). Genetic factors in pain and its treatment. Current Opinion in Anaesthesiology, 20, 478–484.Google Scholar

Sussman, S. & Pakdaman, S. (2020). Appetitive needs and addiction. In Sussman, S. (Ed.) The Cambridge Handbook of Substance and Behavioral Addictions. Cambridge, UK: Cambridge University Press, pp. 3–11.Google Scholar

Szutorisz, H. & Hurd, Y. L. (2016). Epigenetic effects of cannabis exposure. Biological Psychiatry, 79, 586–594.Google Scholar

Volkow, N. D., Wise, R. A. & Baler, R. (2017). The dopamine motive system: implications for drug and food addiction. Nature Reviews Neuroscience, 18, 741–752.Google Scholar

Vonasch, A. J., Clark, C. J., Lau, S., Vohs, K. D. & Baumeister, R. F. (2017). Ordinary people associate addiction with loss of free will. Addictive Behaviors Reports, 5, 56–66.Google Scholar

Willuhn, I., Burgeno, L. M., Groblewski, P. A. & Phillips, P. E. (2014). Excessive cocaine use results from decreased phasic dopamine signaling in the striatum. Nature Neuroscience, 17, 704–709.Google Scholar

References

Abdulrahim, D. & Bowden-Jones, O., on behalf of the NEPTUNE Expert Group (2015). Guidance on the Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances. London: Novel Psychoactive Treatment UK Network (NEPTUNE).Google Scholar

Acciavatti, T., Lupi, M., Santacroce, R., et al. (2017). Novel psychoactive substance consumption is more represented in bipolar disorder than in psychotic disorders: A multicenter-observational study. Human Psychopharmacology, 32(3), doi: 10.1002/hup.2578.Google Scholar

Addison, M., Stockdale, K., McGovern, R., et al. (2018). Exploring intersections between Novel Psychoactive Substances (NPS) and other substance use in a police custody suite setting in the North East of England. Drugs: Education, Prevention & Policy, 25(4), 313–319.Google Scholar

Alatrash, G., Majhail, N. S. & Pile, J.C. (2006). Rhabdomyolysis after ingestion of “foxy,” a hallucinogenic tryptamine derivative. Mayo Clinic Proceedings, 81(4), 550–551.Google Scholar

Alzghari, S. K., Amin, Z. M., Chau, S., et al. (2017). On the horizon: The synthetic opioid U-49900. Cureus, 9(9), e1679. http://doi.org/10.7759/cureus.1679 Google Scholar

Anderson, C. Morrell, C. & Marchevsky, D. (2015). A novel psychoactive substance poses a new challenge in the management of paranoid schizophrenia. BMJ Case Reports, bcr2015209573.http://doi.org/10.1136/bcr-2015-209573 Google Scholar

Anizan, S., Concheiro, M., Lehner, K. R., et al. (2016). Linear pharmacokinetics of 3,4-methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects. Addiction Biology, 21(2), 339–347.Google Scholar

Antia, U., Lee, H. S., Kydd, R. R., Tingle, M. D. & Russell, B. R. (2009a). Pharmacokinetics of ‘party pill’ drug N-benzylpiperazine (BZP) in healthy human participants. Forensic Science International, 186(1–3), 63–67.Google Scholar

Antia, U., Tingle, M. D. & Russell, B. R. (2009b). In vivo interactions between BZP and TFMPP (party pill drugs). The New Zealand Medical Journal, 122(1303), 29–38.Google Scholar

Araújo, A. M., Carvalho, F., Bastos Mde, L., Guedes de Pinho, P. & Carvalho, M. (2015). The hallucinogenic world of tryptamines: An updated review. Archives of Toxicology, 89(8), 1151–1173.Google Scholar

Arbo, M. D., Bastos, M. L. & Carmo, H. F. (2012). Piperazine compounds as drugs of abuse. Drug and Alcohol Dependence, 122(3), 174–185.Google Scholar

Armenian, P., Olson, A., Anaya, A., et al. (2017). Fentanyl and a novel synthetic opioid U-47700 masquerading as street “Norco” in central California: a case report. Annals of Emergency Medicine, 69(1), 87–90.Google Scholar

Armenian, P., Vo, K. T., Barr-Walker, J. & Lynch, K. L. (2018). Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review. Neuropharmacology, 134(Part A), 121–132. doi: 10.1016/j.neuropharm.2017.10.016Google Scholar

Bäckberg, M., Beck, O., Jönsson, K. H. & Helander, A. (2015). Opioid intoxications involving butyrfentanyl, 4-fluorobutyrfentanyl, and fentanyl from the Swedish STRIDA project. Clinical Toxicology (Philadelphia, Pa.), 53(7), 609–617.Google Scholar

Banks, M. L., Worst, T. J. & Sprague, J. E. (2014). Synthetic Cathinones and amphetamine analogues: What’s the rave about? The Journal of Emergency Medicine, 46(5), 632–642.Google Scholar

Barratt, M. J., Cakic, V. & Lenton, S. (2013). Patterns of synthetic cannabinoid use in Australia. Drug and Alcohol Review, 32(2), 141–146.Google Scholar

Barrios, L., Grison-Hernando, H., Boels, D., et al. (2016). Death following ingestion of methylone. International Journal of Legal Medicine, 130(2), 381–385.CrossRef Google Scholar PubMed

Baumann, M. H., Bukhari, M. O., Lehner, K. R., et al. (2017). Neuropharmacology of 3,4-methylenedioxypyrovalerone (MDPV), its metabolites, and related analogs. Current Topics in Behavioral Neurosciences, 32, 93–117.Google Scholar

Baumann, M. H., Clark, R. D., Budzynski, A. G., et al. (2005). N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenediox-ymethamphetamine (MDMA, or ‘Ecstasy’). Neuropsychopharmacology, 30(3), 550–560.Google Scholar

Baumeister, D., Tojo, L. M. & Tracy, D. K. (2015). Legal highs: Staying on top of the flood of novel psychoactive substances. Therapeutic Advances in Psychopharmacology, 5(2), 97–132.Google Scholar

Black, C., Setterfield, L. & Murray, L. (2016). Scottish Schools Adolescent Lifestyle and Substance Use Survey (SALSUS): Drug Use Report (2015). Scotland: Scottish Government, National Statistics publication for Scotland.Google Scholar

Blackman, S. & Bradley, R. (2017). From niche to stigma – Headshops to prison: Exploring the rise and fall of synthetic cannabinoid use among young adults. The International Journal on Drug Policy, 40, 70–77.Google Scholar

Bonar, E. E., Ashrafioun, L. & Ilgen, M. A. (2014). Synthetic cannabinoid use among patients in residential substance use disorder treatment: Prevalence, motives, and correlates. Drug and Alcohol Dependence, 143, 268–271.Google Scholar

Borek, H. A. & Holstege, C. P. (2012). Hyperthermia and multiorgan failure after abuse of “bath salts” containing 3,4-methylenedioxypyrovalerone. Annals of Emergency Medicine, 60(1), 103–105.Google Scholar

Bright, S. J., Bishop, B., Kane, R., Marsh, A. & Barratt, M. J. (2013). Kronic hysteria: Exploring the intersection between Australian synthetic cannabis legislation, the media, and drug-related harm. The International Journal on Drug Policy, 24(3), 231–237.Google Scholar

Brotherhood, A. & Sumnall, H. R. (2011). European Drug Prevention Quality Standards, Manual No 7. Lisbon: EMCDDA.Google Scholar

Brush, D. E., Bird, S. B. & Boyer, E. W. (2004). Monoamine oxidase inhibitor poisoning resulting from Internet misinformation on illicit substances. Journal of Toxicology. Clinical Toxicology, 42(2), 191–195.Google Scholar

Burns, L., Roxburgh, A., Matthews, A., et al. (2014). The rise of new psychoactive substance use in Australia. Drug Testing and Analysis, 6(7–8), 846–849.Google Scholar

Butler, R. A. & Sheridan, J. L. (2007). Highs and lows: patterns of use, positive and negative effects of benzylpiperazine-containing party pills (BZP-party pills) amongst young people in New Zealand. Harm Reduction Journal, 4, 18. doi:10.1186/1477-7517-4-18Google Scholar

Campbell, R., Starkey, F., Holliday, J., et al. (2008). An informal school-based peer-led intervention for smoking prevention in adolescence (ASSIST): A cluster randomised trial. The Lancet, 371(9624), 1595–1602.Google Scholar

Cannaert, A., Storme, J., Franz, F., Auwärter, V. & Stove, C. P. (2016). Detection and activity profiling of synthetic cannabinoids and their metabolites with a newly developed bioassay. Analytical Chemistry, 88(23), 11476–11485.Google Scholar

Carbone, P. N., Carbone, D. L., Carstairs, S. D. & Luzi, S. A. (2013). Sudden cardiac death associated with methylone use. The American Journal of Forensic Medicine and Pathology, 34(1), 26–28.CrossRef Google Scholar PubMed

Carhart-Harris, R. L., King, L. A. & Nutt, D. J. (2011). A web-based survey on mephedrone. Drug and Alcohol Dependence, 118(1), 19–22.Google Scholar

Castaneto, M. S., Gorelick, D. A., Desrosiers, N. A., et al. (2014). Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. Drug and Alcohol Dependence, 144, 12–41.Google Scholar

Catalano, R. F., Fagan, A. A., Gavin, L. E., et al. (2012). Worldwide application of prevention science in adolescent health. The Lancet, 379(9826), 1653–1664.Google Scholar

Caudevilla-Gálligo, F., Riba, J., Ventura, M., et al. (2012). 4-Bromo-2,5-dimethoxyphenethylamine (2C-B): Presence in the recreational drug market in Spain, pattern of use and subjective effects. Journal of Psychopharmacology, 26(7), 1026–1035.Google Scholar

Caviness, C. M., Tzilos, G., Anderson, B. J. & Stein, M. D. (2015). Synthetic cannabinoids: Use and predictors in a community sample of young adults. Substance Abuse, 36(3), 368–373.CrossRef Google Scholar

Cha, S.-S. & Seo, B.-K. (2018). Smartphone use and smartphone addiction in middle school students in Korea: Prevalence, social networking service, and game use. Health Psychology Open, 5(1), 2055102918755046. doi:10.1177/2055102918755046.Google Scholar

Champion, K. E., Newton, N. C., Stapinski, L. A. & Teesson, M. (2016a). Effectiveness of a universal internet-based prevention program for ecstasy and new psychoactive substances: A cluster randomized controlled trial. Addiction, 111(8), 1396–1405.Google Scholar

Champion, K. E., Teeson, M. & Newton, N. C. (2016b). Patterns and correlates of new psychoactive substance use in a sample of Australian high school students. Drug and Alcohol Review, 35(3), 338–344.Google Scholar

Cohen, K., Kapitány-Fövény, M., Mama, Y., et al. (2017). The effects of synthetic cannabinoids on executive function. Psychopharmacology (Berlin), 234(7), 1121–1134.Google Scholar

Cole, J. B., Dunbar, J. F., McIntire, S. A., Regelmann, W. E. & Slusher, T. M. (2015). Butyrfentanyl overdose resulting in diffuse alveolar hemorrhage. Pediatrics, 135(3), e740–743.Google Scholar

Cooper, Z. D. (2016). Adverse effects of synthetic cannabinoids: Management of acute toxicity and withdrawal. Current Psychiatry Reports, 18(5), 52. http://doi.org/10.1007/s11920–016-0694-1 Google Scholar

Cooper, Z. D. & Haney, M. (2008). Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor. Addiction Biology, 13(2), 188–195.Google Scholar

Corazza, O., Assi, S., Malekianragheb, S., et al. (2014). Monitoring novel psychoactive substances allegedly offered online for sale in Persian and Arabic languages. The International Journal on Drug Policy, 25(4), 724–726.CrossRef Google Scholar PubMed

Corazza, O., Assi, S., Simonato, P., et al. (2013). Promoting innovation and excellence to face the rapid diffusion of novel psychoactive substances in the EU: The outcomes of the ReDNet project. Human Psychopharmacology, 28(4), 317–323.Google Scholar

Corazza, O. & Roman-Urrestarazu, A. (Eds.) (2017). Novel Psychoactive Substances: Policy, Economics and Drug Regulation. Berlin: Springer.Google Scholar

Corazza, O. & Roman-Urrestarazu, A. (Eds.) (2018). Handbook on Novel Psychoactive Substances. What Clinicians Should Know about NPS. New York: Routledge.Google Scholar

Corkery, J. M., Durkin, E., Elliott, S., Schifano, F. & Ghodse, A. H. (2012). The recreational tryptamine 5-MeO-DALT (N,N-diallyl-5-methoxytryptamine): A brief review. Progress in Neuropsychopharmacology & Biological Psychiatry, 39(2), 259–262.Google Scholar

Csák, R., Demetrovics, Zs. & Rácz, J. (2013). Transition to injecting 3,4-methylene-dioxy-pyrovalerone (MDPV) among needle exchange program participants in Hungary. Journal of Psychopharmacology, 27(6), 559–563.Google Scholar

Csete, J., Kamarulzaman, A., Kazatchkine, M., et al. (2016). Public Health and International Drug Policy: Report of the Johns Hopkins – Lancet Commission on Drug Policy and Health. Lancet (London, England), 387(10026), 1427–1480.Google Scholar

Cunningham, S. M., Haikal, N. A. & Kraner, J. C. (2016). Fatal intoxication with acetyl fentanyl. Journal of Forensic Sciences, 61 (Supplement 1), S276–280.Google Scholar

Daldrup, T., Heller, C., Matthiesen, U., et al. (1986). [Etryptamine, a new designer drug with a fatal effect]. Zeitschrift für Rechtsmedizin, 97(1), 61–68.Google Scholar

Dargan, P. I., Albert, S. & Wood, D. M. (2010). Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. QJM: An International Journal of Medicine, 103(11), 875–879.Google Scholar

de Boer, D., Bosman, I. J., Hidvégi, E., et al. (2001). Piperazine-like compounds: A new group of designer drugs-of-abuse on the European market. Forensic Science International, 121(1–2), 47–56.Google Scholar

Dean, B. V., Stellpflug, S. J., Burnett, A. M. & Engebretsen, K. M. (2013). 2C or not 2C: Phenethylamine designer drug review. Journal of Medical Toxicology, 9(2), 172–178.Google Scholar

Degenhardt, L. & Dunn, M. (2008). The epidemiology of GHB and ketamine use in an Australian household survey. The International Journal on Drug Policy, 19(4), 311–316.Google Scholar

Deligianni, E., Corkery, J. M., Schifano, F. & Lione, L. A. (2017). An international survey on the awareness, use, preference, and health perception of novel psychoactive substances (NPS). Human Psychopharmacology, 32(3), doi: 10.1002/hup.2581.Google Scholar

Deluca, P., Davey, Z., Corazza, O., et al. (2012). Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. Progress in Neuropsychopharmacology & Biological Psychiatry, 39(2), 221–226.Google Scholar

Demetrovics, Z., Urbán, R., Nagygyörgy, K., et al. (2011). Why do you play? The development of the motives for online gaming questionnaire (MOGQ). Behavioral Research Methods, 43(3), 814–825.Google Scholar

Dick, D. & Torrance, C. (2010). Mixmag drug survey. Mixmag, 225, 44–53.Google Scholar

Domanski, K., Kleinschmidt, K. C., Schulte, J. M., et al. (2017). Two cases of intoxication with new synthetic opioid, U-47700. Clinical Toxicology (Philadelphia, Pa.), 55(1), 46–50.Google Scholar

Elliott, S. (2011). Current awareness of piperazines: Pharmacology and toxicology. Drug Testing and Analysis, 3(7–8), 430–438.Google Scholar

Elliott, S. & Smith, C. (2008). Investigation of the first deaths in the United Kingdom involving the detection and quantitation of the piperazines BZP and 3-TFMPP. Journal of Analytical Toxicology, 32(2), 172–177.Google Scholar

Elliott, S. P., Brandt, S. D. & Smith, C. (2016). The first reported fatality associated with the synthetic opioid 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47700) and implications for forensic analysis. Drug Testing and Analysis, 8(8), 875–879.Google Scholar

EMCDDA (2006). Selected Issue 3: Developments in Drug Use Within Recreational Settings. Luxembourg: Publications Office of the European Union. Available at: www.emcdda.europa.eu/system/files/publications/424/sel2006_3-en_69713.pdf [Accessed June 10, 2018]Google Scholar

EMCDDA (2016a). The Internet and Drug Markets. Luxembourg: Publications Office of the European Union. Available at: www.emcdda.europa.eu/publications/insights/internet-drug-markets [Accessed November 2, 2017]Google Scholar

EMCDDA (2016b). Report on the risk assessment of 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one (α-pyrrolidinovalerophenone, α-PVP) in the framework of the Council Decision on newpsychoactive substances). Luxembourg: Publications Office of the European Union. Available at: www.emcdda.europa.eu/system/files/publications/2934/TDAK16001ENN.pdf [Accessed May 25, 2018]Google Scholar

EMCDDA (2016c). Perspectives on drugs: Health Responses to New Psychoactive Substances. Luxembourg: Publications Office of the European Union. Available at:www.emcdda.europa.eu/system/files/publications/2933/NPS%20health%20responses_POD2016.pdf [Accessed June 05, 2018]Google Scholar

EMCDDA (2017). Germany – Country Drug Report 2017. Luxembourg: Publications Office of the European Union, Available at: www.emcdda.europa.eu/system/files/publications/4528/TD0416906ENN.pdf [Accessed December 10, 2017]Google Scholar

EMCDDA-Europol (2017). Joint Report on a New Psychoactive Substance: N-phenyl-N-[1-(2-Phenylethyl)piperidin-4-yl]-furan-2-carboxamide (furanylfentanyl). Luxembourg: Publications Office of the European Union, Available at: www.emcdda.europa.eu/system/files/publications/4682/JOINT_REPORT_furanylfentanyl_web.pdf [Accessed June 1, 2018]Google Scholar

ESPAD Group (2016). ESPAD Report 2015 – Results from the European School Survey Project on Alcohol and Other Drugs. Luxembourg: Publications Office of the European Union. Available at: www.espad.org/sites/espad.org/files/ESPAD_report_2015.pdf [Accessed October 17, 2017]Google Scholar

Euro-DEN (2015). Guidelines on when to call the Emergency Services 112 for unwell recreational drug users. Lisbon: EMCDDA.Google Scholar

Evenepoel, T. (2015). Drug helplines, online health and NPS. Presentation at the Health responses to NPS EMCDDA expert meeting, October 28–29, 2015, EMCDDA, Lisbon. Available at: www.emcdda.europa.eu/events/meetings/2015/nps-health-responses [Accessed December 20, 2017]Google Scholar

Every-Palmer, S. (2011). Synthetic cannabinoid JWH-018 and psychosis: An explorative study. Drug and Alcohol Dependence, 117(2–3), 152–157.Google Scholar

Fantegrossi, W. E., Harrington, A. W., Kiessel, C. L., et al. (2006). Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats. Pharmacology, Biochemistry and Behavior, 83(1), 122–129.Google Scholar

Fantegrossi, W. E., Moran, J. H., Radominska-Pandya, A. & Prather, P. L. (2014). Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ9-THC: Mechanism underlying greater toxicity? Life Sciences, 97(1), 45–54.Google Scholar

Fattore, L. & Fratta, W. (2011). Beyond THC: The new generation of cannabinoid designer drugs. Frontiers in Behavioral Neuroscience, 5, 60. doi: 10.3389/fnbeh.2011.00060.Google Scholar

Fels, H., Krueger, J., Sachs, H., et al. (2017). Two fatalities associated with synthetic opioids: AH-7921 and MT-45. Forensic Science International, e30–e35. doi: 10.1016/j.forsciint.2017.04.003.Google Scholar

Forsyth, A. J. M. (2012). Virtually a drug scare: Mephedrone and the impact of the Internet on drug news transmission. The International Journal on Drug Policy, 23(3), 198–209.Google Scholar

Gee, P., Richardson, S., Woltersdorf, W. & Moore, G. (2005). Toxic effects of BZP-based herbal party pills in humans: A prospective study in Christchurch, New Zealand. The New Zealand Medical Journal, 118(1227), U1784.Google Scholar

German, C. L., Fleckenstein, A. E. & Hanson, G. R. (2014). Bath salts and synthetic cathinones: An emerging designer drug phenomenon. Life Sciences, 97(1), 2–8.Google Scholar

Gilani, F. (2016). Novel psychoactive substances: The rising wave of “legal highs”. The British Journal of General Practice, 66(642), 8–9.Google Scholar

Ginsburg, B. C., McMahon, L. R., Sanchez, J. J. & Javors, M. A. (2012). Purity of synthetic cannabinoids sold online for recreational use. Journal of Analytical Toxicology, 36(1), 66–68.Google Scholar

Gołembiowska, K., Jurczak, A., Kamińska, K., Noworyta-Sokołowska, K. & Górska, A. (2016). Effect of some psychoactive drugs used as “legal highs” on brain neurotransmitters. Neurotoxicity Research, 29, 394–407.Google Scholar

Gregg, R. A., Tallarida, C. S., Reitz, A., McCurdy, C. & Rawls, S. M. (2013). Mephedrone (4-methylmethcathinone), a principal constituent of psychoactive bath salts, produces behavioral sensitization in rats. Drug and Alcohol Dependence, 133(2), 746–750.Google Scholar

Griswold, M. K., Chai, P. R., Krotulski, A. J., et al. (2017). A novel oral fluid assay (LC-QTOF-MS) for the detection of fentanyl and clandestine opioids in oral fluid after reported heroin overdose. Journal of Medical Toxicology, 13(4), 287–292.Google Scholar

Guerrieri, D., Rapp, E., Roman, M., Druid, H. & Kronstrand, R. (2017). Postmortem and toxicological findings in a series of furanylfentanyl-related deaths. Journal of Analytical Toxicology, 41(3), 242–249.Google Scholar

Guirguis, A., Corkery, J., Stair, J., et al. (2015). Survey of knowledge of legal highs (novel psychoactivesubstances) amongst London pharmacists. Drugs and Alcohol Today, 15(2), 93–99.Google Scholar

Gunderson, E. W., Haughey, H. M., Ait-Daoud, N., Joshi, A. S. & Hart, C. L. (2014). A Survey of synthetic cannabinoid consumption by current cannabis users. Substance Abuse, 35(2), 184–189.Google Scholar

Gustavsson, D. & Escher, C. (2009). [Mephedrone-Internet drug which seems to have come and stay. Fatal cases in Sweden have drawn attention to previously unknown substance]. Lakartidningen, 106(43), 2769–2771.Google Scholar

Hawk, K. F., Vaca, F. E. & D’Onofrio, G. (2015). Reducing fatal opioid overdose: Prevention, treatment and harm reduction strategies. The Yale Journal of Biology and Medicine, 88(3), 235–245.Google Scholar

Health and Social Care Information Centre (2015). Smoking, Drinking and Drug Use among Young People in England – 2013. London: Health and Social Care Information Centre.Google Scholar

Helander, A., Bäckberg, M. & Beck, O. (2014). MT-45, a new psychoactive substance associated with hearing loss and unconsciousness. Clinical Toxicology (Philadelphia, Pa.), 52(8), 901–904.Google Scholar

Helander, A., Bäckberg, M. & Beck, O. (2016). Intoxications involving the fentanyl analogs acetylfentanyl, 4-methoxybutyrfentanyl and furanylfentanyl: Results from the Swedish STRIDA project. Clinical Toxicology (Philadelphia, Pa.), 54(4), 324–332.Google Scholar

Helander, A., Bradley, M., Hasselblad, A., et al. (2017). Acute skin and hair symptoms followed by severe, delayed eye complications in subjects using the synthetic opioid MT-45. The British Journal of Dermatology, 176(4), 1021–1027.Google Scholar

Hermanns-Clausen, M., Kneisel, S., Szabo, B. & Auwärter, V. (2013). Acute toxicity due to the confirmed consumption of synthetic cannabinoids: Clinical and laboratory findings. Addiction, 108(3), 534–544.Google Scholar

Hess, C., Stockhausen, S., Kernbach-Wighton, G. & Madea, B. (2015). Death due to diabetic ketoacidosis: Induction by the consumption of synthetic cannabinoids? Forensic Science International, 257, e6–11. doi: 10.1016/j.forsciint.2015.08.012.Google Scholar

Ikeda, A., Sekiguchi, K., Fujita, K., Yamadera, H. & Koga, Y. (2005). 5-methoxy-N,N-diisopropyltryptamine-induced flashbacks. The American Journal of Psychiatry, 162(4), 815.Google Scholar

Itokawa, M., Iwata, K., Takahashi, M., et al. (2007). Acute confusional state after designer tryptamine abuse. Psychiatry and Clinical Neurosciences, 61(2), 196–199.Google Scholar

Jan, R. K., Lin, J. C., Lee, H., et al. (2010). Determining the subjective effects of TFMPP in human males. Psychopharmacology (Berlin), 211(3), 347–353.Google Scholar

Javadi-Paydar, M., Nguyen, J. D., Vandewater, S. A., Dickerson, T. J. & Taffe, M. A. (2018). Locomotor and reinforcing effects of pentedrone, pentylone and methylone in rats. Neuropharmacology, 134(Part A), 57–64. doi: 10.1016/j.neuropharm.2017.09.002.Google Scholar

Jebadurai, J. K. (2012). Qualitative research of online drug misuse communities with reference to the novel psychoactive substances. Doctoral Thesis at the University of Hertfordshire.Google Scholar

Jones, M. J., Hernandez, B. S., Janis, G. C. & Stellpflug, S. J. (2017). A case of U-47700 overdose with laboratory confirmation and metabolite identification. Clinical Toxicology (Philadelphia, Pa.), 55(1), 55–59.Google Scholar

Joseph, A. M., Manseau, M. W., Lalane, M., Rajparia, A. & Lewis, C. F. (2017). Characteristics associated with synthetic cannabinoid use among patients treated in a public psychiatric emergency setting. The American Journal of Drug and Alcohol Abuse, 43(1), 117–122.Google Scholar

Jovel, A., Felthous, A. & Bhattacharyya, A. (2014). Delirium due to intoxication from the novel synthetic tryptamine 5-MeO-DALT. Journal of Forensic Sciences, 59(3), 844–846.Google Scholar

Kalasho, A. & Vibe Nielsen, S. (2016). 5-MeO-DALT; a novel designer drug on the market causing acute delirium and rhabdomyolysis. Acta Anaesthesiologica Scandinavica, 60(9), 1332–1336.Google Scholar

Kapitány-Fövény, M. & Demetrovics, Z. (2017). Utility of Web search query data in testing theoretical assumptions about mephedrone. Human Psychopharmacology, 32(3). doi: 10.1002/hup.2620Google Scholar

Kapitány-Fövény, M., Farkas, J., Csorba, J., Szabó, T. & Demetrovics, Z. (2013a). Különbségek a szintetikus kannabinoidok és a kannabisz szubjektív hatásaiban, a használati mintázatban és a használat okaiban. Magyar Addiktológiai Társaság IX. Országos Kongresszus, Siófok, 2013.11.21-2013.11.23, p. 25.Google Scholar

Kapitány-Fövény, M., Farkas, J., Pataki, P. A., et al. (2017). Novel psychoactive substance use among treatment-seeking opiate users: The role of life events and psychiatric symptoms. Human Psychopharmacology, 32(3), doi: 10.1002/hup.2602Google Scholar

Kapitány-Fövény, M., Kertész, M., Winstock, A., et al. (2013b). Substitutional potential of mephedrone: An analysis of the subjective effects. Human Psychopharmacology, 28(4), 308–316.Google Scholar

Kapitány-Fövény, M., Vagdalt, E., Ruttkay, Z., et al. (2018). Potential of an interactive drug prevention mobile phone app (Once Upon a High): Questionnaire study among students.. JMIR Serious Games, 6(4), e19. doi: 10.2196/games.9944Google Scholar

Karila, L., Billieux, J., Benyamina, A., Lançon, C. & Cottencin, O. (2016). The effects and risks associated to mephedrone and methylone in humans: A review of the preliminary evidences. Brain Research Bulletin, 126(Part 1), 61–67.Google Scholar

Karila, L., Lafaye, G., Scocard, A., Cottencin, O. & Benyamina, A. (2018). MDPV and α-PVP use in humans: The twisted sisters. Neuropharmacology, 134(Part A), 65–72.Google Scholar

Karila, L., Megarbane, B., Cottencin, O. & Lejoyeux, M. (2015). Synthetic cathinones: A new public health problem. Current Neuropharmacology, 13(1), 12–20.Google Scholar

Katselou, M., Papoutsis, I., Nikolaou, P., Spiliopoulou, C. & Athanaselis, S. (2015). AH-7921: The list of new psychoactive opioids is expanded. Forensic Toxicology, 33(2), 195–201.Google Scholar

Katz, K. D., Leonetti, A. L., Bailey, B. C., et al. (2016). Case series of synthetic cannabinoid intoxication from one toxicology center. Western Journal of Emergency Medicine, 17(3), 290–294.Google Scholar

Kehr, J., Ichinose, F., Yoshitake, S., et al. (2011). Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. British Journal of Pharmacology, 164(8), 1949–1958.Google Scholar

Kelly, B. C., Wells, B. E., Pawson, M., et al. (2013). Novel psychoactive drug use among younger adults involved in US nightlife scenes. Drug and Alcohol Review, 32(6), 10.1111/dar.12058. http://doi.org/10.1111/dar.12058 Google Scholar

Kempf, C., Llorca, P-M., Pizon, F., Brousse, G. & Flaudias, V. (2017). What’s new in addiction prevention in young people: A literature review of the last years of research. Frontiers in Psychology, 8, 1131. doi:10.3389/fpsyg.2017.01131.Google Scholar

Kersten, B. P. & McLaughlin, M. E. (2015). Toxicology and management of novel psychoactive drugs. Journal of Pharmacy Practice, 28(1), 50–65.Google Scholar

Kesha, K., Boggs, C. L., Ripple, M. G., et al. (2013). Methylenedioxypyrovalerone ("bath salts"), related death: Case report and review of the literature. Journal of Forensic Sciences, 58(6), 1654–1659.Google Scholar

Kikura-Hanajiri, R., Kawamura, N. U. & Goda, Y. (2014). Changes in the prevalence of new psychoactive substances before and after the introduction of the generic scheduling of synthetic cannabinoids in Japan. Drug Testing and Analysis, 6(7–8), 832–839.Google Scholar

Kjellgren, A., Jacobsson, K. & Soussan, C. (2016). The quest for well-being and pleasure: Experiences of the novel synthetic opioids AH-7921 and MT-45, as reported by anonymous users online. Journal of Addiction Research & Therapy, 7, 287. doi: 10.4172/2155-6105.1000287Google Scholar

Kovács, K., Tóth, A. R. & Kereszty, E. M. (2012). [A new designer drug: methylone related death]. Orvosi Hetilap, 153(7), 271–276.Google Scholar

Kovaleva, J., Devuyst, E., De Paepe, P. & Verstraete, A. (2008). Acute chlorophenylpiperazine overdose: A case report and review of the literature. Therapeutic Drug Monitoring, 30(3), 394–398.Google Scholar

Labay, L. M., Caruso, J. L., Gilson, T. P., et al. (2016). Synthetic cannabinoid drug use as a cause or contributory cause of death. Forensic Science International, 260, 31–39.Google Scholar

Larabi, I. A., Martin, M., Etting, I., et al. (2018). Drug-facilitated sexual assault (DFSA) involving 4-methylethcathinone (4-MEC), 3,4-Methylenedioxypyrovalerone (MDPV), and doxylamine highlighted by hair analysis. Drug Testing and Analysis. doi: 10.1002/dta.2377.Google Scholar

Lea, T., Reynolds, R. & De Wit, J. (2011). Mephedrone use among same-sex attracted young people in Sydney, Australia. Drug and Alcohol Review, 30(4), 438–440.Google Scholar

Lee, H. P., Chae, P. K., Lee, H. S. & Kim, Y. K. (2007). The five-factor gambling motivation model. Psychiatry Research, 150(1), 21–32.Google Scholar

Lee, H., Kim, J. W. & Choi, T. Y. (2017). Risk factors for smartphone addiction in Korean adolescents: Smartphone use patterns. Journal of Korean Medical Science, 32(10), 1674–1679.Google Scholar

Lin, J. C., Bangs, N., Lee, H., Kydd, R. R. & Russell, B. R. (2009). Determining the subjective and physiological effects of BZP on human females. Psychopharmacology, 207(3), 439–446.Google Scholar

Lin, J. C., Jan, R. K., Kydd, R. R. & Russell, B. R. (2011). Subjective effects in humans following administration of party pill drugs BZP and TFMPP alone and in combination. Drug Testing and Analysis, 3(9), 582–585.Google Scholar

Lozier, M. J., Boyd, M., Stanley, C., et al. (2015). Acetyl fentanyl, a novel fentanyl analog, causes 14 overdose deaths in Rhode Island, March–May 2013. Journal of Medical Toxicology, 11(2), 208–217.Google Scholar

Lusthof, K. J., Oosting, R., Maes, A., et al. (2011). A case of extreme agitation and death after the use of mephedrone in The Netherlands. Forensic Science International, 206(1–3), e93–95. doi: 10.1016/j.forsciint.2010.12.014.Google Scholar

Majeed-Ariss, R., Baildam, E., Campbell, M., et al. (2015). Apps and adolescents: A systematic review of adolescents' use of mobile phone and tablet apps that support personal management of their chronic or long-term physical conditions. Journal of Medical Internet Research, 17(12), e287. doi: 10.2196/jmir.5043Google Scholar

Marrinan, S., Roman-Urrestarazu, A., Naughton, D., et al. (2017). Hair analysis for the detection of drug use-is there potential for evasion? Human Psychopharmacology, 32(3), doi: 10.1002/hup.2587.Google Scholar

Martínez-Clemente, J., López-Arnau, R., Carbó, M., et al. (2013). Mephedrone pharmacokinetics after intravenous and oral administration in rats: Relation to pharmacodynamics. Psychopharmacology, 229(2), 295–306.Google Scholar

Martinotti, G., Lupi, M., Acciavatti, T., et al. (2014). Novel psychoactive substances in young adults with and without psychiatric comorbidities. BioMed Research International, 2014, 815424. doi: 10.1155/2014/815424.Google Scholar

Martinotti, G., Lupi, M., Carlucci, L., et al. (2015). Novel psychoactive substances: Use and knowledge among adolescents and young adults in urban and rural areas. Human Psychopharmacology, 30(4), 295–301.Google Scholar

McCall, H., Adams, N., Mason, D. & Willis, J. (2015). What is chemsex and why does it matter? BMJ, 351, h5790. doi: 10.1136/bmj.h5790Google Scholar

McIntyre, I. M., Trochta, A., Gary, R. D., Malamatos, M. & Lucas, J. R. (2015). acute acetyl fentanyl fatality: A case report with postmortem concentrations. Journal of Analytical Toxicology, 39(6), 490–494.Google Scholar

McIntyre, I. M., Trochta, A., Gary, R. D., Wright, J. & Mena, O. (2016). An acute butyr-fentanyl fatality: A case report with postmortem concentrations. Journal of Analytical Toxicology, 40(2), 162–166.CrossRef Google Scholar PubMed

Mdege, N. D., Meader, N., Lloyd, C., Parrott, S. & McCambridge, J. (2017). The Novel Psychoactive Substances in the UK Project: Empirical and Conceptual Review Work to Produce Research Recommendations. Southampton (UK): NIHR Journals Library. Available at: www.ncbi.nlm.nih.gov/pubmedhealth/PMH0095704/ [Accessed December 20, 2017]Google Scholar

Meader, N., Mdege, N. & McCambridge, J. (2018). The public health evidence-base on novel psychoactive substance use: Scoping review with narrative synthesis of selected bodies of evidence. Journal of Public Health (Oxford, England). doi: 10.1093/pubmed/fdy016Google Scholar

Meltzer, P. C., Butler, D., Deschamps, J. R. & Madras, B. K. (2006). 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogs. A promising class of monoamine uptake inhibitors. Journal of Medicinal Chemistry, 49(4), 1420–1432.Google Scholar

Miliano, C., Serpelloni, G., Rimondo, C., et al. (2016). Neuropharmacology of New Psychoactive Substances (NPS): Focus on the rewarding and reinforcing properties of cannabimimetics and amphetamine-like stimulants. Frontiers in Neuroscience, 10, 153. http://doi.org/10.3389/fnins.2016.00153 Google Scholar

Miller, M. L., Creehan, K. M., Angrish, D., et al. (2013). Changes in ambient temperature differentially alter the thermoregulatory, cardiac and locomotor stimulant effects of 4-methylmethcathinone (mephedrone). Drug and Alcohol Dependence, 127(1–3), 248–253.Google Scholar

Miller, J. M., Stogner, J. M., Miller, B. L. & Blough, S. (2018). Exploring synthetic heroin: Accounts of acetyl fentanyl use from a sample of dually diagnosed drug offenders. Drug and Alcohol Review, 37(1), 121–127.Google Scholar

Ministry of Health – New Zealand (2012). Regulatory impact statement, new regulatory regime for psychoactive substances. Wellington, New Zealand: The Treasury. Available at: www.health.govt.nz/about-ministry/legislation-and-regulation/regulatory-impact-statements/new-regulatory-regime-psychoactive-substances. [Accessed October 16, 2017]Google Scholar

Moore, K., Dargan, P. I., Wood, D. M. & Measham, F. (2013). Do novel psychoactive substances displace established club drugs, supplement them or act as drugs of initiation? The relationship between mephedrone, ecstasy and cocaine. European Addiction Research, 19(5), 276–282.Google Scholar

Morano, R. A., Spies, C., Walker, F. B. & Plank, S. M. (1993). Fatal intoxication involving etryptamine. Journal of Forensic Sciences, 38(3), 721–725.Google Scholar

Móró, L. & Rácz, J. (2013). Online drug user-led harm reduction in Hungary: A review of “Daath”. Harm Reduction Journal, 10, 18. doi: 10.1186/1477-7517-10-18.Google Scholar

Murphy, D. L., Lesch, K. P., Aulakh, C. S. & Pigott, T. A. (1991). Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature, and cardiovascular effects in humans. Pharmacological Reviews, 43(4), 527–552.Google Scholar

Murray, B. L., Murphy, C. M. & Beuhler, M. C. (2012). Death following recreational use of designer drug “bath salts” containing 3,4-methylenedioxypyrovalerone (MDPV). Journal of Medical Toxicology, 8(1), 69–75.Google Scholar

Nagai, H., Saka, K., Nakajima, M., et al. (2014). Sudden death after sustained restraint following self-administration of the designer drug α-pyrrolidinovalerophenone. International Journal of Cardiology, 172(1), 263–265.Google Scholar

Negrei, C., Galateanu, B., Stan, M., et al. (2017). Worldwide legislative challenges related to psychoactive drugs. DARU Journal of Pharmaceutical Sciences, 25, 14. http://doi.org/10.1186/s40199–017-0180-2 Google Scholar

Nurmedov, S., Yilmaz, O., Darcin, A. E., Noyan, O. C. & Dilbaz, N. (2015). Frequency of synthetic cannabinoid use and its relationship with socio-demographic characteristics and treatment outcomes in alcohol- and substance-dependent inpatients: A retrospective study. Klinik Psikofarmakoloji Bulteni – Bulletin of Clinical Psychopharmacology, 25(4), 348–354.Google Scholar

Nutt, D. (2015). Open letter to David Cameron, Prime Minister. www.independent.co.uk/news/uk/home-news/former-government-drugs-adviser-professor-david-nutt-writes-to-pm-arguing-against-banning-legal-10374433.html Google Scholar

Oei, A. C. & Patterson, M. D. (2013). Enhancing cognition with video games: A multiple game training study, Geng, J. J. (Ed.). PLoS ONE, 8(3), e58546. doi:10.1371/journal.pone.0058546.Google Scholar

Ott, J. (2001). Pharmepéna-Psychonautics: Human intranasal, sublingual and oral pharmacology of 5-methoxy-N,N-dimethyl-tryptamine. Journal of Psychoactive Drugs, 33(4), 403–407.Google Scholar

Paglia-Boak, A., Mann, R. E., Adlaf, E. M. & Rehm, J. (2009). Drug Use among Ontario Students, 1977–2009: Detailed OSDUHS Findings. Toronto, Ontario: Centre for Addiction and Mental Health. Available at: http://odesi1.scholarsportal.info/documentation/PHIRN/OSDUHS/Highlights_DrugReport_2009OSDUHS_Final_Web.pdf [Accessed: May 15, 2018]Google Scholar

Paksi, B., Magi, A., Felvinczi, K. & Demetrovics, Zs. (2016). The prevalence of new psychoactive substances in Hungary – Based on a general population survey dealing with addiction related problems (OLAAP 2015). IV. International Conference on Novel Psychoactive Substances (NPS). Budapest, May 30–31, 2016.Google Scholar

Palamar, J. J., Martins, S. S., Su, M. K. & Ompad, D.C. (2015). Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting. Drug and Alcohol Dependence, 156, 112–119.Google Scholar

Palamar, J. J., Su, M. K. & Hoffman, R. S. (2016). Characteristics of novel psychoactive substance exposures reported to New York City Poison Center, 2011–2014. The American Journal of Drug and Alcohol Abuse, 42(1), 39–47.Google Scholar

Palma-Conesa, Á. J., Ventura, M., Galindo, L., et al. (2017). Something new about something old: A 10-year follow-up on classical and new psychoactive tryptamines and results of analysis. Journal of Psychoactive Drugs, 49(4), 297–305.Google Scholar

Papaseit, E., Olesti, E., de la Torre, R., Torrens, M. & Farré, M. (2017). Mephedrone concentrations in cases of clinical intoxication. Current Pharmaceutical Design. doi: 10.2174/1381612823666170704130213.Google Scholar

Papaseit, E., Pérez-Mañá, C., Mateus, J.-A., et al. (2016). Human pharmacology of mephedrone in comparison with MDMA. Neuropsychopharmacology, 41(11), 2704–2713.Google Scholar

Papsun, D., Krywanczyk, A., Vose, J. C., Bundock, E. A. & Logan, B. K. (2016). Analysis of MT-45, a novel synthetic opioid, in human whole blood by LC-MS-MS and its identification in a drug-related death. Journal of Analytical Toxicology, 40(4), 313–317.Google Scholar

Patrick, M. E., O’Malley, P. M., Kloska, D. D., et al. (2016). Novel psychoactive substance use by US adolescents: Characteristics associated with use of synthetic cannabinoids and synthetic cathinones. Drug and Alcohol Review, 35(5), 586–590.Google Scholar

Pearson, J. M., Hargraves, T. L., Hair, L. S., et al. (2012). Three fatal intoxications due to methylone. Journal of Analytical Toxicology, 36(6), 444–451.Google Scholar

Penders, T. M., Gestring, R. E. & Vilensky, D. A. (2012). Intoxication delirium following use of synthetic cathinone derivatives. The American Journal of Drug and Alcohol Abuse, 38(6), 616–617.Google Scholar

Penney, J., Dargan, P. I., Padmore, J., Wood, D. M. & Norman, I. J. (2016). Epidemiology of adolescent substance use in London schools. QJM: An International Journal of Medicine, 109(6), 405–409.Google Scholar

Péterfi, A., Tarján, A., Horváth, G. C., Csesztregi, T. & Nyírády, A. (2014). Changes in patterns of injecting drug use in Hungary: A shift to synthetic cathinones. Drug Testing and Analysis, 6(7–8), 825–831.Google Scholar

Pintori, N., Loi, B. & Mereu, M. (2017). Synthetic cannabinoids: The hidden side of Spice drugs. Behavioral Pharmacology, 28(6), 409–419.Google Scholar

Poklis, J., Poklis, A., Wolf, C., et al. (2016). Two fatal intoxications involving butyryl fentanyl. Journal of Analytical Toxicology, 40(8), 703–708.Google Scholar

Potocka-Banaś, B., Janus, T., Majdanik, S., et al. (2017). Fatal intoxication with α-PVP, a synthetic cathinone derivative. Journal of Forensic Sciences, 62(2), 553–556.Google Scholar

Prekupec, M. P., Mansky, P. A. & Baumann, M. H. (2017). Misuse of novel synthetic opioids: A deadly new trend. Journal of Addiction Medicine, 11(4), 256–265.Google Scholar

Prosser, J. M. & Nelson, L. S. (2012). The toxicology of bath salts: A review of synthetic cathinones. Journal of Medical Toxicology, 8(1), 33–42.Google Scholar

Ralphs, R. & Gray, P. (2017). New psychoactive substances: New service provider challenges. Drugs: Education, Prevention and Policy, 25(4), 301–312.Google Scholar

Ralphs, R., Williams, L., Askew, R. & Norton, A. (2017). Adding Spice to the Porridge: The development of a synthetic cannabinoid market in an English prison. The International Journal on Drug Policy, 40, 57–69.Google Scholar

Rambaran, K. A., Fleming, S. W., An, J., et al. (2017). U-47700: A clinical review of the literature. The Journal of Emergency Medicine, 53(4), 509–519.Google Scholar

RAND (EUROPE) (2016). The role of the ‘dark’ web in the trade of illicit drugs. Research brief. Available at: www.rand.org/content/dam/rand/pubs/research_briefs/RB9900/RB9925/RAND_RB9925.pdf [Accessed: June 06, 2018]Google Scholar

Reuter, P. & Pardo, B. (2017). Can new psychoactive substances be regulated effectively? An assessment of the British Psychoactive Substances Bill. Addiction, 112(1), 25–31.Google Scholar

Rodgman, C. J. C., Verrico, C. D., Worthy, R. B. & Lewis, E. E. (2014). Inpatient detoxification from a synthetic cannabinoid and control of postdetoxification cravings with naltrexone. The Primary Care Companion for CNS Disorders, 16(4), 10.4088/PCC.13l01594. http://doi.org/10.4088/PCC.13l01594 Google Scholar

Romanek, K., Stenzel, J., Schmoll, S., et al. (2017). Synthetic cathinones in Southern Germany – Characteristics of users, substance-patterns, co-ingestions, and complications. Clinical Toxicology (Philadelphia, Pa.), 55(6), 573–578.Google Scholar

Sanders, B., Lankenau, S. E., Bloom, J. J. & Hathazi, D. (2008). “Research Chemicals”: Tryptamine and phenethylamine use among high-risk youth. Substance Use & Misuse, 43(3–4), 389–402.Google Scholar

Schep, L. J., Slaughter, R. J., Hudson, S., Place, R. & Watts, M. (2015). Delayed seizure-like activity following analytically confirmed use of previously unreported synthetic cannabinoid analogues. Human & Experimental Toxicology, 34(5), 557–560.Google Scholar

Schep, L. J., Slaughter, R. J., Vale, J. A., Beasley, D. M. & Gee, P. (2011). The clinical toxicology of the designer party pills benzylpiperazine and trifluoromethylphenylpiperazine. Clinical Toxicology (Philadelphia, Pa.), 49(3), 131–141.Google Scholar

Schifano, F., Orsolini, L., Duccio Papanti, G. & Corkery, J. M. (2015). Novel psychoactive substances of interest for psychiatry. World Psychiatry, 14(1), 15–26.Google Scholar

Schindler, C. W., Thorndike, E. B., Suzuki, M., Rice, K. C. & Baumann, M. H. (2016). Pharmacological mechanisms underlying the cardiovascular effects of the “bath salt” constituent 3,4‐methylenedioxypyrovalerone (MDPV). British Journal of Pharmacology, 173(24), 3492–3501.Google Scholar

Schneir, A., Metushi, I. G., Sloane, C., Benaron, D. J. & Fitzgerald, R. L. (2017). Near death from a novel synthetic opioid labeled U-47700: Emergence of a new opioid class. Clinical Toxicology (Philadelphia, Pa.), 55(1), 51–54.Google Scholar

Shanks, K. G. & Behonick, G. S. (2016). Death after use of the synthetic cannabinoid 5F-AMB. Forensic Science International, 262, e21–24, doi: 10.1016/j.forsciint.2016.03.004.Google Scholar

Shanks, K. G., Clark, W. & Behonick, G. (2016). Death associated with the use of the synthetic cannabinoid ADB-FUBINACA. Journal of Analytical Toxicology, 40(3), 236–239.Google Scholar

Shimizu, E., Watanabe, H., Kojima, T., et al. (2007). Combined intoxication with methylone and 5-MeO-MIPT. Progress in Neuropsychopharmacology & Biological Psychiatry, 31(1), 288–291.Google Scholar

Siddiqi, S., Verney, C., Dargan, P. & Wood, D. M. (2015). Understanding the availability, prevalence of use, desired effects, acute toxicity and dependence potential of the novel opioid MT-45. Clinical Toxicology (Philadelphia, Pa.), 53(1), 54–59.Google Scholar

Simonato, P., Bersani, F. S., Santacroce, R., et al. (2017). Can mobile phone technology support a rapid sharing of information on novel psychoactive substances among health and other professionals internationally? Human Psychopharmacology, 32(3). doi: 10.1002/hup.2580Google Scholar

Simonato, P., Corazza, O., Santonastaso, P., et al. (2013). Novel psychoactive substances as a novel challenge for health professionals; results from an Italian survey. Human Psychopharmacology, 28(4), 324–331.Google Scholar

Sindicich, N. & Burns, L. (2012). Australian trends in ecstasy and related drug markets 2012: Findings from the Ecstasy and Related Drugs Reporting System (EDRS). Australian Drug Trends Series No.100. National Drug and Alcohol Research Centre, University of New South Wales. Available at: https://ndarc.med.unsw.edu.au/sites/default/files/ndarc/resources/EDRS%202012%20national%20report%20FINAL.pdf [Accessed: October 16, 2017]Google Scholar

Sivagnanam, K., Chaudari, D., Lopez, P., Sutherland, M. E. & Ramu, V. K. (2013). “Bath salts” induced severe reversible cardiomyopathy. The American Journal of Case Reports, 14, 288–291.Google Scholar

Smith, K. & Flatley, J. (2011). Drug Misuse Declared: Findings from the 2010/2011 British Crime Survey England and Wales. UK: Home Office.Google Scholar

Smith, S. W. & Garlich, F. M. (2013). Availability and supply of novel psy-choactive substances. In Dargan, P. I. & Wood, D. M. (Eds.), Novelpsychoactive Substances: Classification, Pharmacology and Toxicology. Elsevier, UK: Academic Press, pp. 55–86.Google Scholar

Smolinske, S. C., Rastogi, R. & Schenkel, S. (2005). Foxy methoxy: A new drug of abuse. Journal of Medical Toxicology, 1(1), 22–25.Google Scholar

Smyth, B. P., James, P., Cullen, W. & Darker, C. (2015). “So prohibition can work?” Changes in use of novel psychoactive substances among adolescents attending a drug and alcohol treatment service following a legislative ban. The International Journal on Drug Policy, 26(9), 887–889.Google Scholar

Smyth, B. P., Lyons, S. & Cullen, W. (2017). Decline in new psychoactive substance use disorders following legislation targeting headshops: Evidence from national addiction treatment data. Drug and Alcohol Review, 36(5), 609–617.Google Scholar

Soussan, C. & Kjellgren, A. (2016). The users of Novel Psychoactive Substances: Online survey about their characteristics, attitudes and motivations. The International Journal of Drug Policy, 32, 77–84.Google Scholar

Soussan, C., Andersson, M. & Kjellgren, A. (2018). The diverse reasons for using Novel Psychoactive Substances – A qualitative study of the users’ own perspectives. The International Journal on Drug Policy, 52, 71–78.Google Scholar

Spaderna, M., Addy, P. H. & D’Souza, D. C. (2013). Spicing thing up: Synthetic cannabinoids. Psychopharmacology, 228(4), 525–540.Google Scholar

Spiller, H. A., Ryan, M. L., Weston, R. G. & Jansen, J. (2011). Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States. Clinical Toxicology (Philadelphia, Pa.), 49(6), 499–505.Google Scholar

Srisung, W., Jamal, F. & Prabhakar, S. (2015). Synthetic cannabinoids and acute kidney injury. Proceedings (Baylor University Medical Center), 28(4), 475–477.Google Scholar

Stanciu, C. N., Penders, T. M., Gnanasegaram, S. A., et al. (2017). The behavioral profile of methylenedioxypyrovalerone (MDPV) and α-pyrrolidinopentiophenone (PVP) – A systematic review. Current Drug Abuse Reviews. doi: 10.2174/1874473710666170321122226.Google Scholar

Stanley, J. L., Mogford, D. V., Lawrence, R. J. & Lawrie, S. M. (2016). Use of novel psychoactive substances by inpatients on general adult psychiatric wards. BMJ Open, 6(5), e009430. http://doi.org/10.1136/bmjopen-2015-009430 Google Scholar

Štefková, K., Židková, M., Horsley, R. R., et al. (2017). Pharmacokinetic, ambulatory, and hyperthermic effects of 3,4-methylenedioxy-N-methylcathinone (methylone) in rats. Frontiers in Psychiatry, 8, 232. http://doi.org/10.3389/fpsyt.2017.00232 Google Scholar

Stevens, A., Fortson, R., Measham, F. & Sumnall, H. (2015). ‘Legally flawed, scientifically problematic, potentially harmful: The UK Psychoactive Substance Bill’. International Journal of Drug Policy, 26(12), 1167–1170.Google Scholar

Stogner, J. M. (2014). The potential threat of acetyl fentanyl: Legal issues, contaminated heroin, and acetyl fentanyl "disguised" as other opioids. Annals of Emergency Medicine, 64(6), 637–639.Google Scholar

Strassman, R. J. (1996). Human psychopharmacology of N,N-dimethyltryptamine. Behavioural Brain Research, 73(1–2), 121–124.Google Scholar

Stratton, S. J., Rogers, C., Brickett, K. & Gruzinski, G. (2001). Factors associated with sudden death of individuals requiring restraint for excited delirium. The American Journal of Emergency Medicine, 19(3), 187–191.Google Scholar

Sykutera, M., Cychowska, M. & Bloch-Boguslawska, E. (2015). A fatal case of pentedrone and α-pyrrolidinovalerophenone poisoning. Journal of Analytical Toxicology, 39(4), 324–329.Google Scholar

Takase, I., Koizumi, T., Fujimoto, I., Yanai, A. & Fujimiya, T. (2016). An autopsy case of acetyl fentanyl intoxication caused by insufflation of 'designer drugs'. Legal Medicine (Tokyo), 21, 38–44.Google Scholar

Tanaka, E., Kamata, T., Katagi, M., Tsuchihashi, H. & Honda, K. (2006). A fatal poisoning with 5-methoxy-N,N-diisopropyltryptamine, Foxy. Forensic Science International, 163(1–2), 152–154.Google Scholar

Tancer, M. E. & Johanson, C. E. (2001). The subjective effects of MDMA and mCPP in moderate MDMA users. Drug and Alcohol Dependence, 65(1), 97–101.Google Scholar

TEDI (Trans European Drug Information) (2013). 2nd TEDI Trend Report, Nightlife Empowerment and Well-Being Information Project (NEWIP). Available at: http://fileserver.idpc.net/library/Tedi_trend_report_feb2013.pdf [Accessed June 05, 2018]Google Scholar

Teske, J., Weller, J. P., Fieguth, A., et al. (2010). Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatography-tandem mass spectrometry. Journal of Chromatography, B. Analytical Technologies in the Biomedical and Life Sciences, 878(27), 2659–2663.Google Scholar

Thammongkolchai, T., Termsarasab, P., Alkhachroum, A., et al. (2015). 5-Meo-DALT-induced cyclic myoclonus (P3.013). Neurology, 84 (14 Supplement), P3.013.Google Scholar

The New Psychoactive Substances Review Expert Panel (2014). New Psychoactive Substances: Report of the Expert Panel. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/368583/NPSexpertReviewPanelReport.pdf [Accessed: June 06, 2018]Google Scholar

Thompson, I., Williams, G., Caldwell, B., et al. (2010). Randomised double-blind, placebo-controlled trial of the effects of the 'party pills' BZP/TFMPP alone and in combination with alcohol. Journal of Psychopharmacology, 24(9), 1299–1308.Google Scholar

Tittarelli, R., Mannocchi, G., Pantano, F. & Romolo, F. S. (2015). Recreational use, analysis and toxicity of tryptamines. Current Neuropharmacology, 13(1), 26–46.Google Scholar

Toennes, S. W., Geraths, A., Pogoda, W., et al. (2017). Pharmacokinetic properties of the synthetic cannabinoid JWH-018 and of its metabolites in serum after inhalation. Journal of Pharmaceutical and Biomedical Analysis, 140, 215–222.Google Scholar

Tracy, D. K., Wood, D. M. & Baumeister, D. (2017). Novel psychoactive substances: Identifying and managing acute and chronic harmful use. BMJ, 356. doi: 10.1136/bmj.i6814.Google Scholar

Trecki, J., Gerona, R. R. & Schwartz, M.D. (2015). Perspective: synthetic cannabinoid–related illnesses and deaths. The New England Journal of Medicine, 373(2), 103–107.Google Scholar

Turner, C. F., Ku, L., Rogers, S. M., et al. (1998). Adolescent sexual behavior, drug use, and violence. Science, 280(5365), 867–873.Google Scholar

United Nation Office on Drugs and Crime (UNODC) (2015). Special Segment, Legal responses to NPS: multiple approaches to a multi-faceted problem. Global Smart Update, Vol 14. Available at: www.unodc.org/documents/scientific/Global_SMART_Update_14-web.pdf [Accessed: June 06, 2018]Google Scholar

Ukaigwe, A., Karmacharya, P. & Donato, A. (2014). A gut gone to pot: A case of cannabinoid hyperemesis syndrome due to K2, a synthetic cannabinoid. Case Reports in Emergency Medicine, 167098. http://doi.org/10.1155/2014/167098 Google Scholar

Ustundag, M. F., Ozhan Ibis, E., Yucel, A. & Ozcan, H. (2015). Synthetic cannabis-induced mania. Case Reports in Psychiatry. doi: 10.1155/2015/310930.Google Scholar

Valente, M. J., Guedes de Pinho, P., de Lourdes Bastos, M., Carvalho, F. & Carvalho, M. (2014). Khat and synthetic cathinones: A review. Archives of Toxicology, 88(1), 15–45.Google Scholar

Van Amsterdam, J., Brunt, T. & van den Brink, W. (2015). The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. Journal of Psychopharmacology, 29(3), 254–263.Google Scholar

Van Hout, M. C. (2014). An internet study of user's experiences of the synthetic cathinone 4-methylethcathinone (4-MEC). Journal of Psychoactive Drugs, 46(4), 273–286.Google Scholar

Van Hout, M. C. & Brennan, R. (2012). Curiosity killed M-Cat: A post-legislative study on mephedrone use in Ireland. Drugs: Education Prevention and Policy, 19(2), 156–162.Google Scholar

Vento, A. E., Martinotti, G., Cinosi, E., et al. (2014). Substance use in the club scene of Rome: A pilot study. BioMed Research International, 2014, 617546. http://doi.org/10.1155/2014/617546 Google Scholar

Vidourek, R. A., King, K. A. & Burbage, M.L. (2013). Reasons for synthetic THC use among college students. Journal of Drug Education, 43(4), 353–363.Google Scholar

Vorce, S. P., Knittel, J. L., Holler, J. M., et al. (2014). A fatality involving AH-7921. Journal of Analytical Toxicology, 38(4), 226–230.Google Scholar

Vreeker, A., van der Burg, B. G., van Laar, M. & Brunt, T.M. (2017). Characterizing users of new psychoactive substances using psychometric scales for risk-related behavior. Addictive Behaviors, 70, 72–78.Google Scholar

Warrick, B. J., Wilson, J., Hedge, M., et al. (2012). Lethal serotonin syndrome after methylone and butylone ingestion. Journal of Medical Toxicology, 8(1), 65–68.Google Scholar

Weinstein, A. M., Rosca, P., Fattore, L. & London, E. D. (2017). Synthetic cathinone and cannabinoid designer drugs pose a major risk for public health. Frontiers in Psychiatry, 8, 156. http://doi.org/10.3389/fpsyt.2017.00156 Google Scholar

Westin, A. A., Frost, J., Brede, W. R., et al. (2016). Sudden cardiac death following use of the synthetic cannabinoid MDMB-CHMICA. Journal of Analytical Toxicology, 40(1), 86–87.Google Scholar

White, J., Hawkins, J., Madden, K., et al. (2017). Adapting the ASSIST model of informal peer-led intervention delivery to the Talk to FRANK drug prevention programme in UK secondary schools (ASSIST + FRANK): intervention development, refinement and a pilot cluster randomised controlled trial. Public Health Research, No. 5.7. Southampton (UK): NIHR Journals Library.Google Scholar

Wiley, J. L., Marusich, J. A., Huffman, J. W., Balster, R. L. & Thomas, B. F. (2011). Hijacking of basic research: The case of synthetic cannabinoids. Methods Report (RTI Press), 2011, 17971.Google Scholar

Wilkins, C., Sweetsur, P. & Girling, M. (2008). Patterns of benzylpiperazine/trifluoromethylphenylpiperazine party pill use and adverse effects in a population sample in New Zealand. Drug and Alcohol Review, 27(6), 633–639.Google Scholar

Wilson, J. M., McGeorge, F., Smolinske, S. & Meatherall, R. (2005). A foxy intoxication. Forensic Science International, 148(1), 31–36.Google Scholar

Winstock, A. R. & Barratt, M. J. (2013). Synthetic cannabis: A comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug and Alcohol Depend, 131(1–2), 106–111.Google Scholar

Winstock, A. R. & Barratt, M. (2016). Dark-net markets: the good, the bad and ugly? Available at: www.globaldrugsurvey.com/gds2017-launch/dark-net-markets-the-good-the-bad-and-ugly/ [Accessed: December 20, 2017]Google Scholar

Winstock, A., Barratt, M., Ferris, J. & Maier, L. (2017). Global Drug Survey 2017 – Global Overview and Highlights. Available at: www.globaldrugsurvey.com/wp-content/themes/globaldrugsurvey/results/GDS2017_key-findings-report_final.pdf [Accessed: October 17, 2017]Google Scholar

Winstock, A. R., Marsden, J. & Mitcheson, L. (2010). What should be done about mephedrone? BMJ, 340, c1605. doi: 10.1136/bmj.c1605.Google Scholar

Winstock, A. R., Mitcheson, L. R., Deluca, P., et al. (2011). Mephedrone, new kid for the chop? Addiction, 106(1), 154–161.Google Scholar

Wood, D. M., Ceronie, B. & Dargan, P. I. (2016). Healthcare professionals are less confident in managing acute toxicity related to the use of new psychoactive substances (NPS) compared with classical recreational drugs. QJM: An International Journal of Medicine, 109(8), 527–529.Google Scholar

Wood, D. M., Davies, S., Greene, S. L., et al. (2010). Case series of individuals with analytically confirmed acute mephedrone toxicity. Clinical Toxicology (Philadelphia, Pa), 48(9), 924–927.Google Scholar

Wood, D. M., Heyerdahl, F., Yates, C. B., et al. (2014). The European Drug Emergencies Network (Euro-DEN). Clinical Toxicology (Philadelphia, Pa.), 52(4), 239–241.Google Scholar

Wood, D. M., Measham, F. & Dargan, P. I. (2012). ‘Our favourite drug’: prevalence of use and preference for mephedrone in the London night-time economy 1 year after control. Journal of Substance Use, 17(2), 91–97.Google Scholar

Wyman, J. F., Lavins, E. S., Engelhart, D., et al. (2013). Postmortem tissue distribution of MDPV following lethal intoxication by “bath salts”. Journal of Analytical Toxicology, 37(3), 182–185.Google Scholar

Yin, S. & Ho, M. (2012). Monitoring a toxicological outbreak using Internet search query data. Clinical Toxicology (Philadelphia, Pa.), 50(9), 818–822.Google Scholar

Zawilska, J. B. (2017). An expanding world of novel psychoactive substances: Opioids. Frontiers in Psychiatry, 8, 110. http://doi.org/10.3389/fpsyt.2017.00110 Google Scholar

Zawilska, J. B. & Wojcieszak, J. (2017). α-Pyrrolidinophenones: A new wave of designer cathinones. Forensic Toxicology, 35(2), 201–216.Google Scholar

Zheluk, A., Quinn, C. &, Meylakhs, P. (2014). Internet search and krokodil in the Russian Federation: An infoveillance study. Journal of Medical Internet Research, 16(9), e212. doi: 10.2196/jmir.3203Google Scholar

References

Alexander, B. H., Checkoway, H., Nagahama, S. I. & Domino, K. B. (2000). Cause-specific mortality risks of anesthesiologists. Anesthesiology, 93(4), 922–930.Google Scholar

American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Arlington, VA: American Psychiatric Publishing.Google Scholar

American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders (5th edition). Arlington, VA: American Psychiatric Publishing.Google Scholar

Angres, D. H. (2010). The temperament and character inventory in addiction treatment. Focus, 8(2), 187–198. doi:10.1176/foc.8.2.foc187Google Scholar

Angres, D. H. & Nielsen, A. K. (2007). The role of the TCI-R (Temperament Character Inventory) in individualized treatment plannning in a population of addicted professionals. Journal of Addictive Diseases, 26 (Supplement 1), 51–64. doi:10.1300/J069v26S01_06Google Scholar

Boisaubin, E. V. & Levine, R. E. (2001). Identifying and assisting the impaired physician. American Journal of Medical Sciences, 322(1), 31–36.Google Scholar

Boyd, J. W. (2015a). A call for national standards and oversight of state physician health programs. Journal of Addiction Medicine, 9(6), 431–432. doi:10.1097/adm.0000000000000174Google Scholar

Boyd, J. W. (2015b). Deciding whether to refer a colleague to a physician health program. AMA Journal of Ethics, 17(10), 888–893. doi:10.1001/journalofethics.2015.17.10.spec1-1510Google Scholar

Boyd, J. W. & Knight, J. R. (2012). Ethical and managerial considerations regarding state physician health programs. Journal of Addiction Medicine, 6(4), 243–246. doi:10.1097/ADM.0b013e318262ab09Google Scholar

Brewster, J. M. (1986). Prevalence of alcohol and other drug problems among physicians. JAMA, 255(14), 1913–1920. doi:10.1001/jama.1986.03370140111034Google Scholar

Candilis, P. J. (2016). Physician health programs and the social contract. AMA Journal of Ethics, 18(1), 77–81. doi:10.1001/journalofethics.2016.18.1.corr1-1601Google Scholar

Cloninger, C. R., Svrakic, D. M. & Przybeck, T. R. (1993). A psychobiological model of temperament and character. Archives of General Psychiatry, 50(12), 975–990.Google Scholar

Cloninger, C. R., Zohar, A. H. & Cloninger, K. M. (2010). Promotion of well-being in person-centered mental health care. Focus, 8(2), 165–179. doi:10.1176/foc.8.2.foc165Google Scholar

Cottler, L. B., Ajinkya, S., Merlo, L. J., et al. (2013). Lifetime psychiatric and substance use disorders among impaired physicians in a physicians health program: Comparison to a general treatment population: Psychopathology of impaired physicians. Journal of Addiction Medicine, 7(2), 108–112. doi:10.1097/ADM.0b013e31827fadc9Google Scholar

Dewa, C. S., Loong, D., Bonato, S. & Trojanowski, L. (2017). The relationship between physician burnout and quality of healthcare in terms of safety and acceptability: A systematic review. BMJ Open, 7.Google Scholar

Dorr, D. (1981). MMPI profiles of emotionally impaired physicians. Journal of Clinical Psychology, 37(2), 451–455.Google Scholar

Drummond, D. (2015). Physician burnout: Its origin, symptoms, and five main causes. Family Practice Management, 22(5), 42–47.Google Scholar

DuPont, R. L., Compton, W. M. & McLellan, A. T. (2015). Five-year recovery: A new standard for assessing effectiveness of substance use disorder treatment. Journal of Substance Abuse Treatment, 58, 1–5. doi:10.1016/j.jsat.2015.06.024Google Scholar

DuPont, R. L., McLellan, A. T., Carr, G., Gendel, M. & Skipper, G. E. (2009a). How are addicted physicians treated? A national survey of Physician Health Programs. Journal of Substance Abuse Treatment, 37(1), 1–7. doi:10.1016/j.jsat.2009.03.010Google Scholar

DuPont, R. L., McLellan, A. T., White, W. L., Merlo, L. J. & Gold, M. S. (2009b). Setting the standard for recovery: Physicians' Health Programs. Journal of Substance Abuse Treatment, 36(2), 159–171. doi:10.1016/j.jsat.2008.01.004Google Scholar

Federation of State Medical Boards (2006). Addressing Sexual Boundaries: Guidelines for State Medical Boards. Retrieved from Federation of State Physician Health Programs State Programs. Retrieved from www.fsphp.org/state-programs Google Scholar

Freud, S. (1884). Über Coca. Centralblatt für die gesamte Therapie, 2, 289–314.Google Scholar

Gold, M. S., Melker, R. J., Dennis, D. M., et al. (2006). Fentanyl abuse and dependence: Further evidence for second hand exposure hypothesis. Journal of Addictive Diseases, 25(1), 15–21. doi:10.1300/J069v25n01_04Google Scholar

Grant, J. E., Potenza, M. N., Weinstein, A. & Gorelick, D. A. (2010). Introduction to behavioral addictions. The American Journal of Drug and Alcohol Abuse, 36(5), 233–241. doi:10.3109/00952990.2010.491884Google Scholar

Higgins, S. T., Heil, S. H. & Lussier, J. P. (2004). Clinical implications of reinforcement as a determinant of substance use disorders. Annual Review of Psychology, 55, 431–461. doi:10.1146/annurev.psych.55.090902.142033Google Scholar

Hloch, K., Mladenka, P., Dosedel, M., Adriani, W. & Zoratto, F. (2017). The current clinical knowledge on the treatment of gambling disorder: A summary. Synapse, 71(8). doi:10.1002/syn.21976Google Scholar

Hughes, P. H., Brandenburg, N., Baldwin, D. C. Jr., et al. (1992). Prevalence of substance use among US physicians. JAMA, 267(17), 2333–2339.Google Scholar

Hughes, P. H., Storr, C. L., Brandenburg, N. A., et al. (1999). Physician substance use by medical specialty. Journal of Addictive Diseases, 18(2), 23–37. doi:10.1300/J069v18n02_03Google Scholar

Kessler, R. C., Hwang, I., LaBrie, R., et al. (2008). DSM-IV pathological gambling in the National Comorbidity Survey Replication. Psychological Medicine, 38(9), 1351–1360. doi:10.1017/s0033291708002900Google Scholar

Kraus, S. W., Voon, V. & Potenza, M. N. (2016). Should compulsive sexual behavior be considered an addiction? Addiction, 111(12), 2097–2106. doi:10.1111/add.13297Google Scholar

Lenzer, J. (2016). Physician health programs under fire. BMJ, 353, i3568. doi:10.1136/bmj.i3568Google Scholar

Markel, H. (2012). An Anatomy of Addiction: Sigmund Freud, William Halsted, and the Miracle Drug Cocaine. New York, NY: Vintage Books, Random House, Inc.Google Scholar

McLellan, A. T., Skipper, G. S., Campbell, M. & DuPont, R. L. (2008). Five year outcomes in a cohort study of physicians treated for substance use disorders in the United States. BMJ, 337, a2038. doi:10.1136/bmj.a2038Google Scholar

Merlo, L. J. & Gold, M. S. (2008). Prescription opioid abuse and dependence among physicians: Hypotheses and treatment. Harvard Review of Psychiatry, 16(3), 181–194. doi:10.1080/10673220802160316Google Scholar

Merlo, L. J. & Greene, W. M. (2010). Physician views regarding substance use-related participation in a state physician health program. American Journal on Addictions, 19(6), 529–533. doi:10.1111/j.1521-0391.2010.00088.xGoogle Scholar

Merlo, L. J., Campbell, M. D., Skipper, G. E., Shea, C. L. & DuPont, R. L. (2016). Outcomes for physicians with opioid dependence treated without agonist pharmacotherapy in physician health programs. Journal of Substance Abuse Treatment, 64, 47–54. doi:10.1016/j.jsat.2016.02.004Google Scholar

Merlo, L. J., Goldberger, B. A., Kolodner, D., Fitzgerald, K. & Gold, M. S. (2008). Fentanyl and propofol exposure in the operating room: Sensitization hypotheses and further data. Journal of Addictive Diseases, 27(3), 67–76. doi:10.1080/10550880802122661Google Scholar

Merlo, L. J., Greene, W. M. & Pomm, R. (2011). Mandatory naltrexone treatment prevents relapse among opiate-dependent anesthesiologists returning to practice. Journal of Addiction Medicine, 5(4), 279–283. doi:10.1097/ADM.0b013e31821852a0Google Scholar

Merlo, L. J., Singhakant, S., Cummings, S. M. & Cottler, L. B. (2013a). Reasons for misuse of prescription medication among physicians undergoing monitoring by a physician health program. Journal of Addiction Medicine, 7(5), 349–353. doi:10.1097/ADM.0b013e31829da074Google Scholar

Merlo, L. J., Trejo-Lopez, J., Conwell, T. & Rivenbark, J. (2013b). Patterns of substance use initiation among healthcare professionals in recovery. American Journal on Addictions, 22(6), 605–612. doi:10.1111/j.1521-0391.2013.12017.xGoogle Scholar

Nace, E. P., Birkmayer, F., Sullivan, M. A., et al. (2007). Socially sanctioned coercion mechanisms for addiction treatment. American Journal on Addictions, 16(1), 15–23. doi:10.1080/10550490601077783Google Scholar

Nelson, H. D., Matthews, A. M., Girard, D. E. & Bloom, J. D. (1996). Substance-impaired physicians probationary and voluntary treatment programs compared. Western Journal of Medicine, 165(1–2), 31–36.Google Scholar

Oreskovich, M. R., Shanafelt, T., Dyrbye, L. N., et al. (2015). The prevalence of substance use disorders in American physicians. American Journal on Addictions, 24(1), 30–38. doi:10.1111/ajad.12173Google Scholar

Rash, C. J., Stitzer, M. & Weinstock, J. (2017). Contingency management: New directions and remaining challenges for an evidence-based intervention. Journal of Substance Abuse Treatment, 72, 10–18. doi:10.1016/j.jsat.2016.09.008Google Scholar

Rezvani, A., Bouju, G., Keriven-Dessomme, B., Moret, L. & Grall-Bronnec, M. (2014). Workaholism: Are physicians at risk? Occupational Medicine (London), 64(6), 410–416. doi:10.1093/occmed/kqu081Google Scholar

Rush, B. (1823). An Inquiry into the Effect of Ardent Spirits upon the Human Body and Mind, with an Account of the Means of Preventing and of the Remedies for Curing Them (8th edition). Boston: James Loring.Google Scholar

Shaffer, H. (1984). Uber coca: Freud's cocaine discoveries. Journal of Substance Abuse Treatment, 1(3), 205–217. doi:http://dx.doi.org/10.1016/0740-5472(84)90023-0 Google Scholar

Shanafelt, T. D., Hasan, O., Dyrbye, L. N., et al. (2015). Changes in burnout and satisfaction with work-life balance in physicians and the general US working population between 2011 and 2014. Mayo Clinic Proceedings, 90(12), 1600–1613. doi:10.1016/j.mayocp.2015.08.023Google Scholar

Shanafelt, T. D., Sloan, J. A. & Habermann, T. M. (2003). The well-being of physicians. American Journal of Medicine, 114(6), 513–519.Google Scholar

Sinsky, C. A., Dyrbye, L. N., West, C. P., et al. (2017). Professional satisfaction and the career plans of US physicians. Mayo Clinic Proceedings, 92(11), 1625–1635. doi:10.1016/j.mayocp.2017.08.017Google Scholar

US Department of Health and Human Services (HHS) & Office of the Surgeon General. (November 2016). Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and Health. Washington, DC: HHS.Google Scholar

Vaillant, G. E., Brighton, J. R. & McArthur, C. (1970). Physicians' use of mood-altering drugs. A 20-year follow-up report. New England Journal of Medicine, 282(7), 365–370. doi:10.1056/nejm197002122820705Google Scholar

Warner, D. O., Berge, K., Sun, H., et al. (2013). Substance use disorder among anesthesiology residents, 1975-2009. JAMA, 310(21), 2289–2296. doi:10.1001/jama.2013.281954Google Scholar

Washton, A. M., Gold, M. S. & Pottash, A. C. (1984). Naltrexone in addicted physicians and business executives. NIDA Research Monographs, 55, 185–190.Google Scholar

White, W. L. (1998). Slaying the Dragon: The History of Addiction Treatment and Recovery in America. Normal, IL: Chestnut Health Systems/Lighthouse Institute.Google Scholar

White, W. L., DuPont, R. L. & Skipper, G.E. (2007). Physicians health programs: What counselors can learn from these remarkable programs. Counselor, 8(2), 42–47.Google Scholar

Xiong, W. (2017). Physician burnout: An epidemic or the new norm? American Journal of Psychiatry Residents' Journal, 12(4), 2. doi:10.1176/appi.ajp-rj.2017.120401Google Scholar

Williams, B. W., Flanders, P., Welindt, D. & Williams, M. V. (2018). Importance of neuropsychological screening in physicians referred for performance concerns. PloS ONE, 13(11), e0207874–e0207874. doi:10.1371/journal.pone.0207874Google Scholar

Wood, B. A. (2014). Performance audit: North Carolina physicians health program. North Carolina Office of the State Health Auditor.Google Scholar

Yip, S. W. & Potenza, M. N. (2014). Treatment of gambling disorders. Current Treatment Options in Psychiatry, 1(2), 189–203. doi:10.1007/s40501-014-0014-5Google Scholar

References

Auer, M. & Griffiths, M. D. (2013). Voluntary limit setting and player choice in most intense online gamblers: An empirical study of gambling behaviour. Journal of Gambling Studies, 29, 647–660.Google Scholar

Auer, M. & Griffiths, M. D. (2014a). Personalised feedback in the promotion of responsible gambling: A brief overview. Responsible Gambling Review, 1, 27–36.Google Scholar

Auer, M. & Griffiths, M. D. (2014b). An empirical investigation of theoretical loss and gambling intensity. Journal of Gambling Studies, 30, 879–887.Google Scholar

Auer, M. & Griffiths, M. D. (2015a). Testing normative and self-appraisal feedback in an online slot-machine pop-up message in a real-world setting. Frontiers in Psychology, 6, 339. doi: 10.3389/fpsyg.2015.00339Google Scholar

Auer, M. & Griffiths, M. D. (2015b). The use of personalized behavioral feedback for problematic online gamblers: An empirical study. Frontiers in Psychology, 6, 1406. doi: 10.3389/fpsyg.2015.01406.Google Scholar

Auer, M. & Griffiths, M. D. (2015c). Theoretical loss and gambling intensity (revisited): A response to Braverman et al. (2013). Journal of Gambling Studies, 31, 921–931.Google Scholar

Auer, M. & Griffiths, M. D. (2016). Personalized behavioral feedback for online gamblers: A real world empirical study. Frontiers in Psychology, 7, 1875. doi: 10.3389/fpsyg.2016.01875Google Scholar

Auer, M. & Griffiths, M. D. (2017a). Self-reported losses versus actual losses in online gambling: An empirical study. Journal of Gambling Studies, 33, 795–806.Google Scholar

Auer, M. & Griffiths, M. D. (2017b). Cognitive dissonance, personalized feedback, and online gambling behavior: An exploratory study using objective tracking data and subjective self-report. International Journal of Mental Health and Addiction. Epub ahead of print. doi: 10.1007/s11469-017-9808-1Google Scholar

Auer, M., Malischnig, D. & Griffiths, M. D. (2014). Is ‘pop-up’ messaging in online slot machine gambling effective? An empirical research note. Journal of Gambling Issues, 29, 1–10.Google Scholar

Auer, M., Schneeberger, A. & Griffiths, M. D. (2012). Theoretical loss and gambling intensity: A simulation study. Gaming Law Review and Economics, 16, 269–273.Google Scholar

Braverman, J., LaPlante, D. A., Nelson, S. E. & Shaffer, H. J. (2013). Using crossgame behavioral markers for early identification of high-risk Internet gamblers. Psychology of Addictive Behaviors, 27, 868–877.Google Scholar

Braverman, J. & Shaffer, H. J. (2012). How do gamblers start gambling: Identifying behavioral markers for high-risk Internet gambling. European Journal of Public Health, 22, 273–278.Google Scholar

Braverman, J., Tom, M. A. & Shaffer, H. J. (2014). Accuracy of self-reported versus actual online-gambling wins and losses. Psychological Assessment, 26, 865–877.Google Scholar

Broda, A., LaPlante, D. A., Nelson, S. E., et al. (2008). Virtual harm reduction efforts for Internet gambling: Effects of deposit limits on actual Internet sports gambling behaviour. Harm Reduction Journal, 5, 27.Google Scholar

Buchanan, T. (2000). Potential of the Internet for personality research. In Birnbaum, M. H. (Ed.), Psychological Experiments on the Internet. San Diego: Academic Press, pp.121–140.Google Scholar

Buchanan, T. (2007). Personality testing on the Internet: What we know, and what we do not. In Joinson, A. N., McKenna, K. Y. A., Postmes, T. & Reips, U. R. (Eds.), Oxford Handbook of Internet Psychology. Oxford: Oxford University Press, pp. 447–459.Google Scholar

Delfabbro, P. H., King, D. L. & Griffiths, M. D. (2012). Behavioural profiling of problem gamblers: A critical review. International Gambling Studies, 12, 349–366.Google Scholar

Dragicevic, S., Percy, C., Kudic, A. & Parke, J. (2015). A descriptive analysis of demographic and behavioral data from internet gamblers and those who self-exclude from online gambling platforms. Journal of Gambling Studies, 31, 105–132.Google Scholar

Forsström, D., Hesser, H. & Carlbring, P. (2016). Usage of a responsible gambling tool: A descriptive analysis of latent class analysis of user behavior. Journal of Gambling Studies, 32, 889–904.Google Scholar

Gainsbury, S. M. (2015). Online gambling addiction: The relationship between Internet gambling and disordered gambling. Current Addiction Reports, 2(2), 185–193.Google Scholar

Gray, H. M., LaPlante, D. A. & Shaffer, H. J. (2012). Behavioral characteristics of Internet gamblers who trigger corporate responsible gambling interventions. Psychology of Addictive Behaviors, 26, 527–535.Google Scholar

Griffiths, M. D. (2003). Internet gambling: Issues, concerns and recommendations. CyberPsychology and Behavior, 6, 557–568.Google Scholar

Griffiths, M. D. (2010). The use of online methodologies in data collection for gambling and gaming addictions. International Journal of Mental Health and Addiction, 8, 8–20.Google Scholar

Griffiths, M. D. & Auer, M. (2011). Approaches to understanding online versus offline gaming impacts. Casino and Gaming International, 7(3), 45–48.Google Scholar

Griffiths, M. D. & Parke, J. (2002). The social impact of Internet gambling. Social Science Computer Review, 20, 312–320.Google Scholar

Griffiths, M. D. & Whitty, M. W. (2010). Online behavioural tracking in Internet gambling research: Ethical and methodological issues. International Journal of Internet Research Ethics, 3, 104–117.Google Scholar

Griffiths, M. D. & Wood, R. T. A. (2008a). Gambling loyalty schemes: Treading a fine line? Casino and Gaming International, 4(2), 105–108.Google Scholar

Griffiths, M. D. & Wood, R. T. A. (2008b). Responsible gaming and best practice: How can academics help? Casino and Gaming International, 4(1), 107–112.Google Scholar

Griffiths, M. D., Wood, R. T. A. & Parke, J. (2009). Social responsibility tools in online gambling: A survey of attitudes and behaviour among Internet gamblers. CyberPsychology and Behavior, 12, 413–421.Google Scholar

Griffiths, M. D., Wood, R. T. A., Parke, J. & Parke, A. (2007). Gaming research and best practice: Gaming industry, social responsibility and academia. Casino and Gaming International, 3, 97–103.Google Scholar

Harris, A. & Griffiths, M. D. (2017). A critical review of the harm-minimisation tools available for electronic gambling. Journal of Gambling Studies, 33, 187–221.Google Scholar

Joinson, A. N., Paine, C., Buchanan, T. & Reips, U-D. (2008). Measuring self-disclosure online: Blurring and non-response to sensitive items in web-based surveys. Computers in Human Behavior, 24, 2158–2171.Google Scholar

Kuss, D. J. & Griffiths, M. D. (2012). Internet gambling behavior. In Yan, Z. (Ed.), Encyclopedia of Cyber Behavior. Pennsylvania: IGI Global, pp. 735–753.Google Scholar

LaBrie, R. A., Kaplan, S., LaPlante, D. A., Nelson, S. E. & Shaffer, H. J. (2008). Inside the virtual casino: A prospective longitudinal study of Internet casino gambling. European Journal of Public Health, 18(4), 410–416.Google Scholar

LaBrie, R. A., LaPlante, D. A., Nelson, S.E., Schumann, A. & Shaffer, H. J. (2007). Assessing the playing field: A prospective longitudinal study of internet sports gambling behavior. Journal of Gambling Studies, 23, 347–363.Google Scholar

LaPlante, D. A., Kleschinsky, J. H., LaBrie, R. A., Nelson, S. E. & Shaffer, H. J. (2009). Sitting at the virtual poker table: A prospective epidemiological study of actual Internet poker gambling behavior. Computers in Human Behavior, 25, 711–717.Google Scholar

LaPlante, D. A., Schumann, A., LaBrie, R. A. & Shaffer, H. J. (2008). Population trends in Internet sports gambling. Computers in Human Behavior, 24(5), 2399–2414.Google Scholar

Leino, T., Sagoe, D., Griffiths, M. D., et al. (2017). Gambling behavior in alcohol-serving and non-alcohol-serving venues: A study of electronic gaming machine players using account records. Addiction Research and Theory, 25, 201–207.Google Scholar

Leino, T., Torsheim, T., Blaszczynski, A., et al. (2015). The relationship between structural characteristics and gambling behavior: A population based study. Journal of Gambling Studies, 31, 1297–1315.Google Scholar

Miller, W. R. & Rollnick, S. (1991). Motivational Interviewing: Preparing People to Change Addictive Behavior. New York: Guilford Press.Google Scholar

Nelson, S. E., LaPlante, D. A., Peller, A. J., et al. (2008). Real limits in the virtual world: Self-limiting behavior of Internet gamblers. Journal of Gambling Studies, 24(4), 463–477.Google Scholar

Wardle, H., Sproston, K., Orford, J., et al. (2007). The British Gambling Prevalence Survey 2007. London: The Stationery Office.Google Scholar

Whitty, M. T. (2004). Peering into online bedroom windows: Considering the ethical implications of investigating Internet relationships and sexuality. In Buchanan, E. (Ed.), Readings in Virtual Research Ethics: Issues and Controversies. Hershey, USA: Idea Group Inc., pp. 203–218.Google Scholar

Wohl, M. J. A., Davis, C. G. & Hollingshead, S. J. (2017). How much have you won or lost? Personalized behavioral feedback about gambling expenditures regulates play. Computers in Human Behavior, 70, 437–455.Google Scholar

Wood, R. T. A. & Griffiths, M. D. (2007). Online data collection from gamblers: Methodological issues. International Journal of Mental Health and Addiction, 5, 151–163.Google Scholar

Wood, R. T. A. & Griffiths, M. D. (2010). Social responsibility in online gambling: Voluntary limit setting. World Online Gambling Law Report, 9(11), 10–11.Google Scholar

Wood, R. T. A. & Wohl, M. J. (2015). Assessing the effectiveness of a responsible gambling behavioural feedback tool for reducing the gambling expenditure of at-risk players. International Gambling Studies, 15(2), 1–16.Google Scholar

Wood, R. T. A., Griffiths, M. D. & Eatough, V. (2004). Online data collection from videogame players: Methodological issues. Cyberpsychology and Behavior, 7, 511–518.Google Scholar

Wysocki, D. K. (1998). Let your fingers to do the talking: Sex on an adult chat-line. Sexualities, 1, 425–452.Google Scholar

Xuan, Z. M. & Shaffer, H. J. (2009). How do gamblers end gambling: Longitudinal analysis of internet gambling behaviors prior to account closure due to gambling related problems. Journal of Gambling Studies, 25, 239–252.Google Scholar

References

Ahmed, S. H., Avena, N. M., Berridge, K. C., Gearhardt, A. N. & Guillem, K. (2013). Food addiction. In Neuroscience in the 21st Century. Springer, pp. 2833–2857.Google Scholar

American Psychiatric Association (2013a). Diagnostic and Statistical Manual of Mental Disorders. Arlington, VA: American Psychiatric Publishing.Google Scholar

American Psychiatric Association (2013b). Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Retrieved from http://dsm.psychiatryonline.org/book.aspx?bookid=556 Google Scholar

Anderson, P., Chisholm, D. & Fuhr, D. C. (2009). Effectiveness and cost-effectiveness of policies and programmes to reduce the harm caused by alcohol. The Lancet, 373(9682), 2234–2246.Google Scholar

Arnow, B., Kenardy, J. & Agras, W. S. (1992). Binge eating among the obese: A descriptive study. Journal of Behavioral Medicine, 15(2), 155–170. doi:10.1007/bf00848323Google Scholar

Avena, N. M., Bocarsly, M. E., Rada, P., Kim, A. & Hoebel, B. G. (2008a). After daily bingeing on a sucrose solution, food deprivation induces anxiety and accumbens dopamine/acetylcholine imbalance. Physiology & Behavior, 94(3), 309–315.Google Scholar

Avena, N. M., Rada, P. & Hoebel, B. G. (2008b). Evidence for sugar addiction: Behavioral and neurochemical effects of intermittent, excessive sugar intake. Neuroscience & Biobehavioral Reviews, 32(1), 20–39. doi:10.1016/j.neubiorev.2007.04.019Google Scholar

Avena, N. M., Rada, P. & Hoebel, B. G. (2009). Sugar and fat bingeing have notable differences in addictive-like behavior. The Journal of Nutrition, 139(3), 623–628.Google Scholar

Balster, R. L. (1991). Drug abuse potential evaluation in animals. British Journal of Addiction, 86(12), 1549–1558.Google Scholar

Berridge, K. C. (1996). Food reward: Brain substrates of wanting and liking. Neuroscience & Biobehavioral Reviews, 20(1), 1–25.Google Scholar

Blaszczynski, A. & Nower, L. (2002). A pathways model of problem and pathological gambling. Addiction, 97(5), 487–499.Google Scholar

Bocarsly, M. E., Berner, L. A., Hoebel, B. G. & Avena, N. M. (2011). Rats that binge eat fat-rich food do not show somatic signs or anxiety associated with opiate-like withdrawal: Implications for nutrient-specific food addiction behaviors. Physiology & Behavior, 104(5), 865–872.Google Scholar

Boggiano, M. M., Artiga, A. I., Pritchett, C. E., et al. (2007). High intake of palatable food predicts binge-eating independent of susceptibility to obesity: An animal model of lean vs obese binge-eating and obesity with and without binge-eating. International Journal of Obesity, 31(9), 1357–1367.Google Scholar

Boggiano, M. M., Dorsey, J. R., Thomas, J. M. & Murdaugh, D. L. (2009). The Pavlovian power of palatable food: Lessons for weight-loss adherence from a new rodent model of cue-induced overeating. International Journal of Obesity (London), 33(6), 693–701. doi:10.1038/ijo.2009.57Google Scholar

Brownley, K. A., Berkman, N. D., Sedway, J. A., Lohr, K. N. & Bulik, C. M. (2007). Binge eating disorder treatment: A systematic review of randomized controlled trials. International Journal of Eating Disorders, 40(4), 337–348.Google Scholar

Carey, K. B. (1996). Substance use reduction in the context of outpatient psychiatric treatment: A collaborative, motivational, harm reduction approach. Community Mental Health Journal, 32(3), 291–306.Google Scholar

Carroll, K. M., Ball, S. A., Nich, C., et al. (2006). Motivational interviewing to improve treatment engagement and outcome in individuals seeking treatment for substance abuse: A multisite effectiveness study. Drug & Alcohol Dependence, 81(3), 301–312.Google Scholar

Carter, L. P., Stitzer, M. L., Henningfield, J. E., et al. (2009). Abuse liability assessment of tobacco products including potential reduced exposure products. Cancer Epidemiology, Biomarkers & Prevention, 18(12), 3241–3262. doi:10.1158/1055-9965.EPI-09-0948Google Scholar

Carter, W. P., Hudson, J. I., Lalonde, J. K., et al. (2003). Pharmacologic treatment of binge eating disorder. International Journal of Eating Disorders, 34(S1), S74–88.Google Scholar

Cassin, S. E., von Ranson, K. M., Heng, K., Brar, J. & Wojtowicz, A. E. (2008). Adapted motivational interviewing for women with binge eating disorder: A randomized controlled trial. Psychology of Addictive Behaviors, 22(3), 417.Google Scholar

Chappel, J. N. & DuPont, R. L. (1999). Twelve-step and mutual-help programs for addictive disorders. Psychiatric Clinics, 22(2), 425–446.Google Scholar

Cooper, M. L., Russell, M. & George, W. H. (1988). Coping, expectancies, and alcohol abuse: A test of social learning formulations. Journal of Abnormal Psychology, 97(2), 218.Google Scholar

Corsica, J. A. & Pelchat, M. L. (2010). Food addiction: True or false? Current Opinion in Gastroenterology, 26(2), 165–169. doi:10.1097/MOG.0b013e328336528dGoogle Scholar

Corwin, R. L. (2006). Bingeing rats: A model of intermittent excessive behavior? Appetite, 46(1), 11–15. doi:10.1016/j.appet.2004.09.002Google Scholar

Corwin, R. L. & Grigson, P. S. (2009). Symposium overview – Food addiction: Fact or fiction? Journal of Nutrition, 139(3), 617–619. doi:10.3945/jn.108.097691Google Scholar

Davis, C. & Carter, J. C. (2009). Compulsive overeating as an addiction disorder. A review of theory and evidence. Appetite, 53(1), 1–8. doi:10.1016/j.appet.2009.05.018Google Scholar

Davis, C., Curtis, C., Levitan, R. D., et al. (2011). Evidence that ‘food addiction’ is a valid phenotype of obesity. Appetite, 57(3), 711–717. doi:10.1016/j.appet.2011.08.017Google Scholar

Davis, C. & Mason, A. (2020). Prevention and treatment of “food addiction” In Sussman, S. (Ed.) The Cambridge Handbook of Substance and Behavioral Addictions. Cambridge, UK: Cambridge University Press, pp. 230–240.Google Scholar

Donny, E. C., Houtsmuller, E. & Stitzer, M. L. (2007). Smoking in the absence of nicotine: Behavioral, subjective and physiological effects over 11 days. Addiction, 102(2), 324–334. doi:10.1111/j.1360-0443.2006.01670.xGoogle Scholar

Eiser, J. R. (1985). Smoking: The social learning of an addiction. Journal of Social and Clinical Psychology, 3(4), 446.Google Scholar

Emrick, C. D., Tonigan, J. S., Montgomery, H. & Little, L. (1993). Alcoholics anonymous: What is currently known? In McCrady, B. S. & Miller, W. R. (Eds.), Research on Alcoholics Anonymous: Opportunities and Alternatives. Rutgers Center of Alcohol Studies, pp. 41–76.Google Scholar

Epel, E., Lapidus, R., McEwen, B. & Brownell, K. (2001). Stress may add bite to appetite in women: A laboratory study of stress-induced cortisol and eating behavior. Psychoneuroendocrinology, 26(1), 37–9.Google Scholar

“Food Addicts Anonymous.” FAA. Accessed January 23, 2020. http://www.foodaddictsanonymous.org/faa-food-plan Google Scholar

Gearhardt, A. N., Corbin, W. R. & Brownell, K. D. (2009). Preliminary validation of the Yale Food Addiction Scale. Appetite, 52(2), 430–436. doi:10.1016/j.appet.2008.12.003Google Scholar

Gearhardt, A. N., Corbin, W. R. & Brownell, K. D. (2016). Development of the Yale Food Addiction Scale Version 2.0. Psychology of Addictive Behaviors, 30(1), 113.Google Scholar

Gearhardt, A. N., Davis, C., Kuschner, R. & Brownell, K. D. (2011a). The addiction potential of hyperpalatable foods. Current Drug Abuse Reviews, 4(3), 140–145.Google Scholar

Gearhardt, A. N., Murray, S. & Avena, N. M. (2015). Emerging evidence of addiction in problematic eating behavior. Emerging Trends in the Social and Behavioral Sciences: An Interdisciplinary, Searchable, and Linkable Resource. John Wiley & Sons, Inc.Google Scholar

Gearhardt, A. N., Yokum, S., Orr, P. T., et al. (2011b). Neural correlates of food addiction. Archives of General Psychiatry, 68(8), 808–816. doi:10.1001/archgenpsychiatry.2011.32Google Scholar

Gilhooly, C., Das, S., Golden, J., et al. (2007). Food cravings and energy regulation: The characteristics of craved foods and their relationship with eating behaviors and weight change during 6 months of dietary energy restriction. International Journal of Obesity, 31(12), 1849–1858.Google Scholar

Gold, M. S., Frost-Pineda, K. & Jacobs, W. S. (2003). Overeating, binge eating, and eating disorders as addictions. Psychiatric Annals, 33(2), 117–122.Google Scholar

Goldfein, J. A., Walsh, B. T., LaChaussee, J. L., Kissileff, H. R. & Devlin, M. J. (1993). Eating behavior in binge eating disorder. International Journal of Eating Disordorders, 14(4), 427–431.Google Scholar

Griffiths, M. (1999). Gambling technologies: Prospects for problem gambling. Journal of Gambling Studies, 15(3), 265–283.Google Scholar

Guss, J. L., Kissileff, H. R., Devlin, M. J., Zimmerli, E. & Walsh, B. T. (2002). Binge size increases with body mass index in women with binge-eating disorder. Obesity Research, 10(10), 1021–1029. doi:10.1038/oby.2002.139Google Scholar

Hadigan, C. M., Kissileff, H. R. & Walsh, B. T. (1989). Patterns of food selection during meals in women with bulimia. American Journal of Clinical Nutrition, 50(4), 759–766.Google Scholar

Hagan, M. M., Chandler, P. C., Wauford, P. K., Rybak, R. J. & Oswald, K. D. (2003). The role of palatable food and hunger as trigger factors in an animal model of stress induced binge eating. International Journal of Eating Disorders, 34(2), 183–197. doi:10.1002/eat.10168Google Scholar

Haney, M. (2009). Self-administration of cocaine, cannabis and heroin in the human laboratory: Benefits and pitfalls. Addiction Biology, 14(1), 9–21. doi:10.1111/j.1369-1600.2008.00121.xGoogle Scholar

Hardman, C. A., Rogers, P. J., Dallas, R., et al. (2015). “Food addiction is real”. The effects of exposure to this message on self-diagnosed food addiction and eating behaviour. Appetite, 91, 179–184.Google Scholar

Hebebrand, J., Albayrak, Ö., Adan, R., et al. (2014). “Eating addiction”, rather than “food addiction”, better captures addictive-like eating behavior. Neuroscience & Biobehavioral Reviews, 47, 295–306.Google Scholar

Herz, A. (1997). Endogenous opioid systems and alcohol addiction. Psychopharmacology (Berlin), 129(2), 99–111.Google Scholar

Higgins, S. T., Budney, A. J., Bickel, W. K., et al. (1994). Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Archives of General Psychiatry, 51(7), 568–576.Google Scholar

Hoebel, B. G., Avena, N. M., Bocarsly, M. E. & Rada, P. (2009). Natural addiction: A behavioral and circuit model based on sugar addiction in rats. Journal of Addiction Medicine, 3(1), 33–41. doi:10.1097/ADM.0b013e31819aa621Google Scholar

Humphreys, K. (2003). Circles of Recovery: Self-Help Organizations for Addictions. Cambridge: Cambridge University Press.Google Scholar

Hwa, L. S., Chu, A., Levinson, S. A., et al. (2011). Persistent escalation of alcohol drinking in C57BL/6J mice with intermittent access to 20% ethanol. Alcoholism: Clinical and Experimental Research, 35(11), 1938–1947. doi:10.1111/j.1530-0277.2011.01545.xGoogle Scholar

Ifland, J. R., Preuss, H. G., Marcus, M. T., et al. (2009). Refined food addiction: A classic substance use disorder. Medical Hypotheses, 72(5), 518–526. doi:10.1016/j.mehy.2008.11.035Google Scholar

Ifland, J. R., Preuss, H. G., Marcus, M. T., et al. (2015). Clearing the confusion around processed food addiction. Journal of the American College of Nutrition, 34(3), 240–243. doi:10.1080/07315724.2015.1022466Google Scholar

Johnson, P. M. & Kenny, P. J. (2010). Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats. Nature Neuroscience, 13(5), 635–641.Google Scholar

Kadden, R. (1995). Cognitive-Behavioral Coping Skills Therapy Manual: A Clinical Research Guide for therapists treating Individuals with Alcohol Abuse and Dependence. DIANE Publishing.Google Scholar

Keys, A., Brožek, J., Henschel, A., Mickelsen, O. & Taylor, H. L. (1950). The Biology of Human Starvation. (Two volumes.) University of Minnesota Press.Google Scholar

Kim, S., Shou, J., Abera, S. & Ziff, E. B. (2017). Sucrose withdrawal induces depression and anxiety-like behavior by Kir2.1 upregulation in the nucleus accumbens. Neuropharmacology, 130, 10–17. doi:10.1016/j.neuropharm.2017.11.041Google Scholar

Klatsky, A. L., Armstrong, M. A. & Kipp, H. (1990). Correlates of alcoholic beverage preference: Traits of persons who choose wine, liquor or beer. British Journal of Addiction, 85(10), 1279–1289.Google Scholar

Koob, G. F. & Kreek, M. J. (2007). Stress, dysregulation of drug reward pathways, and the transition to drug dependence. American Journal of Psychiatry, 164(8), 1149–1159. doi:10.1176/appi.ajp.2007.05030503Google Scholar

Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F. & Rosenheck, R. A. (2001). Naltrexone in the treatment of alcohol dependence. New England Journal of Medicine, 345(24), 1734–1739.Google Scholar

Latner, J. D., Puhl, R. M., Murakami, J. M. & O'Brien, K. S. (2014). Food addiction as a causal model of obesity. Effects on stigma, blame, and perceived psychopathology. Appetite, 77, 77–82. doi:10.1016/j.appet.2014.03.004Google Scholar

Lee, N. M., Hall, W. D., Lucke, J., Forlini, C. & Carter, A. (2014). Food addiction and its impact on weight-based stigma and the treatment of obese individuals in the U.S. and Australia. Nutrients, 6(11), 5312–5326. doi:10.3390/nu6115312Google Scholar

Levy, D. T., Chaloupka, F. & Gitchell, J. (2004). The effects of tobacco control policies on smoking rates: A tobacco control scorecard. Journal of Public Health Management and Practice, 10(4), 338–353.Google Scholar

Lile, J. A. & Nader, M. A. (2003). The abuse liability and therapeutic potential of drugs evaluated for cocaine addiction as predicted by animal models. Current Neuropharmacology, 1(1), 21–46.Google Scholar

Magill, M. & Ray, L. A. (2009). Cognitive-behavioral treatment with adult alcohol and illicit drug users: A meta-analysis of randomized controlled trials. Journal of Studies on Alcohol and Drugs, 70(4), 516–527.Google Scholar

Marlatt, G. A. & Witkiewitz, K. (2002). Harm reduction approaches to alcohol use: Health promotion, prevention, and treatment. Addictive Behaviors, 27(6), 867–886.Google Scholar

Miller, W. R. & Rollnick, S. (2012). Motivational Interviewing: Helping People Change. Guilford Press.Google Scholar

Niaura, R. (2000). Cognitive social learning and related perspectives on drug craving. Addiction, 95(8s2), 155–163.Google Scholar

O'Brien, C. P. & Gardner, E. L. (2005). Critical assessment of how to study addiction and its treatment: human and non-human animal models. Pharmacology & Therapeutics, 108(1), 18–58.Google Scholar

Oliver, G. & Wardle, J. (1999). Perceived effects of stress on food choice. Physiology & Behavoir, 66(3), 511–515.Google Scholar

Oliver, G., Wardle, J. & Gibson, E. L. (2000). Stress and food choice: A laboratory study. Psychosomatic Medicine, 62(6), 853–865.Google Scholar

Oser, M. L., McKellar, J., Moos, B. S. & Moos, R. H. (2010). Changes in ambivalence mediate the relation between entering treatment and change in alcohol use and problems. Addictive Behaviors, 35(4), 367–369.Google Scholar

Oswald, K. D., Murdaugh, D. L., King, V. L. & Boggiano, M. M. (2011). Motivation for palatable food despite consequences in an animal model of binge eating. International Journal of Eating Disorders, 44(3), 203–211.Google Scholar

Petry, N. M., Ammerman, Y., Bohl, J., et al. (2006). Cognitive-behavioral therapy for pathological gamblers. Journal of Consulting and Clinical Psychology, 74(3), 555.Google Scholar

Polk, S. E., Schulte, E. M., Furman, C. R. & Gearhardt, A. N. (2017). Wanting and liking: Separable components in problematic eating behavior? Appetite, 115, 45–53. doi:10.1016/j.appet.2016.11.015Google Scholar

Potenza, M. N. (2008). Review. The neurobiology of pathological gambling and drug addiction: an overview and new findings. Philosophical Transactions of the Royal Society, London B, 363(1507), 3181–3189. doi:10.1098/rstb.2008.0100Google Scholar

Pursey, K. M., Collins, C. E., Stanwell, P. & Burrows, T. L. (2015). Foods and dietary profiles associated with ‘food addiction’ in young adults. Addictive Behaviors Reports, 2, 41–48.Google Scholar

Robinson, M. J., Burghardt, P. R., Patterson, C. M., et al. (2015). Individual differences in cue-induced motivation and striatal systems in rats susceptible to diet-induced obesity. Neuropsychopharmacology, 40(9), 2113–2123. doi:10.1038/npp.2015.71Google Scholar

Rosen, J. C., Leitenberg, H., Fisher, C. & Khazam, C. (1986). Binge‐eating episodes in bulimia nervosa: The amount and type of food consumed. International Journal of Eating Disorders, 5(2), 255–267.Google Scholar

Ruddock, H. K., Christiansen, P., Halford, J. C. G. & Hardman, C. A. (2017). The development and validation of the Addiction-like Eating Behaviour Scale. International Journal of Obesity (London), 41(11), 1710–1717. doi:10.1038/ijo.2017.158Google Scholar

Russell‐Mayhew, S., von Ranson, K. M. & Masson, P. C. (2010). How does overeaters anonymous help its members? A qualitative analysis. European Eating Disorders Review, 18(1), 33–42.Google Scholar

Scherbaum, N., Kluwig, J., Specka, M., et al. (2005). Group psychotherapy for opiate addicts in methadone maintenance treatment – A controlled trial. European Addiction Research, 11(4), 163–171.Google Scholar

Schulte, E. M., Avena, N. M. & Gearhardt, A. N. (2015). Which foods may be addictive? The roles of processing, fat content, and glycemic load. PLoS ONE, 10(2), e0117959.Google Scholar

Schulte, E. M., Potenza, M. N. & Gearhardt, A. N. (2017a). A commentary on the “eating addiction” versus “food addiction” perspectives on addictive-like food consumption. Appetite, 115, 9–15. doi:10.1016/j.appet.2016.10.033Google Scholar

Schulte, E. M., Potenza, M. N. & Gearhardt, A. N. (2017b). How much does the addiction-like eating behaviour scale add to the debate regarding food versus eating addictions? International Journal of Obesity, 42(4), 946.Google Scholar

Schulte, E. M., Smeal, J. K. & Gearhardt, A. N. (2017). Foods are differentially associated with subjective effect report questions of abuse liability. PLoS ONE, 12(8), e0184220. doi:10.1371/journal.pone.0184220Google Scholar

Seidell, J. C. & Halberstadt, J. (2015). The global burden of obesity and the challenges of prevention. Annals of Nutrition and Metabolism, 66 (Supplement 2), 7–12. doi:10.1159/000375143Google Scholar

Sinha, R. (2001). How does stress increase risk of drug abuse and relapse? Psychopharmacology (Berlin), 158(4), 343–359. doi:10.1007/s002130100917Google Scholar

Smith, D. G. & Robbins, T. W. (2013). The neurobiological underpinnings of obesity and binge eating: A rationale for adopting the food addiction model. Biological Psychiatry, 73(9), 804–810. doi:10.1016/j.biopsych.2012.08.026Google Scholar

Sorenson, M. (2014). Food Addiction: Current Understanding and Implications for Regulation and Research. https://dash.harvard.edu/handle/1/11938740 Google Scholar

Stice, E., Burger, K. S. & Yokum, S. (2013). Relative ability of fat and sugar tastes to activate reward, gustatory, and somatosensory regions. American Journal of Clinical Nutrition, 98(6), 1377–1384. doi:10.3945/ajcn.113.069443Google Scholar

Sussman, S. (2017). Substance and Behavioral Addictions: Concepts, Causes, and Cures. Cambridge: Cambridge University Press.Google Scholar

Sylvain, C., Ladouceur, R. & Boisvert, J.-M. (1997). Cognitive and behavioral treatment of pathological gambling: A controlled study. Journal of Consulting and Clinical Psychology, 65(5), 727.Google Scholar

Toneatto, T. & Dragonetti, R. (2008). Effectiveness of community‐based treatment for problem gambling: A quasi‐experimental evaluation of cognitive‐behavioral vs. twelve‐step therapy. American Journal on Addictions, 17(4), 298–303.Google Scholar

Tryon, M. S., Stanhope, K. L., Epel, E. S., et al. (2015). Excessive sugar consumption may be a difficult habit to break: A view from the brain and body. Journal of Clinical Endocrinology and Metabolism, 100(6), 2239–2247. doi:10.1210/jc.2014-4353Google Scholar

Vanderlinden, J., Dalle Grave, R., Vandereycken, W. & Noorduin, C. (2001). Which factors do provoke binge-eating? An exploratory study in female students. Eating Behaviors, 2(1), 79–83.Google Scholar

Volkow, N. D. & Wise, R. A. (2005). How can drug addiction help us understand obesity? Nature Neuroscience, 8(5), 555–560. doi:10.1038/nn1452Google Scholar

Volkow, N. D., Wang, G. J., Fowler, J. S. & Telang, F. (2008). Overlapping neuronal circuits in addiction and obesity: Evidence of systems pathology. Philosophical Transactions of the Royal Society, London B, 363(1507), 3191–3200. doi:10.1098/rstb.2008.0107Google Scholar

Volkow, N. D., Wang, G. J., Fowler, J. S., Tomasi, D. & Baler, R. (2012). Food and drug reward: Overlapping circuits in human obesity and addiction. Current Topics in Behavioral Neurosciences, 11, 1–24. doi:10.1007/7854_2011_169Google Scholar

Wadden, T. A., Foster, G. D., Sarwer, D. B., et al. (2004). Dieting and the development of eating disorders in obese women: Results of a randomized controlled trial. American Journal of Clinical Nutrition, 80(3), 560–568.Google Scholar

Walsh, B. T., Kissileff, H. R., Cassidy, S. M. & Dantzic, S. (1989). Eating behavior of women with bulimia. Archives of General Psychiatry, 46(1), 54–58.Google Scholar

Wang, G. J., Volkow, N. D., Thanos, P. K. & Fowler, J. S. (2004). Similarity between obesity and drug addiction as assessed by neurofunctional imaging: A concept review. Journal of Addictive Diseases, 23(3), 39–53. doi:10.1300/J069v23n03_04Google Scholar

Waters, A., Hill, A. & Waller, G. (2001). Internal and external antecedents of binge eating episodes in a group of women with bulimia nervosa. International Journal of Eating Disorders, 29(1), 17–22.Google Scholar

Weingarten, H. P. & Elston, D. (1991). Food cravings in a college population. Appetite, 17(3), 167–175.Google Scholar

Welte, J. W., Barnes, G. M., Wieczorek, W. F., Tidwell, M. C. & Parker, J. C. (2004). Risk factors for pathological gambling. Addictive Behaviors, 29(2), 323–335.Google Scholar

White, M. A. & Grilo, C. M. (2005). Psychometric properties of the Food Craving Inventory among obese patients with binge eating disorder. Eating Behaviors, 6(3), 239–245. doi:10.1016/j.eatbeh.2005.01.001Google Scholar

Wilson, G. T. (2000). Eating disorders and addiction. Drugs & Society, 15(1–2), 87–101.Google Scholar

Yanovski, S. Z. (2003). Sugar and fat: Cravings and aversions. Journal of Nutrition, 133(3), 835S–837S.Google Scholar

Yanovski, S. Z., Leet, M., Yanovski, J. A., et al. (1992). Food selection and intake of obese women with binge-eating disorder. American Journal of Clinical Nutrition, 56(6), 975–980.Google Scholar

Zellner, D. A., Loaiza, S., Gonzalez, Z., et al. (2006). Food selection changes under stress. Physiology & Behavior, 87(4), 789–793. doi:10.1016/j.physbeh.2006.01.014Google Scholar

Ziauddeen, H. & Fletcher, P. C. (2013). Is food addiction a valid and useful concept? Obesity Reviews, 14(1), 19–28. doi:10.1111/j.1467-789X.2012.01046.xGoogle Scholar

Ziauddeen, H., Farooqi, I. S. & Fletcher, P. C. (2012). Obesity and the brain: How convincing is the addiction model? Nature Reviews Neuroscience, 13(4), 279–286.Google Scholar

References

Adams, J. & Kirkby, R. J. (2002). Excessive exercise as an addiction: A review. Addiction Research and Theory, 10, 415–437.Google Scholar

Adams, J. M., Miller, T. W. & Kraus, R. F. (2003). Exercise dependence: Diagnostic and therapeutic issues for patients in psychotherapy. Journal of Contemporary Psychotherapy, 33, 93–107.Google Scholar

American Psychiatric Association [APA] (2000). Diagnostic and Statistical Manual of Mental Disorders (4th edition, text revision). Washington, DC: American Psychiatric Publishing.Google Scholar

American Psychiatric Association [APA] (2013). Diagnostic and Statistical Manual of Mental Disorders (5th edition). Washington, DC: American Psychiatric Publishing.Google Scholar

American Psychological Association [APA] (2017). Personality. www.apa.org/topics/personality/Google Scholar

Anandkumar, S., Manivasagam, K., Kee, T. V. S. & Meyding-Lamade, U. (2018). Effect of physical therapy management of nonspecific low back pain with exercise addiction behaviors: A case series. Physiotherapy Theory and Practice, 34, 316–328. doi: 10.1080/09593985.2017.1394410Google Scholar

Andreassen, C. S., Griffiths, M. D., Gjertsen, S. R., et al. (2013). The relationship between behavioral addictions and the five-factor model of personality. Journal of Behavioral Addictions, 2, 90–99. doi: 10.1556/JBA.2.2013.003Google Scholar

Anderson, S. J., Basson, C. J. & Geils, C. (1997). Personality style and mood states associated with a negative addiction to running. Sports Medicine, 4, 6–11.Google Scholar

Baekeland, F. (1970). Exercise deprivation. Sleep and psychological reactions. Archives of General Psychiatry, 22, 365–369. doi: 10.1001/archpsyc.1970.01740280077014Google Scholar

Bamber, D., Cockerill, I. M. & Carroll, D. (2000). The pathological status of exercise dependence British Journal of Sports Medicine, 34, 125–132. doi: dx.doi.org/10.1136/bjsm.34.2.125Google Scholar

Berger, N., Muller, A., Brahler, E., Philipsen, A. & de Zwaan, M. (2014). Association of symptoms of attention-deficit/hyperactivity disorder with symptoms of excessive exercising in an adult general population sample. BMC Psychiatry, 14, 250. doi:10.1186/s12888-014-0250-7Google Scholar

Besser, A., Flett, G. L. & Hewitt, P. L. (2004). Perfectionism, cognition, and affect in response to performance failure vs. success. Journal of Rational-Emotive & Cognitive-Behavior Therapy, 22, 297–324. doi:10.1023/b:jore.0000047313.35872.5cGoogle Scholar

Blaydon, M. J. & Lindner, K. J. (2002). Eating disorders and exercise dependence in triathletes. Eating Disorder, 10(1), 49–60. doi: 10.1080/106402602753573559Google Scholar

Carmack, M. A. & Martens, R. (1979). Measuring commitment to running: A survey of runners’ attitudes and mental states. Journal of Sport Psychology, 1, 25–42. doi:10.1123/jsp.1.1.25Google Scholar

Chapman, C. L. & DeCastro, J. M. (1990). Running addiction: Measurement and associated psychological characteristics. The Journal of Sports Medicine and Physical Fitness, 30, 283–290.Google Scholar

Coen, S. P. & Ogles, B. M. (1993). Psychological characteristics of the obligatory runner: A critical examination of the anorexia analogue hypothesis. Journal of Sport & Exercise Psychology, 15, 338–354. doi:10.1123/jsep.15.3.338Google Scholar

Cook, B. J. & Hausenblas, H. A. (2011). Eating disorder specific health-related quality of life and exercise in college females. Quality of Life Research, 20, 1385–1390. doi:10.1007/s11136-011-9879-6Google Scholar

Cook, B. J., Hausenblas, H. A., Crosby, R. D., Cao, L. & Wonderlich, S. A. (2015). Exercise dependence as a mediator of the exercise and eating disorders relationship: A pilot study. Eating Behaviors, 16, 9–12. doi: 10.1016/j.eatbeh.2014.10.012Google Scholar

Cook, B. J., Hausenblas, H. A., Tuccitto, D. & Giacobbi, P. (2011). Eating disorders and exercise: A structural equation modeling analysis of a conceptual model. European Eating Disorders Review, 19, 216–225. doi: 10.1002/erv.1111Google Scholar

Cooke, L. M., Liardi, V. L. & Hall, C. R. (2011). Does the shoe FIT? An examination of the relationship of exercise identity with exercise frequency, intensity, and duration. Journal of Sport & Exercise Psychology, 33, 138–148.Google Scholar

Costa, S. & Oliva, P. (2011). Attività fisica e benessere: percezione del sé fisico e motivazione all’esercizio. [Physical activity and well-being: Physical self-perception and exercise motivation]”. GIPS, 12, 3–7.Google Scholar

Costa, S., Hausenblas, H. A., Oliva, P., Cuzzocrea, F. & Larcan, R. (2013). The role of age, gender, mood states and exercise frequency on exercise dependence. Journal of Behavioral Addictions, 2, 216–223. doi:10.1556/jba.2.2013.014Google Scholar

Cunningham, H. E., Pearman, S. & Brewerton, T. D. (2016). Conceptualizing primary and secondary pathological exercise using available measures of excessive exercise. International Journal of Eating Disorders, 49(8), 778–792. doi: 10.1002/eat.22551Google Scholar

Davis, C. & Fox, J. (1993). Excessive exercise and weight preoccupation in women. Addictive Behaviors, 18, 201–211. doi:10.1016/0306-4603(93)90050-jGoogle Scholar

Di Nicola, M., Martinotti, G., Mazza, M., et al. (2010). Quetiapine as add-on treatment for bipolar I disorder with comorbid compulsive buying and physical exercise addiction. Progress in Neuropsychopharmacology and Biological Psychiatry, 34, 713–714.Google Scholar

Di Nicola, M., Tedeschi, D., De Risio, L., et al. (2015). Co-occurrence of alcohol use disorder and behavioral addictions: Relevance of impulsivity and craving. Drug and Alcohol Dependence, 148, 118–125. doi:10.1016/j.drugalcdep.2014.12.028Google Scholar

Egorov, A. Y. & Szabo, A. (2013). The exercise paradox: An interactional model for a clearer conceptualization of exercise addiction. Journal of Behavioral Addictions, 2, 199–208. doi:10.1556/jba.2.2013.4.2Google Scholar

Flett, G. L. & Hewitt, P. L. (2005). The perils of perfectionism in sports and exercise. Current Directions in Psychological Science, 14, 14–18. doi:10.1111/j.0963-7214.2005.00326.xGoogle Scholar

Flett, G. L. & Hewitt, P. L. (2002). Perfectionism and maladjustment: An overview of theoretical, definitional, and treatment issues. In Flett, G. L. & Hewitt, P. L. (Eds.), Perfectionism: Theory, Research, and Treatment. American Psychological Association, pp. 5–31. https://doi.org/10.1037/10458-001 Google Scholar

Flett, G. L. & Hewitt, P. L. (2006). Positive versus negative perfectionism in psychopathology. Behavior Modification, 30, 472–495. doi:10.1177/0145445506288026Google Scholar

Flett, G. L., Pole-Langdon, L. & Hewitt, P. L. (2003). Trait perfectionism and perfectionistic self-presentation in compulsive exercise. Unpublished manuscript. York University, Toronto, Ontario, Canada.Google Scholar

Fairburn, C. G. & Beglin, S. J. (1994). Assessment of eating disorders: Interview or self-report questionnaire? International Journal of Eating Disorders, 16, 363–370. doi:10.1037/t03974-000Google Scholar

Freimuth, M. (2008). Addicted? Recognizing Destructive Behavior Before It’s Too Late. Lanham, MD: Rowman & Littlefield Publishers.Google Scholar

Freimuth, M., Moniz, S. & Kim, S. R. (2011). Clarifying exercise addiction: Differential diagnosis, co-occurring disorders, and phases of addiction. International Journal of Environmental Research and Public Health, 8, 4069–4081.Google Scholar

Garner, D. M., Olmstead, M.P. & Polivy, J. (1983). Development and validation of a multidimensional eating disorder inventory for anorexia nervosa and bulimia. International Journal of Eating Disorders, 2, 15–34. doi:10.1002/1098-108x(198321)2:2<15::aid-eat2260020203>3.0.co;2-6Google Scholar

Gayton, W. F., Loignon, A. C. & Porta, W. (2016). Exercise dependence: The dark side of exercise. Annals of Sports Medicine and Research, 3(7), 1085.Google Scholar

Glasser, W. (1976). Positive Addiction. New York, NY: Harper & Row.Google Scholar

Griffiths, M. (1996). Behavioural addiction: An issue for everybody? Employee Counselling Today, 8, 19–25. doi: 10.1108/13665629610116872Google Scholar

Griffiths, M., Szabo, A. & Terry, A. (2005). The exercise addiction inventory: A quick and easy screening tool for health practitioners. British Journal of Sports Medicine, 39, 346–347. doi: 10.1136/bjsm.2004.017020Google Scholar

Hagan, A. L. & Hausenblas, H. A. (2003). The relationship between exercise dependence symptoms and perfectionism. American Journal of Health Studies, 18, 133–137.Google Scholar

Hailey, B. J. & Bailey, L. A. (1982). Negative addiction in runners: A quantitative approach. Journal of Sport Behavior, 5, 150–154.Google Scholar

Hall, H. K., Hill, A. P., Appleton, P. R. & Kozub, S. A. (2009). The mediating influence of unconditional self-acceptance and labile self-esteem on the relationship between multidimensional perfectionism and exercise dependence. Psychology of Sport and Exercise,10, 35–44. doi:10.1016/j.psychsport.2008.05.003Google Scholar

Hart, E. A., Leary, M. R. & Rejeski, W. J. (1989). The measurement of social physique anxiety. Journal of Sport and Exercise Psychology, 11, 94–104.Google Scholar

Hausenblas, H. A. & Fallon, E. A. (2002). Relationship among body image, exercise behavior, and exercise dependence symptoms. International Journal of Eating Disorders, 32, 179–185. doi:10.1002/eat.10071Google Scholar

Hausenblas, H. A. & Giacobbi, P. R. Jr. (2004). Relationship between exercise dependence symptoms and personality. Personality and Individual Differences, 36, 1265–1273. doi:10.1016/s0191-8869(03)00214-9Google Scholar

Hausenblas, H. A. & Symons Downs, D. (2002). Exercise dependence: A systematic review. Psychology of Sport and Exercise, 3, 89–23. doi: 10.1016/s1469-0292(00)00015-7Google Scholar

Hausenblas, H. A., Cook, B. J. & Chittester, N. I. (2008). Can exercise treat eating disorders? Exercise and Sport Sciences Reviews, 36, 43–47. doi: 10.1097/jes.0b013e31815e4040Google Scholar

Hausenblas, H. A., Schreiber, K. & Smoliga, J. M. (2017). Practice pointer: Exercise addiction. BMJ, 26, 357. doi: 10.1136/bmj.j1745Google Scholar

Hewitt, P. L. & Flett, G. L. (1996). Personality traits and the coping process. In Zeidner, M. & Endler, N. S. (Eds.), Handbook of Coping: Theory, Research, Applications. Oxford, England: John Wiley & Sons, pp. 410–433.Google Scholar

Hewitt, P. L., Flett, G. L. & Ediger, E. (1996). Perfectionism and depression: Longitudinal assessment of a specific vulnerability hypothesis. Journal of Abnormal Psychology, 105, 276–280. doi:10.1037//0021-843x.105.2.276Google Scholar

Jee, Y.-S. (2016). Exercise addiction and rehabilitation. Journal of Exercise Rehabilitation, 12, 67–68.Google Scholar

Jibaja-Rusth, M. L. (1989). The development of a psycho-social risk profile for becoming an obligatory runner. Unpublished doctoral dissertation, University of Houston, Houston.Google Scholar

Korolenko, T. P. (1991). Addictive behavior: Its general traits and regular development. The Bekhterev Review of Psychiatry and Medical Psychology, 1, 8–15.Google Scholar

Lejoyeux, M., Avril, M., Embouazza, H. & Nivoli, F. (2008). Prevalence of exercise dependence and other behavioral addictions among clients of a Parisian fitness room. Comprehensive Psychiatry, 49, 353–358. doi: 10.1016/j.comppsych.2007.12.005Google Scholar

Lichtenstein, M. B., Christiansen, E., Elklit, A., Bilenberg, N. & Støving, R. K. (2014). Exercise addiction: A study of eating disorder symptoms, quality of life, personality traits and attachment styles. Psychiatry Research, 215, 410–416. doi:10.1016/j.psychres.2013.11.010Google Scholar

Lichtenstein, M. B., Hinze, C. J., Emborg, B., Thomsen, F. & Hemmingsen, S. D. (2017). Compulsive exercise: Links, risks and challenges faced. Psychology Research and Behavior Management, 30, 85–95. doi: 10.2147/PRBM.S113093.Google Scholar

Lu, F. J., Hsu, E. Y., Wang, J. M., et al. (2012). Exercisers’ identities and exercise dependence: The mediating effect of exercise commitment. Perceptual and Motor Skills, 115, 618–631. doi:10.2466/06.13.21.pms.115.5.618-631Google Scholar

Meulemans, S., Pribis, P., Grajales, T. & Krivak, G. (2014). Gender differences in exercise dependence and eating disorders in young adults: A path analysis of a conceptual model. Nutrients, 6, 4895–4905. doi: 10.3390/nu6114895Google Scholar

Miller, K. J. & Mesagno, C. (2014). Personality traits and exercise dependence: Exploring the role of narcissism and perfectionism. International Journal of Sport and Exercise Psychology, 12, 368–381. doi:10.1080/1612197x.2014.932821Google Scholar

Monok, K., Berczik, K., Urban, R., et al. (2012). Psychometric properties and concurrent validity of two exercise addiction measures: A population wide study. Psychology of Sport and Exercise, 13, 387–404. doi:10.1016/j.psychsport.2012.06.003Google Scholar

Morgan, W. P. (1979). Negative addiction in runners. The Physician and Sportsmedicine, 7, 57–77. doi:10.1080/00913847.1979.11948436Google Scholar

Murray, A. L., McKenzie, K., Newman, E. & Brown, E. (2013). Exercise identity as a risk factor for exercise dependence. British Journal of Health Psychology, 18, 369–382. doi: 10.1111/j.2044-8287.2012.02091Google Scholar

O’Connor, R. C. (2007). The relations between perfectionism and suicidality: A systematic review. Suicide and Life-Threatening Behavior, 37, 698–714. doi:10.1521/suli.2007.37.6.698Google Scholar

O’Connor, P. J. & Smith, J. C. (1999). Physical activity and eating disorders. In Rippe, J. M. (Ed.), Lifestyle Medicine. Cambridge, MA: Blackwell Science, pp. 1005–1015.Google Scholar

Oliva, P., Costa, S. & Rosalba, L. (2013). Physical self-concept and its relationship to exercise dependence symptoms in young regular physical exercisers. American Journal of Sports Science and Medicine, 1, 1–6.Google Scholar

Rudy, E. B. & Estok, P. J. (1989). Measurement and significance of negative addiction in runners. Western Journal of Nursing Research, 11, 548–558. doi:10.1177/019394598901100504Google Scholar

Sherry, S. B., Hewitt, P. L., Flett, G. L. & Harvey, M. (2003). Perfectionism dimensions, perfectionistic attitudes, dependent attitudes, and depression in psychiatric patients and university students. Journal of Counseling Psychology, 50, 373–386. doi:10.1037/0022-0167.50.3.373Google Scholar

Smith, D., Hale, B. D. & Collins, D. J. (1998). Measurement of exercise dependence in bodybuilders. Journal of Sports Medicine and Physical Fitness, 8, 1–9.Google Scholar

Spano, L. (2001). The relationship between exercise and anxiety, obsessive-compulsiveness, and narcissism. Personality and Individual Differences, 30, 87–93. doi:10.1016/s0191-8869(00)00012-xGoogle Scholar

Stets, J. E. & Burke, P. J. (2000). Identity theory and social identity theory. Social Psychology Quarterly, 63, 224. doi:10.2307/2695870Google Scholar

Stice, E., Presnell, K. & Spangler, D. (2002). Risk factors for binge eating onset in adolescent girls: A 2-year prospective investigation. Health Psychology, 21, 131–138. doi:10.1037//0278-6133.21.2.131Google Scholar

Symons Downs, D., Hausenblas, H. A. & Nigg, C. R. (2004). Factorial validity and psychometric examination of the exercise dependence scale-revised. Measurement in Physical Education and Exercise Science, 8(4), 183–201. doi: 10.1207/s15327841mpee0804_1Google Scholar

Szabo, A., Griffiths, M. D., de la Vega Marcos, R., Mervó, B. & Demetrovics, Z. (2015). Methodological and conceptual limitations in exercise addiction research. Yale Journal of Biology and Medicine, 88, 303–308.Google Scholar

Szabo, A., Griffiths, M. D., Høglid, R. A. & Demetrovics, Z. (2018). Drug, nicotine, and alcohol use among exercisers: Does substance addiction co-occur with exercise addiction? Addictive Behaviors Reports, 7, 26–31. doi:10.1016/j.abrep.2017.12.001Google Scholar

Terry, A., Szabo, A. & Griffiths, M. (2004). The exercise addiction inventory: A new brief screening tool. Addiction Research and Theory, 12, 489–499. doi:10.1080/16066350310001637363Google Scholar

Thornton, E. W. & Scott, S. E. (1995). Motivation in the committed runner: Correlations between self-report scales and behaviour. Health Promotion International, 10, 177–184.Google Scholar

Veale, D. (1987). Exercise dependence. British Journal of Addiction, 82, 735–740. doi:10.1111/j.1360-0443.1987.tb01539.xGoogle Scholar

Veale, D. (1995). Does primary exercise dependence really exist? In Annett, J., Cripps, B. & Steinberg, H. (Eds.), Exercise Addiction: Motivation for Participation in Sport and Exercise. Leicester, UK: British Psychological Society, pp. 1–5.Google Scholar

Villella, C., et al. (2010). Behavioural addictions in adolescents and young adults: Results from a prevalence study. Journal of Gambling Studies, 27, 203–214. doi: 10.1007/s10899-010-9206-0Google Scholar

References

American Psychiatric Association [APA] (2000). Diagnostic and Statistical Manual of Mental Disorders (4th edition). Washington, DC: American Psychiatric Association.Google Scholar

American Psychiatric Association [APA] (2013). Diagnostic and Statistical Manual of Mental Disorders (5th edition). Washington, DC: American Psychiatric Association.Google Scholar

Ashrafioun, L. & Bonar, E. E. (2014a). Development of a brief scale to assess frequency of symptoms and problems associated with tanning. Journal of the American Academy of Dermatology, 70(3), 588-589. doi:10.1016/j.jaad.2013.11.041Google Scholar

Ashrafioun, L. & Bonar, E. E. (2014b). Tanning addiction and psychopathology: Further evaluation of anxiety disorders and substance abuse. Journal of the American Academy of Dermatology, 70(3), 473–480. doi:10.1016/j.jaad.2013.10.057Google Scholar

Ashrafioun, L. & Bonar, E. E. (2015). Psychometric assessment of the craving to tan questionnaire. American Journal of Drug and Alcohol Abuse, 41(1), 74–81. doi:10.3109/00952990.2014.939754Google Scholar

Aubert, P. M., Seibyl, J. P., Price, J. L., et al. (2016). Dopamine efflux in response to ultraviolet radiation in addicted sunbed users. Psychiatry Research, 251, 7–14. doi:10.1016/j.pscychresns.2016.04.001Google Scholar

Aumann, T. D., Raabus, M., Tomas, D., et al. (2016). Differences in number of midbrain dopamine neurons associated with summer and winter photoperiods in humans. PLoS ONE, 11(7), e0158847. doi:10.1371/journal.pone.0158847Google Scholar

Baler, R. D. & Volkow, N. D. (2006). Drug addiction: the neurobiology of disrupted self-control. Trends in Molecular Medicine, 12(12), 559–566. doi:10.1016/j.molmed.2006.10.005Google Scholar

Banerjee, S. C., Hay, J. L. & Greene, K. (2013). Cognitive rationalizations for tanning-bed use: a preliminary exploration. American Journal of Health Behavior, 37(5), 577–586. doi:10.5993/ajhb.37.5.1Google Scholar

Berridge, K. C. & Robinson, T. E. (2016). Liking, wanting, and the incentive-sensitization theory of addiction. American Psychologist, 71(8), 670–679. doi:10.1037/amp0000059Google Scholar

Blum, K. et al. (2020). Precision Behavioral Management (PBM): a novel genetically guided therapy to combat Reward Deficiency Syndrome (RDS) relevant to the opiate crisis. In Sussman, S. (Ed.) The Cambridge Handbook of Substance and Behavioral Addictions. Cambridge, UK: Cambridge University Press, pp. 297–306Google Scholar

Boniol, M., Autier, P., Boyle, P. & Gandini, S. (2012). Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis. BMJ, 345, e4757. doi:10.1136/bmj.e4757Google Scholar

Cartmel, B., Dewan, A., Ferrucci, L. M., et al. (2014). Novel gene identified in an exome-wide association study of tanning dependence. Experimental Dermatology, 23(10), 757–759. doi:10.1111/exd.12503Google Scholar

Chait, S. R., Thompson, J. K. & Jacobsen, P. B. (2015). Preliminary development and evaluation of an appearance-based dissonance induction intervention for reducing UV exposure. Body Image, 12, 68–72. doi:10.1016/j.bodyim.2014.09.004Google Scholar

Dulcis, D., Jamshidi, P., Leutgeb, S. & Spitzer, N. C. (2013). Neurotransmitter switching in the adult brain regulates behavior. Science, 340(6131), 449–453. doi:10.1126/science.1234152Google Scholar

Earleywine, M., LaBrie, J. W. & Pedersen, E. R. (2008). A brief Rutgers Alcohol Problem Index with less potential for bias. Addictive Behaviors, 33(9), 1249–1253. doi:10.1016/j.addbeh.2008.05.006Google Scholar

FDA (2014). General and plastic surgery devices: reclassification of ultraviolet lamps for tanning, henceforth to be known as sunlamp products and ultraviolet lamps intended for use in sunlamp products. Final order. Federal Registister, 79(105), 31205–31214.Google Scholar

FDA (2015). General and plastic surgery devices: restricted sale, distribution, and use of sunlamp products. Retrieved from www.federalregister.gov/documents/2015/12/22/2015-32024/general-and-plastic-surgery-devices-restricted-sale-distribution-and-use-of-sunlamp-products Google Scholar

Feldman, S. R., Liguori, A., Kucenic, M., et al. (2004). Ultraviolet exposure is a reinforcing stimulus in frequent indoor tanners. Journal of the American Academy of Dermatology, 51(1), 45–51. doi:10.1016/j.jaad.2004.01.053Google Scholar

Fell, G. L., Robinson, K. C., Mao, J., Woolf, C. J. & Fisher, D. E. (2014). Skin beta-endorphin mediates addiction to UV light. Cell, 157(7), 1527–1534. doi:10.1016/j.cell.2014.04.032Google Scholar

Feng, J., Frisard, C., Nahar, V. K., et al. (2017). Gender differences in indoor tanning habits and location. Journal of the American Academy of Dermatology. doi:10.1016/j.jaad.2017.10.015Google Scholar

First, M., Spitzer, R., Gibbon, M. & Williams, J. (1995). Structured Clinical Interview for DSM-IV Axis I Disorders (SCID). New York: New York State Psychiatric Institute Biometrics Research Department.Google Scholar

Fisher, D. E. & James, W. D. (2010). Indoor tanning – science, behavior, and policy. New England Journal of Medicine, 363(10), 901–903. doi:10.1056/NEJMp1005999Google Scholar

Flannery, B. A., Volpicelli, J. R. & Pettinati, H. M. (1999). Psychometric properties of the Penn Alcohol Craving Scale. Alcoholism: Clinical and Experimental Research, 23(8), 1289–1295.Google Scholar

Flight, M. H. (2013). Synaptic transmission: summer blues. Nature Reviews Neuroscience, 14(6), 378. doi:10.1038/nrn3517Google Scholar

Flores, K. G., Erdei, E., Luo, L., et al. (2013). A pilot study of genetic variants in dopamine regulators with indoor tanning and melanoma. Experimental Dermatology, 22(9), 576–581. doi:10.1111/exd.12200Google Scholar

Gambichler, T., Bader, A., Vojvodic, M., et al. (2002). Plasma levels of opioid peptides after sunbed exposures. British Journal of Dermatology, 147(6), 1207–1211.Google Scholar

Gibbons, F. X., Gerrard, M., Lane, D. J., Mahler, H. I. & Kulik, J. A. (2005). Using UV photography to reduce use of tanning booths: a test of cognitive mediation. Health Psychology, 24(4), 358–363. doi:10.1037/0278-6133.24.4.358Google Scholar

Gillen, M. M. & Markey, C. N. (2012). The role of body image and depression in tanning behaviors and attitudes. Journal of Behavioral Medicine, 38(3), 74–82. doi:10.1080/08964289.2012.685499Google Scholar

Guy, G. P. Jr., Berkowitz, Z., Everett Jones, S., et al. (2015). Trends in indoor tanning among US high school students, 2009–2013. JAMA Dermatology, 151(4), 448–450. doi:10.1001/jamadermatol.2014.4677Google Scholar

Guy, G. P. Jr., Berkowitz, Z., Everett Jones, S., Watson, M. & Richardson, L. C. (2017). Prevalence of indoor tanning and association with sunburn among youth in the United States. JAMA Dermatology, 153(5), 387–390. doi:10.1001/jamadermatol.2016.6273Google Scholar

Guy, G. P. Jr., Berkowitz, Z., Jones, S. E., et al. (2014). State indoor tanning laws and adolescent indoor tanning. American Journal of Public Health, 104(4), e69–74. doi:10.2105/ajph.2013.301850Google Scholar

Guy, G. P. Jr., Berkowitz, Z., Watson, M., Holman, D. M. & Richardson, L. C. (2013). Indoor tanning among young non-Hispanic white females. JAMA Internal Medicine, 173(20), 1920–1922. doi:10.1001/jamainternmed.2013.10013Google Scholar

Guy, G. P. Jr., Watson, M., Richardson, L. C. & Lushniak, B. D. (2016). Reducing indoor tanning – an opportunity for melanoma prevention. JAMA Dermatology, 152(3), 257–259. doi:10.1001/jamadermatol.2015.3007Google Scholar

Harrington, C. R., Beswick, T. C., Graves, M., et al. (2012). Activation of the mesostriatal reward pathway with exposure to ultraviolet radiation (UVR) vs. sham UVR in frequent tanners: a pilot study. Addiction Biology, 17(3), 680–686. doi:10.1111/j.1369-1600.2010.00312.xGoogle Scholar

Harrington, C. R., Beswick, T. C., Leitenberger, J., et al. (2011). Addictive-like behaviours to ultraviolet light among frequent indoor tanners. Clinical and Experimental Dermatology, 36(1), 33–38. doi:10.1111/j.1365-2230.2010.03882.xGoogle Scholar

Heckman, C. J. & Manne, S. L. (2012). Shedding Light on Indoor Tanning. Dordrecht; New York: Springer.Google Scholar

Heckman, C. J., Cohen-Filipic, J., Darlow, S., et al. (2014a). Psychiatric and addictive symptoms of young adult female indoor tanners. American Journal of Health Promotion, 28(3), 168–174. doi:10.4278/ajhp.120912-QUAN-442Google Scholar

Heckman, C., Darlow, S., Cohen-Filipic, J. & Kloss, J. (2016). Mood changes after indoor tanning among college women: associations with psychiatric/addictive symptoms. Health Psychol Res, 4(1), 5453. doi:10.4081/hpr.2016.5453Google Scholar

Heckman, C. J., Darlow, S., Kloss, J. D., et al. (2014b). Measurement of tanning dependence. Journal of the European Academy of Dermatology and Venereology, 28(9), 1179–1185. doi:10.1111/jdv.12243Google Scholar

Heckman, C. J., Darlow, S. D., Kloss, J. D., Munshi, T. & Manne, S. L. (2015). Contextual factors, indoor tanning, and tanning dependence in young women. American Journal of Health Behavior, 39(3), 372–379. doi:10.5993/ajhb.39.3.10Google Scholar

Heckman, C. J., Egleston, B. L., Wilson, D. B. & Ingersoll, K. S. (2008). A preliminary investigation of the predictors of tanning dependence. American Journal of Health Behavior, 32(5), 451–464. doi:10.5555/ajhb.2008.32.5.451Google Scholar

Hillhouse, J. J. & Turrisi, R. (2002). Examination of the efficacy of an appearance-focused intervention to reduce UV exposure. Journal of Behavioral Medicine, 25(4), 395–409.Google Scholar

Hillhouse, J. J., Baker, M. K., Turrisi, R., et al. (2012). Evaluating a measure of tanning abuse and dependence. Archives of Dermatology, 148(7), 815–819. doi:10.1001/archdermatol.2011.2929Google Scholar

Hillhouse, J., Stapleton, J. & Turrisi, R. (2005). Association of frequent indoor UV tanning with seasonal affective disorder. Archives of Dermatology, 141(11), 1465. doi:10.1001/archderm.141.11.1465Google Scholar

Hillhouse, J., Turrisi, R. & Shields, A. L. (2007). Patterns of indoor tanning use: implications for clinical interventions. Archives of Dermatology, 143(12), 1530–1535. doi:10.1001/archderm.143.12.1530Google Scholar

Hillhouse, J., Turrisi, R., Stapleton, J. & Robinson, J. (2008). A randomized controlled trial of an appearance-focused intervention to prevent skin cancer. Cancer, 113(11), 3257–3266. doi:10.1002/cncr.23922Google Scholar

Hillhouse, J., Turrisi, R., Stapleton, J. & Robinson, J. (2010). Effect of seasonal affective disorder and pathological tanning motives on efficacy of an appearance-focused intervention to prevent skin cancer. Archives of Dermatology, 146(5), 485–491. doi:10.1001/archdermatol.2010.85Google Scholar

Holman, D. M., Fox, K. A., Glenn, J. D., et al. (2013). Strategies to reduce indoor tanning: current research gaps and future opportunities for prevention. American Journal of Preventative Medicine, 44(6), 672–681. doi:10.1016/j.amepre.2013.02.014Google Scholar

Jussila, A., Huotari-Orava, R., Ylianttila, L., Partonen, T. & Snellman, E. (2016). Narrow-band ultraviolet B radiation induces the expression of beta-endorphin in human skin in vivo. Journal of Photochemistry and Photobiology B, 155, 104–108. doi:10.1016/j.jphotobiol.2016.01.007Google Scholar

Kaur, M., Liguori, A., Lang, W., et al. (2006). Induction of withdrawal-like symptoms in a small randomized, controlled trial of opioid blockade in frequent tanners. Journal of the American Academy of Dermatology, 54(4), 709–711. doi:10.1016/j.jaad.2005.11.1059Google Scholar

Kourosh, A. S., Harrington, C. R. & Adinoff, B. (2010). Tanning as a behavioral addiction. American Journal of Drug and Alcohol Abuse, 36(5), 284–290. doi:10.3109/00952990.2010.491883Google Scholar

Le Foll, B., Gallo, A., Le Strat, Y., Lu, L. & Gorwood, P. (2009). Genetics of dopamine receptors and drug addiction: a comprehensive review. Behavioral Pharmacology, 20(1), 1–17. doi:10.1097/FBP.0b013e3283242f05Google Scholar

Leary, M. R., Saltzman, J. L. & Georgeson, J. C. (1997). Appearance motivation, obsessive-compulsive tendencies and excessive suntanning in a community sample. Journal of Health Psychology, 2(4), 493–499. doi:10.1177/135910539700200406Google Scholar

Levins, P. C., Carr, D. B., Fisher, J. E., Momtaz, K. & Parrish, J. A. (1983). Plasma beta-endorphin and beta-lipoprotein response to ultraviolet radiation. The Lancet, 2(8342), 166.Google Scholar

Levran, O., Yuferov, V. & Kreek, M. J. (2012). The genetics of the opioid system and specific drug addictions. Human Genetics, 131(6), 823–842. doi:10.1007/s00439-012-1172-4Google Scholar

Lim, H. W., James, W. D., Rigel, D. S., et al. (2011). Adverse effects of ultraviolet radiation from the use of indoor tanning equipment: time to ban the tan. Journal of the American Academy of Dermatology, 64(5), 893–902. doi:10.1016/j.jaad.2011.03.007Google Scholar

Mays, D., Atkins, M. B., Ahn, J. & Tercyak, K. P. (2017). Indoor tanning dependence in young adult women. Cancer Epidemiology, Biomarkers & Preention, 26(11), 1636–1643. doi:10.1158/1055-9965.EPI-17-0403Google Scholar

Miller, K. A., Piombo, S. E., Cho, J., et al. (2018). Prevalence of tanning addiction and behavioral health conditions among ethnically and racially diverse adolescents. Journal of Investigative Dermatology, 138(7), 1511–1517. doi:10.1016/j.jid.2018.02.018Google Scholar

Mosher, C. E. & Danoff-Burg, S. (2010a). Addiction to indoor tanning: relation to anxiety, depression, and substance use. Archives of Dermatology, 146(4), 412–417. doi:10.1001/archdermatol.2009.385Google Scholar

Mosher, C. E. & Danoff-Burg, S. (2010b). Indoor tanning, mental health, and substance use among college students: the significance of gender. Journal of Health Psychology, 15(6), 819–827. doi:10.1177/1359105309357091Google Scholar

Nilsen, L. T., Hannevik, M. & Veierod, M. B. (2016). Ultraviolet exposure from indoor tanning devices: a systematic review. British Journal of Dermatology, 174(4), 730–740. doi:10.1111/bjd.14388Google Scholar

NIMH (2018). Seasonal Affective Disorder. Retrieved from www.nimh.nih.gov/health/topics/seasonal-affective-disorder/index.shtml Google Scholar

Petit, A., Lejoyeux, M., Reynaud, M. & Karila, L. (2014). Excessive indoor tanning as a behavioral addiction: a literature review. Current Pharmaceutical Design, 20(25), 4070–4075.Google Scholar

Poorsattar, S. P. & Hornung, R. L. (2007). UV light abuse and high-risk tanning behavior among undergraduate college students. Journal of the American Academy of Dermatology, 56(3), 375–379. doi:10.1016/j.jaad.2006.08.064Google Scholar

Poorsattar, S. P. & Hornung, R. L. (2010). Tanning addiction: current trends and future treatment. Expert Review of Dermatology, 5(2), 123–125. doi:10.1586/edm.10.14Google Scholar

Rozin, P. & Stoess, C. (1993). Is there a general tendency to become addicted? Addictive Behavior, 18(1), 81–87.Google Scholar

Schneider, S., Schirmbeck, F., Bock, C., et al. (2015). Casting shadows on the prevalence of tanning dependence: an assessment of mCAGE criteria. Acta Dermato-Venereologica, 95(2), 162–168. doi:10.2340/00015555-1907Google Scholar

Seidenberg, A. B., Mahalingam-Dhingra, A., Weinstock, M. A., Sinclair, C. & Geller, A. C. (2015). Youth indoor tanning and skin cancer prevention: lessons from tobacco control. American Journal of Preventative Medicine, 48(2), 188–194. doi:10.1016/j.amepre.2014.08.034Google Scholar

Skobowiat, C., Dowdy, J. C., Sayre, R. M., Tuckey, R. C. & Slominski, A. (2011). Cutaneous hypothalamic-pituitary-adrenal axis homolog: regulation by ultraviolet radiation. American Journal of Physiology Endocrinology and Metabolism, 301(3), E484–493. doi:10.1152/ajpendo.00217.2011.10.1152/ajpendo.00217.2011Google Scholar

Spiro, J., Parker, S., Oliver, I., et al. (1987). Effect of PUVA on plasma and skin immunoreactive alpha-melanocyte stimulating hormone concentrations. British Journal of Dermatology, 117(6), 703–707.Google Scholar

Stapleton, J. L., Hillhouse, J., Levonyan-Radloff, K. & Manne, S. L. (2017). Review of interventions to reduce ultraviolet tanning: need for treatments targeting excessive tanning, an emerging addictive behavior. Psychology of Addictive Behaviors, 31(8), 962–978. doi:10.1037/adb0000289Google Scholar

Stapleton, J. L., Hillhouse, J. J., Turrisi, R., et al. (2016). The Behavioral Addiction Indoor Tanning Screener (BAITS): an evaluation of a brief measure of behavioral addictive symptoms. Acta Dermato-Venereologica, 96(4), 552–553. doi:10.2340/00015555-2290Google Scholar

Sussman, S. (2017). Substance and Behavioral Addictions: Concepts, Causes, and Cures. Cambridge, UK; New York, NY: Cambridge University Press.Google Scholar

Sussman, S. & Sussman, A. N. (2011). Considering the definition of addiction. International Journal of Environmental Research and Public Health, 8(10), 4025–4038. doi:10.3390/ijerph8104025Google Scholar

Turrisi, R., Mastroleo, N. R., Stapleton, J. & Mallett, K. (2008). A comparison of 2 brief intervention approaches to reduce indoor tanning behavior in young women who indoor tan very frequently. Archives of Dermatology, 144(11), 1521–1524. doi:10.1001/archderm.144.11.1521Google Scholar

US Congress, t. C., 2nd Session (2010). Compilation of patient protection and affordable care act, as amended through May 1, 2010. Chapter 49, Section 5000B. Imposition of tax on indoor tanning services. Retrieved from http://housedocs.house.gov/energycommerce/ppacacon.pdf Google Scholar

US Department of Health and Human Services (2014). The Surgeon General’s Call to Action to Prevent Skin Cancer. Washington, DC.Google Scholar

Volkow, N. D., Fowler, J. S., Wang, G. J. & Swanson, J. M. (2004). Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Molecular Psychiatry, 9(6), 557–569. doi:10.1038/sj.mp.4001507Google Scholar

Warlow, S. M. et al. (2020). Sensitization of incentive salience and the transition to addiction. In Sussman, S. (Ed.) The Cambridge Handbook of Substance and Behavioral Addictions. Cambridge, UK: Cambridge University Press, pp. 23–37.Google Scholar

Warthan, M. M., Uchida, T. & Wagner, R. F. Jr. (2005). UV light tanning as a type of substance-related disorder. Archives of Dermatology, 141(8), 963–966. doi:10.1001/archderm.141.8.963Google Scholar

Wintzen, M., de Winter, S., Out-Luiting, J. J., van Duinen, S. G. & Vermeer, B. J. (2001a). Presence of immunoreactive beta-endorphin in human skin. Experimental Dermatology, 10(5), 305–311.Google Scholar

Wintzen, M., Ostijn, D. M., Polderman, M. C., et al. (2001b). Total body exposure to ultraviolet radiation does not influence plasma levels of immunoreactive beta-endorphin in man. Photodermatology, Photoimmunology & Photomedicine, 17(6), 256–260.Google Scholar

World Health Organization (2018). Ultraviolet Radiation (UV). Retrieved from www.who.int/uv/en/Google Scholar

References

Abudy, A., Juven-Wetzler, A. & Zohar, J. (2011). Pharmacological management of treatment-resistant obsessive-compulsive disorder. CNS Drugs, 25(7), 585–596. https://doi.org/10.2165/11587860-000000000-00000 Google Scholar

Adler, L. A., Spencer, T. J., Milton, D. R., Moore, R. J. & Michelson, D. (2005). Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. The Journal of Clinical Psychiatry, 66(3), 294–299.Google Scholar

Alexander, B. K. & Schweighofer, A. R. F. (1988). Defining “addiction.” Canadian Psychology/Psychologie Canadienne, 29(2), 151–162. https://doi.org/10.1037/h0084530 Google Scholar

Alonso, P., Cuadras, D., Gabriëls, L., et al. (2015). Deep brain stimulation for obsessive-compulsive disorder: a meta-analysis of treatment outcome and predictors of response. PLoS ONE, 10(7), e0133591. https://doi.org/10.1371/journal.pone.0133591 Google Scholar

American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders (5th edition). Washington, DC: American Psychiatric Publishing.Google Scholar

Amiri, S., Farhang, S., Ghoreishizadeh, M. A., Malek, A. & Mohammadzadeh, S. (2012). Double-blind controlled trial of venlafaxine for treatment of adults with attention deficit/hyperactivity disorder. Human Psychopharmacology, 27(1), 76–81. https://doi.org/10.1002/hup.1274 Google Scholar

Anholt, G. E., van Oppen, P., Emmelkamp, P. M. G., et al. (2009). Measuring obsessive-compulsive symptoms: Padua Inventory-Revised vs. Yale-Brown Obsessive Compulsive Scale. Journal of Anxiety Disorders, 23(6), 830–835. https://doi.org/10.1016/j.janxdis.2009.04.004 Google Scholar

Argo, T. R. & Black, D. W. (2004). Clinical characteristics. In Pathological Gambling: A Clinical Guide to Treatment. Arlington, VA, US: American Psychiatric Publishing, Inc., pp. 39–53.Google Scholar

Arnsten, A. F. T. (2006a). Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways. The Journal of Clinical Psychiatry, 67 (Supplement 8), 7–12.Google Scholar

Arnsten, A. F. T. (2006b). Stimulants: therapeutic actions in ADHD. Neuropsychopharmacology, 31(11), 2376–2383. https://doi.org/10.1038/sj.npp.1301164 Google Scholar

Aron, A. R. & Poldrack, R. A. (2005). The cognitive neuroscience of response inhibition: relevance for genetic research in attention-deficit/hyperactivity disorder. Biological Psychiatry, 57(11), 1285–1292. https://doi.org/10.1016/j.biopsych.2004.10.026 Google Scholar

Aron, A. R., Dowson, J. H., Sahakian, B. J. & Robbins, T. W. (2003a). Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder. Biological Psychiatry, 54(12), 1465–1468.Google Scholar

Aron, A. R., Fletcher, P. C., Bullmore, E. T., Sahakian, B. J. & Robbins, T. W. (2003b). Stop-signal inhibition disrupted by damage to right inferior frontal gyrus in humans. Nature Neuroscience, 6(2), 115–116. https://doi.org/10.1038/nn1003 Google Scholar

Aron, A. R., Robbins, T. W. & Poldrack, R. A. (2014). Inhibition and the right inferior frontal cortex: one decade on. Trends in Cognitive Sciences, 18(4), 177–185. https://doi.org/10.1016/j.tics.2013.12.003 Google Scholar

Avena, N. M., Gearhardt, A. N., Gold, M. S., Wang, G.-J. & Potenza, M. N. (2012). Tossing the baby out with the bathwater after a brief rinse? The potential downside of dismissing food addiction based on limited data. Nature Reviews Neuroscience, 13(7), 514; author reply 514. https://doi.org/10.1038/nrn3212-c1 Google Scholar

Band, G. P. & van Boxtel, G. J. (1999). Inhibitory motor control in stop paradigms: review and reinterpretation of neural mechanisms. Acta Psychologica, 101(2–3), 179–211.Google Scholar

Bandelow, B., Zohar, J., Hollander, E. & WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disoders (2008). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision. The World Journal of Biological Psychiatry, 9(4), 248–312. https://doi.org/10.1080/15622970802465807 Google Scholar

Bari, A. & Robbins, T. W. (2013). Inhibition and impulsivity: behavioral and neural basis of response control. Progress in Neurobiology, 108, 44–79. https://doi.org/10.1016/j.pneurobio.2013.06.005 Google Scholar

Barkley, R. A. (1997). Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychological Bulletin, 121(1), 65–94. https://doi.org/10.1037/0033-2909.121.1.65 Google Scholar

Barkley, R. A. & Fischer, M. (2010). The unique contribution of emotional impulsiveness to impairment in major life activities in hyperactive children as adults. Journal of the American Academy of Child and Adolescent Psychiatry, 49(5), 503–513.Google Scholar

Bechara, A., Damasio, A. R., Damasio, H. & Anderson, S. W. (1994). Insensitivity to future consequences following damage to human prefrontal cortex. Cognition, 50(1–3), 7–15.Google Scholar

Bechara, A., Damasio, H., Tranel, D. & Anderson, S. W. (1998). Dissociation of working memory from decision making within the human prefrontal cortex. Journal of Neuroscience, 18(1), 428–437. https://doi.org/10.1523/JNEUROSCI.18-01-00428.1998 Google Scholar

Belin, D., Mar, A. C., Dalley, J. W., Robbins, T. W. & Everitt, B. J. (2008). High impulsivity predicts the switch to compulsive cocaine-taking. Science, 320(5881), 1352–1355. https://doi.org/10.1126/science.1158136 Google Scholar

Belin-Rauscent, A., Everitt, B. J. & Belin, D. (2012). Intrastriatal shifts mediate the transition from drug-seeking actions to habits. Biological Psychiatry, 72(5), 343–345. https://doi.org/10.1016/j.biopsych.2012.07.001 Google Scholar

Bernardi, S. & Pallanti, S. (2009). Internet addiction: a descriptive clinical study focusing on comorbidities and dissociative symptoms. Comprehensive Psychiatry, 50(6), 510–516. https://doi.org/10.1016/j.comppsych.2008.11.011 Google Scholar

Berns, G. S., Laibson, D. & Loewenstein, G. (2007). Intertemporal choice – toward an integrative framework. Trends in Cognitive Sciences, 11(11), 482–488. doi.org/10.1016/j.tics.2007.08.011 Google Scholar

Biederman, J. (2005). Attention-deficit/hyperactivity disorder: a selective overview. Biological Psychiatry, 57(11), 1215–1220. https://doi.org/10.1016/j.biopsych.2004.10.020 Google Scholar

Biederman, J., Spencer, T. & Wilens, T. (2004). Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder. The International Journal of Neuropsychopharmacology, 7(1), 77–97. https://doi.org/10.1017/S1461145703003973 Google Scholar

Bienvenu, O. J., Samuels, J. F., Wuyek, L. A., et al. (2012). Is obsessive-compulsive disorder an anxiety disorder, and what, if any, are spectrum conditions? A family study perspective. Psychological Medicine, 42(1), 1–13. https://doi.org/10.1017/S0033291711000742 Google Scholar

Billieux, J., Schimmenti, A., Khazaal, Y., Maurage, P. & Heeren, A. (2015). Are we overpathologizing everyday life? A tenable blueprint for behavioral addiction research. Journal of Behavioral Addictions, 4(3), 119–123. https://doi.org/10.1556/2006.4.2015.009 Google Scholar

Black, D. W. & Moyer, T. (1998). Clinical features and psychiatric comorbidity of subjects with pathological gambling behavior. Psychiatric Services, 49(11), 1434–1439. https://doi.org/10.1176/ps.49.11.1434 Google Scholar

Black, D. W., Moyer, T. & Schlosser, S. (2003). Quality of life and family history in pathological gambling. The Journal of Nervous and Mental Disease, 191(2), 124–126. https://doi.org/10.1097/01.NMD.0000050942.86352.47 Google Scholar

Blanco, C., Petkova, E., Ibáñez, A. & Sáiz-Ruiz, J. (2002). A pilot placebo-controlled study of fluvoxamine for pathological gambling. Annals of Clinical Psychiatry, 14(1), 9–15.Google Scholar

Boonstra, A. M., Kooij, J. J. S., Oosterlaan, J., Sergeant, J. A. & Buitelaar, J. K. (2005). Does methylphenidate improve inhibition and other cognitive abilities in adults with childhood-onset ADHD? Journal of Clinical and Experimental Neuropsychology, 27(3), 278–298. https://doi.org/10.1080/13803390490515757 Google Scholar

Bottesi, G., Ghisi, M., Ouimet, A. J., Tira, M. D. & Sanavio, E. (2015). Compulsivity and impulsivity in pathological gambling: does a dimensional-transdiagnostic approach add clinical utility to DSM-5 classification? Journal of Gambling Studies, 31(3), 825–847. https://doi.org/10.1007/s10899-014-9470-5 Google Scholar

Bowers, M. S., Chen, B. T. & Bonci, A. (2010). AMPA receptor synaptic plasticity induced by psychostimulants: the past, present, and therapeutic future. Neuron, 67(1), 11–24. https://doi.org/10.1016/j.neuron.2010.06.004 Google Scholar

Brady, K. T. & Randall, C. L. (1999). Gender differences in substance use disorders. The Psychiatric Clinics of North America, 22(2), 241–252.Google Scholar

Brewer, J. A. & Potenza, M. N. (2008). The neurobiology and genetics of impulse control disorders: relationships to drug addictions. Biochemical Pharmacology, 75(1), 63–75. https://doi.org/10.1016/j.bcp.2007.06.043 Google Scholar

Breyer, J. L., Botzet, A. M., Winters, K. C., et al. (2009). Young adult gambling behaviors and their relationship with the persistence of ADHD. Journal of Gambling Studies, 25(2), 227–238. https://doi.org/10.1007/s10899-009-9126-z Google Scholar

Burns, G. L., Keortge, S. G., Formea, G. M. & Sternberger, L. G. (1996). Revision of the Padua Inventory of obsessive compulsive disorder symptoms: distinctions between worry, obsessions, and compulsions. Behaviour Research and Therapy, 34(2), 163–173.Google Scholar

Carli, V., Durkee, T., Wasserman, D., et al. (2013). The association between pathological internet use and comorbid psychopathology: a systematic review. Psychopathology, 46(1), 1–13. https://doi.org/10.1159/000337971 Google Scholar

Chamberlain, S. & Fineberg, N. A. (2013). The neurobiology of obsessive-compulsive disorder. In Ochsner, K. N. & Kosslyn, S. (Eds.), The Oxford Handbook of Cognitive Neuroscience: Volume 2: The Cutting Edges. New York, NY: Oxford University Press. https://doi.org/10.1093/oxfordhb/9780199988709.013.0029 Google Scholar

Chamberlain, S. R. & Grant, J. E. (2018). Initial validation of a transdiagnostic compulsivity questionnaire: the Cambridge–Chicago Compulsivity Trait Scale. CNS Spectrums, 1–7. https://doi.org/10.1017/S1092852918000810 Google Scholar

Chamberlain, S. R., Müller, U., Blackwell, A. D., et al. (2006). Neurochemical modulation of response inhibition and probabilistic learning in humans. Science, 311(5762), 861–863. https://doi.org/10.1126/science.1121218 Google Scholar

Chambers, C. D., Bellgrove, M. A., Stokes, M. G., et al. (2006). Executive “brake failure” following deactivation of human frontal lobe. Journal of Cognitive Neuroscience, 18(3), 444–455. https://doi.org/10.1162/089892906775990606 Google Scholar

Chambers, R. A. & Potenza, M. N. (2003). Neurodevelopment, impulsivity, and adolescent gambling. Journal of Gambling Studies, 19(1), 53–84.Google Scholar

Chambers, R. A., Taylor, J. R. & Potenza, M. N. (2003). Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability. The American Journal of Psychiatry, 160(6), 1041–1052. https://doi.org/10.1176/appi.ajp.160.6.1041 Google Scholar

Clark, L. (2014). Disordered gambling: the evolving concept of behavioral addiction. Annals of the New York Academy of Sciences, 1327, 46–61. https://doi.org/10.1111/nyas.12558 Google Scholar

Clark, L. & Limbrick-Oldfield, E. H. (2013). Disordered gambling: a behavioral addiction. Current Opinion in Neurobiology, 23(4), 655–659. https://doi.org/10.1016/j.conb.2013.01.004 Google Scholar

Conversano, C., Marazziti, D., Carmassi, C., et al. (2012). Pathological gambling: a systematic review of biochemical, neuroimaging, and neuropsychological findings. Harvard Review of Psychiatry, 20(3), 130–148. https://doi.org/10.3109/10673229.2012.694318 Google Scholar

Corbisiero, S., Stieglitz, R.-D., Retz, W. & Rösler, M. (2013). Is emotional dysregulation part of the psychopathology of ADHD in adults? Attention Deficit and Hyperactivity Disorders, 5(2), 83–92. https://doi.org/10.1007/s12402-012-0097-z Google Scholar

Corbit, L. H., Nie, H. & Janak, P. H. (2012). Habitual alcohol seeking: time course and the contribution of subregions of the dorsal striatum. Biological Psychiatry, 72(5), 389–395. https://doi.org/10.1016/j.biopsych.2012.02.024 Google Scholar

Cuthbert, B. N. & Insel, T. R. (2013). Toward the future of psychiatric diagnosis: the seven pillars of RDoC. BMC Medicine, 11, 126. https://doi.org/10.1186/1741-7015-11-126 Google Scholar

Dalley, J. W., Everitt, B. J. & Robbins, T. W. (2011). Impulsivity, compulsivity, and top-down cognitive control. Neuron, 69(4), 680–694. https://doi.org/10.1016/j.neuron.2011.01.020 Google Scholar

Dalley, J. W., Mar, A. C., Economidou, D. & Robbins, T. W. (2008). Neurobehavioral mechanisms of impulsivity: fronto-striatal systems and functional neurochemistry. Pharmacology, Biochemistry, and Behavior, 90(2), 250–260. https://doi.org/10.1016/j.pbb.2007.12.021 Google Scholar

Daruna, J. H. & Barnes, P. A. (1993). A neurodevelopmental view of impulsivity. In The Impulsive Client: Theory, Research, and Treatment. Washington, DC: American Psychological Association, pp. 23–37. https://doi.org/10.1037/10500-002 Google Scholar

de Ruiter, M. B., Veltman, D. J., Goudriaan, A. E., et al. (2009). Response perseveration and ventral prefrontal sensitivity to reward and punishment in male problem gamblers and smokers. Neuropsychopharmacology, 34(4), 1027–1038. https://doi.org/10.1038/npp.2008.175 Google Scholar

Denys, D., Mantione, M., Figee, M., et al. (2010). Deep brain stimulation of the nucleus accumbens for treatment-refractory obsessive-compulsive disorder. Archives of General Psychiatry, 67(10), 1061–1068. https://doi.org/10.1001/archgenpsychiatry.2010.122 Google Scholar

Dodds, C. M., Morein-Zamir, S. & Robbins, T. W. (2011). Dissociating inhibition, attention, and response control in the frontoparietal network using functional magnetic resonance imaging. Cerebral Cortex, 21(5), 1155–1165. https://doi.org/10.1093/cercor/bhq187 Google Scholar

Eisen, J. L., Pinto, A., Mancebo, M. C., et al. (2010). A 2-year prospective follow-up study of the course of obsessive-compulsive disorder. The Journal of Clinical Psychiatry, 71(8), 1033–1039. https://doi.org/10.4088/JCP.08m04806blu Google Scholar

Ettelt, S., Ruhrmann, S., Barnow, S., et al. (2007). Impulsiveness in obsessive-compulsive disorder: results from a family study. Acta Psychiatrica Scandinavica, 115(1), 41–47. https://doi.org/10.1111/j.1600-0447.2006.00835.x Google Scholar

Evenden, J. L. (1999). Varieties of impulsivity. Psychopharmacology, 146(4), 348–361.Google Scholar

Everitt, B. J., Dickinson, A. & Robbins, T. W. (2001). The neuropsychological basis of addictive behaviour. Brain Research. Brain Research Reviews, 36(2–3), 129–138.Google Scholar

Everitt, B. J. & Robbins, T. W. (2005). Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nature Neuroscience, 8(11), 1481–1489. https://doi.org/10.1038/nn1579 Google Scholar

Everitt, B. J. & Robbins, T. W. (2013). From the ventral to the dorsal striatum: devolving views of their roles in drug addiction. Neuroscience & Biobehavioral Reviews, 37(9, Part A), 1946–1954. https://doi.org/10.1016/j.neubiorev.2013.02.010 Google Scholar

Eysenck, S. B. G., Pearson, P. R., Easting, G. & Allsopp, J. F. (1985). Age norms for impulsiveness, venturesomeness and empathy in adults. Personality and Individual Differences, 6(5), 613–619. https://doi.org/10.1016/0191-8869(85)90011-X Google Scholar

Faraone, S. V., Biederman, J., Spencer, T., et al. (2005). Efficacy of atomoxetine in adult attention-deficit/hyperactivity disorder: a drug-placebo response curve analysis. Behavioral and Brain Functions, 1, 16. https://doi.org/10.1186/1744-9081-1-16 Google Scholar

Faregh, N. & Derevensky, J. (2011). Gambling behavior among adolescents with attention deficit/hyperactivity disorder. Journal of Gambling Studies, 27(2), 243–256. https://doi.org/10.1007/s10899-010-9211-3 Google Scholar

Fayyad, J., De Graaf, R., Kessler, R., et al. (2007). Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. The British Journal of Psychiatry, 190, 402–409. https://doi.org/10.1192/bjp.bp.106.034389 Google Scholar

Fineberg, N. A., Apergis-Schoute, A. M., Vaghi, M. M., et al. (2018). Mapping compulsivity in the DSM-5 obsessive compulsive and related disorders: cognitive domains, neural circuitry, and treatment. The International Journal of Neuropsychopharmacology, 21(1), 42–58. https://doi.org/10.1093/ijnp/pyx088 Google Scholar

Fineberg, N. A., Brown, A., Reghunandanan, S. & Pampaloni, I. (2012). Evidence-based pharmacotherapy of obsessive-compulsive disorder. The International Journal of Neuropsychopharmacology, 15(8), 1173–1191. https://doi.org/10.1017/S1461145711001829 Google Scholar

Fineberg, N. A., Chamberlain, S. R., Goudriaan, A. E., et al. (2014). New developments in human neurocognition: clinical, genetic, and brain imaging correlates of impulsivity and compulsivity. CNS Spectrums, 19(1), 69–89. https://doi.org/10.1017/S1092852913000801 Google Scholar

Fineberg, N. A., Day, G. A., de Koenigswarter, N., et al. (2015). The neuropsychology of obsessive-compulsive personality disorder: a new analysis. CNS Spectrums, 20(5), 490–499. https://doi.org/10.1017/S1092852914000662 Google Scholar

Fineberg, N. A., Potenza, M. N., Chamberlain, S. R., et al.B (2010). Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative review. Neuropsychopharmacology, 35(3), 591–604. https://doi.org/10.1038/npp.2009.185 Google Scholar

Fineberg, N. A., Stein, D. J., Premkumar, P., et al. (2006). Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials. International Clinical Psychopharmacology, 21(6), 337–343. https://doi.org/10.1097/01.yic.0000215083.57801.11 Google Scholar

Foa, E. B. (2010). Cognitive behavioral therapy of obsessive-compulsive disorder. Dialogues in Clinical Neuroscience, 12(2), 199–207.Google Scholar

Fong, T. W., Reid, R. C. & Parhami, I. (2012). Behavioral addictions: where to draw the lines? The Psychiatric Clinics of North America, 35(2), 279–296. https://doi.org/10.1016/j.psc.2012.03.001 Google Scholar

Fontenelle, L. F., Oostermeijer, S., Harrison, B. J., Pantelis, C. & Yücel, M. (2011). Obsessive-compulsive disorder, impulse control disorders and drug addiction: common features and potential treatments. Drugs, 71(7), 827–840. https://doi.org/10.2165/11591790-000000000-00000 Google Scholar

Geller, D. A. (2006). Obsessive-compulsive and spectrum disorders in children and adolescents. The Psychiatric Clinics of North America, 29(2), 353–370. https://doi.org/10.1016/j.psc.2006.02.012 Google Scholar

Ghanizadeh, A., Freeman, R. D. & Berk, M. (2013). Efficacy and adverse effects of venlafaxine in children and adolescents with ADHD: a systematic review of non-controlled and controlled trials. Reviews on Recent Clinical Trials, 8(1), 2–8.Google Scholar

Gillan, C. M., Robbins, T. W., Sahakian, B. J., van den Heuvel, O. A. & van Wingen, G. (2016). The role of habit in compulsivity. European Neuropsychopharmacology, 26(5), 828–840. https://doi.org/10.1016/j.euroneuro.2015.12.033 Google Scholar

Grall-Bronnec, M., Wainstein, L., Augy, J., et al. (2011). Attention deficit hyperactivity disorder among pathological and at-risk gamblers seeking treatment: a hidden disorder. European Addiction Research, 17(5), 231–240. https://doi.org/10.1159/000328628 Google Scholar

Grant, J. E. (2008). Impulse Control Disorders: A Clinician’s Guide to Understanding and Treating Behavioral Addictions. New York: W. W. Norton.Google Scholar

Grant, J. E. (2014). Clinical practice: obsessive-compulsive disorder. The New England Journal of Medicine, 371(7), 646–653. https://doi.org/10.1056/NEJMcp1402176 Google Scholar

Grant, J. E. & Chamberlain, S. R. (2014). Impulsive action and impulsive choice across substance and behavioral addictions: cause or consequence? Addictive Behaviors, 39(11), 1632–1639. https://doi.org/10.1016/j.addbeh.2014.04.022 Google Scholar

Grant, J. E. & Chamberlain, S. R. (2016). Expanding the definition of addiction: DSM-5 vs. ICD-11. CNS Spectrums, 21(4), 300–303. https://doi.org/10.1017/S1092852916000183 Google Scholar

Grant, J. E. & Kim, S. W. (2001). Demographic and clinical features of 131 adult pathological gamblers. The Journal of Clinical Psychiatry, 62(12), 957–962.Google Scholar

Grant, J. E. & Kim, S. W. (2005). Quality of life in kleptomania and pathological gambling. Comprehensive Psychiatry, 46(1), 34–37. https://doi.org/10.1016/j.comppsych.2004.07.022 Google Scholar

Grant, J. E. & Potenza, M. N. (2006a). Compulsive aspects of impulse-control disorders. The Psychiatric Clinics of North America, 29(2), 539–551. https://doi.org/10.1016/j.psc.2006.02.002 Google Scholar

Grant, J. E. & Potenza, M. N. (2006b). Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation. International Clinical Psychopharmacology, 21(4), 203–209.Google Scholar

Grant, J. E., Brewer, J. A. & Potenza, M. N. (2006). The neurobiology of substance and behavioral addictions. CNS Spectrums, 11(12), 924–930.Google Scholar

Grant, J. E., Chamberlain, S. R., Odlaug, B. L., Potenza, M. N. & Kim, S. W. (2010a). Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: a pilot study. Psychopharmacology, 212(4), 603–612. https://doi.org/10.1007/s00213-010-1994-5 Google Scholar

Grant, J. E., Kim, S. W. & Odlaug, B. L. (2007). N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biological Psychiatry, 62(6), 652–657. https://doi.org/10.1016/j.biopsych.2006.11.021 Google Scholar

Grant, J. E., Kim, S. W. & Odlaug, B. L. (2009). A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania. Biological Psychiatry, 65(7), 600–606. https://doi.org/10.1016/j.biopsych.2008.11.022 Google Scholar

Grant, J. E., Kim, S. W., Potenza, M. N., et al. (2003). Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial. International Clinical Psychopharmacology, 18(4), 243–249. https://doi.org/10.1097/01.yic.0000073881.93678.21 Google Scholar

Grant, J. E., Odlaug, B. L. & Mooney, M. E. (2012). Telescoping phenomenon in pathological gambling: association with gender and comorbidities. The Journal of Nervous and Mental Disease, 200(11), 996–998. https://doi.org/10.1097/NMD.0b013e3182718a4d Google Scholar

Grant, J. E., Odlaug, B. L., Potenza, M. N., Hollander, E. & Kim, S. W. (2010b). Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study. The British Journal of Psychiatry, 197(4), 330–331. https://doi.org/10.1192/bjp.bp.110.078105 Google Scholar

Grant, J. E., Potenza, M. N., Hollander, E., et al. (2006). Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. The American Journal of Psychiatry, 163(2), 303–312. https://doi.org/10.1176/appi.ajp.163.2.303 Google Scholar

Grant, J. E., Potenza, M. N., Weinstein, A. & Gorelick, D. A. (2010c). Introduction to behavioral addictions. The American Journal of Drug and Alcohol Abuse, 36(5), 233–241. https://doi.org/10.3109/00952990.2010.491884 Google Scholar

Greenberg, B. D., Price, L. H., Rauch, S. L., et al. (2003). Neurosurgery for intractable obsessive-compulsive disorder and depression: critical issues. Neurosurgery Clinics of North America, 14(2), 199–212.Google Scholar

Greenberg, B. D., Rauch, S. L. & Haber, S. N. (2010). Invasive circuitry-based neurotherapeutics: stereotactic ablation and deep brain stimulation for OCD. Neuropsychopharmacology, 35(1), 317–336. https://doi.org/10.1038/npp.2009.128 Google Scholar

Greenhill, L. L., Biederman, J., Boellner, S. W., et al. (2006). A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 45(5), 503–511. https://doi.org/10.1097/01.chi.0000205709.63571.c9 Google Scholar

Gunstad, J. & Phillips, K. A. (2003). Axis I comorbidity in body dysmorphic disorder. Comprehensive Psychiatry, 44(4), 270–276. https://doi.org/10.1016/S0010-440X(03)00088-9 Google Scholar

Hasler, G., Kazuba, D. & Murphy, D. L. (2006). Factor analysis of obsessive-compulsive disorder YBOCS-SC symptoms and association with 5-HTTLPR SERT polymorphism. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, 141B(4), 403–408. https://doi.org/10.1002/ajmg.b.30309 Google Scholar

Hasler, G., LaSalle-Ricci, V. H., Ronquillo, J. G., et al. (2005). Obsessive-compulsive disorder symptom dimensions show specific relationships to psychiatric comorbidity. Psychiatry Research, 135(2), 121–132. https://doi.org/10.1016/j.psychres.2005.03.003 Google Scholar

Hodgins, D. C., Stea, J. N. & Grant, J. E. (2011). Gambling disorders. The Lancet, 378(9806), 1874–1884. https://doi.org/10.1016/S0140-6736(10)62185-X Google Scholar

Hogarth, L. & Chase, H. W. (2011). Parallel goal-directed and habitual control of human drug-seeking: implications for dependence vulnerability. Journal of Experimental Psychology: Animal Behavior Processes, 37(3), 261–276. https://doi.org/10.1037/a0022913 Google Scholar

Hogarth, L., Chase, H. W. & Baess, K. (2012). Impaired goal-directed behavioural control in human impulsivity. Quarterly Journal of Experimental Psychology, 65(2), 305–316. https://doi.org/10.1080/17470218.2010.518242 Google Scholar

Holden, C. (2001). “Behavioral” addictions: do they exist? Science, 294(5544), 980–982. https://doi.org/10.1126/science.294.5544.980 Google Scholar

Hollander, E. & Wong, C. M. (1995). Body dysmorphic disorder, pathological gambling, and sexual compulsions. The Journal of Clinical Psychiatry, 56 (Supplement 4), 7–12; discussion 13.Google Scholar

Hollander, E., DeCaria, C. M., Finkell, J. N., et al. (2000). A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling. Biological Psychiatry, 47(9), 813–817.Google Scholar

Hollander, E., Doernberg, E., Shavitt, R., et al.W (2016). The cost and impact of compulsivity: a research perspective. European Neuropsychopharmacology, 26(5), 800–809. https://doi.org/10.1016/j.euroneuro.2016.02.006 Google Scholar

Hong, S.-I., Sacco, P. & Cunningham-Williams, R. M. (2009). An empirical typology of lifetime and current gambling behaviors: association with health status of older adults. Aging & Mental Health, 13(2), 265–273. https://doi.org/10.1080/13607860802459849 Google Scholar

Insel, T., Cuthbert, B., Garvey, M., et al. (2010). Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. The American Journal of Psychiatry, 167(7), 748–751. https://doi.org/10.1176/appi.ajp.2010.09091379 Google Scholar

Jaffe, J. (1990). Drug addiction and drug abuse. In Gilman, A. G., Goodman, L. & Gilman, A. (Eds.), Goodman & Gilman’s The Pharmacological Basis of Therapeutics (6th edition). New York: Macmillan.Google Scholar

Jentsch, J. D. & Taylor, J. R. (1999). Impulsivity resulting from frontostriatal dysfunction in drug abuse: implications for the control of behavior by reward-related stimuli. Psychopharmacology, 146(4), 373–390.Google Scholar

Kable, J. W. & Glimcher, P. W. (2007). The neural correlates of subjective value during intertemporal choice. Nature Neuroscience, 10(12), 1625–1633. https://doi.org/10.1038/nn2007 Google Scholar

Kable, J. W. & Glimcher, P. W. (2009). The neurobiology of decision: consensus and controversy. Neuron, 63(6), 733–745. https://doi.org/10.1016/j.neuron.2009.09.003 Google Scholar

Kable, J. W. & Glimcher, P. W. (2010). An “as soon as possible” effect in human intertemporal decision making: behavioral evidence and neural mechanisms. Journal of Neurophysiology, 103(5), 2513–2531. https://doi.org/10.1152/jn.00177.2009 Google Scholar

Kalivas, P. W., Lalumiere, R. T., Knackstedt, L. & Shen, H. (2009). Glutamate transmission in addiction. Neuropharmacology, 56 (Supplement 1), 169–173. https://doi.org/10.1016/j.neuropharm.2008.07.011 Google Scholar

Kashyap, H., Fontenelle, L. F., Miguel, E. C., et al. (2012). “Impulsive compulsivity” in obsessive-compulsive disorder: a phenotypic marker of patients with poor clinical outcome. Journal of Psychiatric Research, 46(9), 1146–1152. https://doi.org/10.1016/j.jpsychires.2012.04.022 Google Scholar

Kenny, P. J. (2011). Reward mechanisms in obesity: new insights and future directions. Neuron, 69(4), 664–679. https://doi.org/10.1016/j.neuron.2011.02.016 Google Scholar

Kessler, R. C., Adler, L., Ames, M., et al. (2005). The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychological Medicine, 35(2), 245–256.Google Scholar

Kessler, R. C., Adler, L., Barkley, R., et al. (2006). The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. The American Journal of Psychiatry, 163(4), 716–723. https://doi.org/10.1176/ajp.2006.163.4.716 Google Scholar

Kessler, R. C., Berglund, P. A., Chiu, W. T., et al. (2013). The prevalence and correlates of binge eating disorder in the World Health Organization World Mental Health Surveys. Biological Psychiatry, 73(9), 904–914. https://doi.org/10.1016/j.biopsych.2012.11.020 Google Scholar

Kessler, R. C., McGonagle, K. A., Zhao, S., et al. (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey. Archives of General Psychiatry, 51(1), 8–19.Google Scholar

Keyes, K. M., Martins, S. S., Blanco, C. & Hasin, D. S. (2010). Telescoping and gender differences in alcohol dependence: new evidence from two national surveys. The American Journal of Psychiatry, 167(8), 969–976. https://doi.org/10.1176/appi.ajp.2009.09081161 Google Scholar

Kim, S. W. (1998). Opioid antagonists in the treatment of impulse-control disorders. The Journal of Clinical Psychiatry, 59(4), 159–164. https://doi.org/10.4088/JCP.v59n0403 Google Scholar

Kim, S. W., Grant, J. E., Adson, D. E. & Shin, Y. C. (2001). Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biological Psychiatry, 49(11), 914–921. https://doi.org/10.1016/S0006-3223(01)01079-4 Google Scholar

Kim, S. W., Grant, J. E., Adson, D. E., Shin, Y. C. & Zaninelli, R. (2002). A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. The Journal of Clinical Psychiatry, 63(6), 501–507.Google Scholar

Koob, G. F. & Le Moal, M. (2005). Plasticity of reward neurocircuitry and the “dark side” of drug addiction. Nature Neuroscience, 8(11), 1442–1444. https://doi.org/10.1038/nn1105-1442 Google Scholar

Koob, G. F. & Volkow, N. D. (2010). Neurocircuitry of addiction. Neuropsychopharmacology, 35(1), 217–238. https://doi.org/10.1038/npp.2009.110 Google Scholar

Kooij, J. J. S., Huss, M., Asherson, P., et al. (2012). Distinguishing comorbidity and successful management of adult ADHD. Journal of Attention Disorders, 16(5 Supplement), 3S–19S. https://doi.org/10.1177/1087054711435361 Google Scholar

Kor, A., Fogel, Y., Reid, R. C. & Potenza, M. N. (2013). Should hypersexual disorder be classified as an addiction? Sexual Addiction & Compulsivity, 20(1–2). https://doi.org/10.1080/10720162.2013.768132 Google Scholar

Laibson, D. (1997). Golden eggs and hyperbolic discounting. The Quarterly Journal of Economics, 112(2), 443–478. https://doi.org/10.1162/003355397555253 Google Scholar

Leckman, J. F., Denys, D., Simpson, H. B., et al. (2010). Obsessive-compulsive disorder: a review of the diagnostic criteria and possible subtypes and dimensional specifiers for DSM-V. Depression and Anxiety, 27(6), 507–527. https://doi.org/10.1002/da.20669 Google Scholar

Leckman, J. F., Grice, D. E., Boardman, J., et al. (1997). Symptoms of obsessive-compulsive disorder. The American Journal of Psychiatry, 154(7), 911–917. https://doi.org/10.1176/ajp.154.7.911 Google Scholar

Leeman, R. F. & Potenza, M. N. (2012). Similarities and differences between pathological gambling and substance use disorders: a focus on impulsivity and compulsivity. Psychopharmacology, 219(2), 469–490. https://doi.org/10.1007/s00213-011-2550-7 Google Scholar

Leeman, R. F. & Potenza, M. N. (2013). A targeted review of the neurobiology and genetics of behavioural addictions: an emerging area of research. Canadian Journal of Psychiatry, 58(5), 260–273. https://doi.org/10.1177/070674371305800503 Google Scholar

Leppink, E. W. & Grant, J. E. (2017). Pharmacological augmentations of SRIs for obsessive compulsive disorder. In The Wiley Handbook of Obsessive Compulsive Disorders. Wiley-Blackwell, pp. 311–340. https://doi.org/10.1002/9781118890233.ch16 Google Scholar

Limbrick-Oldfield, E. H., van Holst, R. J. & Clark, L. (2013). Fronto-striatal dysregulation in drug addiction and pathological gambling: consistent inconsistencies? NeuroImage Clinical, 2, 385–393. https://doi.org/10.1016/j.nicl.2013.02.005 Google Scholar

Lochner, C. & Stein, D. J. (2010). Obsessive-compulsive spectrum disorders in obsessive-compulsive disorder and other anxiety disorders. Psychopathology, 43(6), 389–396. https://doi.org/10.1159/000321070 Google Scholar

Logan, G. D., Cowan, W. B. & Davis, K. A. (1984). On the ability to inhibit simple and choice reaction time responses: a model and a method. Journal of Experimental Psychology: Human Perception and Performance, 10(2), 276–291.Google Scholar

Lopes, A. C., Greenberg, B. D., Norén, G., et al. (2009). Treatment of resistant obsessive-compulsive disorder with ventral capsular/ventral striatal gamma capsulotomy: a pilot prospective study. The Journal of Neuropsychiatry and Clinical Neurosciences, 21(4), 381–392. https://doi.org/10.1176/jnp.2009.21.4.381 Google Scholar

MacKillop, J., Weafer, J., Gray, J. C., et al. (2016). The latent structure of impulsivity: impulsive choice, impulsive action, and impulsive personality traits. Psychopharmacology, 233(18), 3361–3370. https://doi.org/10.1007/s00213-016-4372-0 Google Scholar

Maclaren, V. V., Fugelsang, J. A., Harrigan, K. A. & Dixon, M. J. (2011). The personality of pathological gamblers: a meta-analysis. Clinical Psychology Review, 31(6), 1057–1067. https://doi.org/10.1016/j.cpr.2011.02.002 Google Scholar

Madaan, V., Kinnan, S., Daughton, J. & Kratochvil, C. J. (2006). Innovations and recent trends in the treatment of ADHD. Expert Review of Neurotherapeutics, 6(9), 1375–1385. https://doi.org/10.1586/14737175.6.9.1375 Google Scholar

Makris, N., Rathi, Y., Mouradian, P., et al. (2016). Variability and anatomical specificity of the orbitofrontothalamic fibers of passage in the ventral capsule/ventral striatum (VC/VS): precision care for patient-specific tractography-guided targeting of deep brain stimulation (DBS) in obsessive compulsive disorder (OCD). Brain Imaging and Behavior, 10(4), 1054–1067. https://doi.org/10.1007/s11682-015-9462-9 Google Scholar

Malloy-Diniz, L., Fuentes, D., Leite, W. B., Correa, H. & Bechara, A. (2007). Impulsive behavior in adults with attention deficit/ hyperactivity disorder: characterization of attentional, motor and cognitive impulsiveness. Journal of the International Neuropsychological Society, 13(4), 693–698. https://doi.org/10.1017/S1355617707070889 Google Scholar

Mancebo, M. C., Eisen, J. L., Pinto, A., et al. (2006). The Brown Longitudinal Obsessive Compulsive Study: treatments received and patient impressions of improvement. The Journal of Clinical Psychiatry, 67(11), 1713–1720.Google Scholar

Martin, P. R. & Petry, N. M. (2005). Are non-substance-related addictions really addictions? The American Journal on Addictions, 14(1), 1–7. https://doi.org/10.1080/10550490590899808 Google Scholar

Mataix-Cols, D., Marks, I. M., Greist, J. H., Kobak, K. A. & Baer, L. (2002). Obsessive-compulsive symptom dimensions as predictors of compliance with and response to behaviour therapy: results from a controlled trial. Psychotherapy and Psychosomatics, 71(5), 255–262. https://doi.org/10.1159/000064812 Google Scholar

Mataix-Cols, D., Rauch, S. L., Manzo, P. A., Jenike, M. A. & Baer, L. (1999). Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. The American Journal of Psychiatry, 156(9), 1409–1416. https://doi.org/10.1176/ajp.156.9.1409 Google Scholar

Mataix-Cols, D., Rosario-Campos, M. C. do & Leckman, J. F. (2005). A multidimensional model of obsessive-compulsive disorder. The American Journal of Psychiatry, 162(2), 228–238. https://doi.org/10.1176/appi.ajp.162.2.228 Google Scholar

Mataix-Cols, D., Wooderson, S., Lawrence, N., et al. (2004). Distinct neural correlates of washing, checking, and hoarding symptom dimensions in obsessive-compulsive disorder. Archives of General Psychiatry, 61(6), 564–576. https://doi.org/10.1001/archpsyc.61.6.564 Google Scholar

Michelson, D., Adler, L., Spencer, T., et al. (2003). Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biological Psychiatry, 53(2), 112–120. https://doi.org/10.1016/S0006-3223(02)01671-2 Google Scholar

Moeller, F. G., Barratt, E. S., Dougherty, D. M., Schmitz, J. M. & Swann, A. C. (2001). Psychiatric aspects of impulsivity. The American Journal of Psychiatry, 158(11), 1783–1793. https://doi.org/10.1176/appi.ajp.158.11.1783 Google Scholar

Monterosso, J. R. & Luo, S. (2010). An argument against dual valuation system competition: cognitive capacities supporting future orientation mediate rather than compete with visceral motivations. Journal of Neuroscience, Psychology, and Economics, 3(1), 1–14. https://doi.org/10.1037/a0016827 Google Scholar

Morasco, B. J. & Petry, N. M. (2006). Gambling problems and health functioning in individuals receiving disability. Disability and Rehabilitation, 28(10), 619–623. https://doi.org/10.1080/09638280500242507 Google Scholar

Mortier, P., Demyttenaere, K., Nock, M. K., et al. (2015). [The epidemiology of ADHD in first-year university students]. Tijdschrift Voor Psychiatrie, 57(9), 635–644.Google Scholar

Narayanaswamy, J. C., Viswanath, B., Veshnal Cherian, A., et al. (2012). Impact of age of onset of illness on clinical phenotype in OCD. Psychiatry Research, 200(2–3), 554–559. https://doi.org/10.1016/j.psychres.2012.03.037 Google Scholar

Neal, D. T., Wood, W. & Quinn, J. M. (2006). Habits – a repeat performance. Current Directions in Psychological Science, 15(4), 198–202. https://doi.org/10.1111/j.1467-8721.2006.00435.x Google Scholar

Nelson, A. & Killcross, S. (2006). Amphetamine exposure enhances habit formation. The Journal of Neuroscience, 26(14), 3805–3812. https://doi.org/10.1523/JNEUROSCI.4305-05.2006 Google Scholar

Nigg, J. T. (2013). Attention-deficit/hyperactivity disorder and adverse health outcomes. Clinical Psychology Review, 33(2), 215–228. https://doi.org/10.1016/j.cpr.2012.11.005 Google Scholar

Nordin, C., Gupta, R. C. & Sjödin, I. (2007). Cerebrospinal fluid amino acids in pathological gamblers and healthy controls. Neuropsychobiology, 56(2–3), 152–158. https://doi.org/10.1159/000115782 Google Scholar

O’Brien, C. P., Volkow, N. & Li, T.-K. (2006). What’s in a word? Addiction versus dependence in DSM-V. The American Journal of Psychiatry, 163(5), 764–765. https://doi.org/10.1176/ajp.2006.163.5.764 Google Scholar

Odlaug, B. L., Lust, K., Schreiber, L. R. N., et al. (2013). Compulsive sexual behavior in young adults. Annals of Clinical Psychiatry, 25(3), 193–200.Google Scholar

Olive, M. F., Cleva, R. M., Kalivas, P. W. & Malcolm, R. J. (2012). Glutamatergic medications for the treatment of drug and behavioral addictions. Pharmacology, Biochemistry, and Behavior, 100(4), 801–810. https://doi.org/10.1016/j.pbb.2011.04.015 Google Scholar

Oquendo, M. A. & Mann, J. J. (2000). The biology of impulsivity and suicidality. The Psychiatric Clinics of North America, 23(1), 11–25.Google Scholar

Owen, A. M., Roberts, A. C., Polkey, C. E., Sahakian, B. J. & Robbins, T. W. (1991). Extra-dimensional versus intra-dimensional set shifting performance following frontal lobe excisions, temporal lobe excisions or amygdalo-hippocampectomy in man. Neuropsychologia, 29(10), 993–1006.Google Scholar

Pallesen, S., Molde, H., Arnestad, H. M., et al. (2007). Outcome of pharmacological treatments of pathological gambling: a review and meta-analysis. Journal of Clinical Psychopharmacology, 27(4), 357–364. https://doi.org/10.1097/jcp.013e3180dcc304d Google Scholar

Patton, J. H., Stanford, M. S. & Barratt, E. S. (1995). Factor structure of the Barratt Impulsiveness Scale. Journal of Clinical Psychology, 51(6), 768–774.Google Scholar

Peters, J. & Büchel, C. (2011). The neural mechanisms of inter-temporal decision-making: understanding variability. Trends in Cognitive Sciences, 15(5), 227–239. https://doi.org/10.1016/j.tics.2011.03.002 Google Scholar

Petry, N. M. (2006). Should the scope of addictive behaviors be broadened to include pathological gambling? Addiction, 101 (Supplement 1), 152–160. https://doi.org/10.1111/j.1360-0443.2006.01593.x Google Scholar

Petry, N. M. & Kiluk, B. D. (2002). Suicidal ideation and suicide attempts in treatment-seeking pathological gamblers. The Journal of Nervous and Mental Disease, 190(7), 462–469. https://doi.org/10.1097/01.NMD.0000022447.27689.96 Google Scholar

Petry, N. M. & O’Brien, C. P. (2013). Internet gaming disorder and the DSM-5. Addiction, 108(7), 1186–1187. https://doi.org/10.1111/add.12162 Google Scholar

Petry, N. M., Stinson, F. S. & Grant, B. F. (2005). Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. The Journal of Clinical Psychiatry, 66(5), 564–574.Google Scholar

Phillips, K. A., Menard, W., Fay, C. & Weisberg, R. (2005). Demographic characteristics, phenomenology, comorbidity, and family history in 200 individuals with body dysmorphic disorder. Psychosomatics, 46(4), 317–325. https://doi.org/10.1176/appi.psy.46.4.317 Google Scholar

Phillips, K. A., Stein, D. J., Rauch, S., et al. (2010). Should an obsessive-compulsive spectrum grouping of disorders be included in DSM-V? Depression and Anxiety, 27(6), 528–555. https://doi.org/10.1002/da.20705 Google Scholar

Pittenger, C., Bloch, M. H. & Williams, K. (2011). Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. Pharmacology & Therapeutics, 132(3), 314–332. https://doi.org/10.1016/j.pharmthera.2011.09.006 Google Scholar

Potenza, M. N. (2006). Should addictive disorders include non-substance-related conditions? Addiction, 101 (Supplement 1), 142–151. https://doi.org/10.1111/j.1360-0443.2006.01591.x Google Scholar

Potenza, M. N. (2007). Impulsivity and compulsivity in pathological gambling and obsessive-compulsive disorder. Revista Brasileira De Psiquiatria, 29(2), 105–106.Google Scholar

Potenza, M. N. (2008). Review. The neurobiology of pathological gambling and drug addiction: an overview and new findings. Philosophical Transactions of the Royal Society of London, Series B, Biological Sciences, 363(1507), 3181–3189. https://doi.org/10.1098/rstb.2008.0100 Google Scholar

Potenza, M. N. (2014). Non-substance addictive behaviors in the context of DSM-5. Addictive Behaviors, 39(1), 1–2. https://doi.org/10.1016/j.addbeh.2013.09.004 Google Scholar

Potenza, M. N., Balodis, I. M., Franco, C. A., et al. (2013). Neurobiological considerations in understanding behavioral treatments for pathological gambling. Psychology of Addictive Behaviors, 27(2), 380–392. https://doi.org/10.1037/a0032389 Google Scholar

Reddy, Y. C. J., Alur, A. M., Manjunath, S., Kandavel, T. & Math, S. B. (2010). Long-term follow-up study of patients with serotonin reuptake inhibitor-nonresponsive obsessive-compulsive disorder. Journal of Clinical Psychopharmacology, 30(3), 267–272. https://doi.org/10.1097/JCP.0b013e3181dbfb53 Google Scholar

Reed, D. D. et al. (2020). Behavioral economic considerations of novel addictions and nonaddictive behavior: research and analytic methods. In Sussman, S. (Ed.) The Cambridge Handbook of Substance and Behavioral Addictions. Cambridge, UK: Cambridge University Press, pp. 73–86.Google Scholar

Reghunandanan, S., Fineberg, N. A. & Stein, D. J. (2015). Pathogenesis. In Reghunandanan, S., Fineberg, N. A. & Stein, D. J. (Eds.), Obsessive-Compulsive and Related Disorders. New York, NY: Oxford University Press, pp. 13–35.Google Scholar

Reid, R. C. (2013). Personal perspectives on hypersexual disorder. Sexual Addiction & Compulsivity, 20(1–2), 4–18. https://doi.org/10.1080/10720162.2013.772876 Google Scholar

Reid, R. C., Carpenter, B. N., Hook, J. N., et al. (2012). Report of findings in a DSM-5 field trial for hypersexual disorder. The Journal of Sexual Medicine, 9(11), 2868–2877. https://doi.org/10.1111/j.1743-6109.2012.02936.x Google Scholar

Robbins, T. W. (2017). Cross-species studies of cognition relevant to drug discovery: a translational approach. British Journal of Pharmacology, 174(19), 3191–3199. https://doi.org/10.1111/bph.13826 Google Scholar

Robbins, T. W., Gillan, C. M., Smith, D. G., de Wit, S. & Ersche, K. D. (2012). Neurocognitive endophenotypes of impulsivity and compulsivity: towards dimensional psychiatry. Trends in Cognitive Sciences, 16(1), 81–91. https://doi.org/10.1016/j.tics.2011.11.009 Google Scholar

Rodriguez, C. I., Kegeles, L. S., Levinson, A., et al. (2013). Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology, 38(12), 2475–2483. https://doi.org/10.1038/npp.2013.150 Google Scholar

Rogers, R. D., Everitt, B. J., Baldacchino, A., et al. (1999). Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depleted normal volunteers: evidence for monoaminergic mechanisms. Neuropsychopharmacology, 20(4), 322–339. https://doi.org/10.1016/S0893-133X(98)00091-8 Google Scholar

Ruscio, A. M., Stein, D. J., Chiu, W. T. & Kessler, R. C. (2010). The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Molecular Psychiatry, 15(1), 53–63. https://doi.org/10.1038/mp.2008.94 Google Scholar

Saiz-Ruiz, J., Blanco, C., Ibáñez, A., et al. (2005). Sertraline treatment of pathological gambling: a pilot study. The Journal of Clinical Psychiatry, 66(1), 28–33.Google Scholar

Samuel, D. B. & Widiger, T. A. (2011). Conscientiousness and obsessive-compulsive personality disorder. Personality Disorders, 2(3), 161–174. https://doi.org/10.1037/a0021216 Google Scholar

Sanavio, E. (1988). Obsessions and compulsions: the Padua Inventory. Behaviour Research and Therapy, 26(2), 169–177.Google Scholar

Scherrer, J. F., Xian, H., Slutske, W. S., Eisen, S. A. & Potenza, M. N. (2015). Associations between obsessive-compulsive classes and pathological gambling in a national cohort of male twins. JAMA Psychiatry, 72(4), 342–349. https://doi.org/10.1001/jamapsychiatry.2014.2497 Google Scholar

Schultz, W. (2011). Potential vulnerabilities of neuronal reward, risk, and decision mechanisms to addictive drugs. Neuron, 69(4), 603–617. https://doi.org/10.1016/j.neuron.2011.02.014 Google Scholar

Shaffer, H. J. (1999). On the nature and meaning of addiction. National Forum, 79(4), 9–14.Google Scholar

Sica, C., Bottesi, G., Orsucci, A., et al. (2015). “Not Just Right Experiences” are specific to obsessive-compulsive disorder: further evidence from Italian clinical samples. Journal of Anxiety Disorders, 31, 73–83. https://doi.org/10.1016/j.janxdis.2015.02.002 Google Scholar

Simpson, H. B., Maher, M. J., Wang, Y., et al. (2011). Patient adherence predicts outcome from cognitive behavioral therapy in obsessive-compulsive disorder. Journal of Consulting and Clinical Psychology, 79(2), 247–252. https://doi.org/10.1037/a0022659 Google Scholar

Simpson, H. B., Shungu, D. C., Bender, J., et al. (2012). Investigation of cortical glutamate–glutamine and γ-aminobutyric acid in obsessive–compulsive disorder by proton magnetic resonance spectroscopy. Neuropsychopharmacology, 37(12), 2684–2692. https://doi.org/10.1038/npp.2012.132 Google Scholar

Skoog, G. & Skoog, I. (1999). A 40-year follow-up of patients with obsessive-compulsive disorder. Archives of General Psychiatry, 56(2), 121–127.Google Scholar

Slutske, W. S. (2006). Natural recovery and treatment-seeking in pathological gambling: results of two U.S. national surveys. The American Journal of Psychiatry, 163(2), 297–302. https://doi.org/10.1176/appi.ajp.163.2.297 Google Scholar

Stanford, M. S., Mathias, C. W., Dougherty, D. M., et al. (2009). Fifty years of the Barratt Impulsiveness Scale: an update and review. Personality and Individual Differences, 47(5), 385–395. https://doi.org/10.1016/j.paid.2009.04.008 Google Scholar

Starcevic, V., Berle, D., Brakoulias, V., et al. (2013). Obsessive-compulsive personality disorder co-occurring with obsessive-compulsive disorder: conceptual and clinical implications. The Australian and New Zealand Journal of Psychiatry, 47(1), 65–73. https://doi.org/10.1177/0004867412450645 Google Scholar

Stein, D. J., Hollander, E., Simeon, D. & Cohen, L. (1994). Impulsivity scores in patients with obsessive-compulsive disorder. The Journal of Nervous and Mental Disease, 182(4), 240–241.Google Scholar

Sulzer, D. (2011). How addictive drugs disrupt presynaptic dopamine neurotransmission. Neuron, 69(4), 628–649. https://doi.org/10.1016/j.neuron.2011.02.010 Google Scholar

Swann, A. C., Lijffijt, M., Lane, S. D., Steinberg, J. L. & Moeller, F. G. (2009). Trait impulsivity and response inhibition in antisocial personality disorder. Journal of Psychiatric Research, 43(12), 1057–1063. https://doi.org/10.1016/j.jpsychires.2009.03.003 Google Scholar

van den Heuvel, O. A., Remijnse, P. L., Mataix-Cols, D., et al. (2009). The major symptom dimensions of obsessive-compulsive disorder are mediated by partially distinct neural systems. Brain, 132(4), 853–868. https://doi.org/10.1093/brain/awn267 Google Scholar

van den Heuvel, O. A., van Wingen, G., Soriano-Mas, C., et al. (2016). Brain circuitry of compulsivity. European Neuropsychopharmacology, 26(5), 810–827. https://doi.org/10.1016/j.euroneuro.2015.12.005 Google Scholar

van Emmerik-van Oortmerssen, K., van de Glind, G., van den Brink, W., et al. (2012). Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis. Drug and Alcohol Dependence, 122(1–2), 11–19. https://doi.org/10.1016/j.drugalcdep.2011.12.007 Google Scholar

van Holst, R. J., van den Brink, W., Veltman, D. J. & Goudriaan, A. E. (2010a). Brain imaging studies in pathological gambling. Current Psychiatry Reports, 12(5), 418–425. https://doi.org/10.1007/s11920-010-0141-7 Google Scholar

van Holst, R. J., van den Brink, W., Veltman, D. J. & Goudriaan, A. E. (2010b). Why gamblers fail to win: a review of cognitive and neuroimaging findings in pathological gambling. Neuroscience & Biobehavioral Reviews, 34(1), 87–107. https://doi.org/10.1016/j.neubiorev.2009.07.007 Google Scholar

Vanes, L. D., van Holst, R. J., Jansen, J. M., et al. (2014). Contingency learning in alcohol dependence and pathological gambling: learning and unlearning reward contingencies. Alcoholism, Clinical and Experimental Research, 38(6), 1602–1610. https://doi.org/10.1111/acer.12393 Google Scholar

Volkow, N. D. & Li, T.-K. (2004). Drug addiction: the neurobiology of behaviour gone awry. Nature Reviews Neuroscience, 5(12), 963–970. https://doi.org/10.1038/nrn1539 Google Scholar

Voon, V., Derbyshire, K., Rück, C., et al. (2015). Disorders of compulsivity: a common bias towards learning habits. Molecular Psychiatry, 20(3), 345–352. https://doi.org/10.1038/mp.2014.44 Google Scholar

Wareham, J. D. & Potenza, M. N. (2010). Pathological gambling and substance use disorders. The American Journal of Drug and Alcohol Abuse, 36(5), 242–247. https://doi.org/10.3109/00952991003721118 Google Scholar

Wilens, T. E. (2006). Mechanism of action of agents used in attention-deficit/hyperactivity disorder. The Journal of Clinical Psychiatry, 67 (Supplement 8), 32–38.Google Scholar

Winstanley, C. A., Eagle, D. M. & Robbins, T. W. (2006). Behavioral models of impulsivity in relation to ADHD: translation between clinical and preclinical studies. Clinical Psychology Review, 26(4), 379–395. https://doi.org/10.1016/j.cpr.2006.01.001 Google Scholar

Wood, W., Quinn, J. M. & Kashy, D. A. (2002). Habits in everyday life: thought, emotion, and action. Journal of Personality and Social Psychology, 83(6), 1281–1297.Google Scholar

Wu, K., Hanna, G. L., Rosenberg, D. R. & Arnold, P. D. (2012). The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder. Pharmacology, Biochemistry, and Behavior, 100(4), 726–735. https://doi.org/10.1016/j.pbb.2011.10.007 Google Scholar

Ziauddeen, H. & Fletcher, P. C. (2013). Is food addiction a valid and useful concept? Obesity Reviews, 14(1), 19–28. https://doi.org/10.1111/j.1467-789X.2012.01046.x Google Scholar

Ziauddeen, H., Farooqi, I. S. & Fletcher, P. C. (2012a). Food addiction: is there a baby in the bathwater? Nature Reviews Neuroscience, 13(7), 514. https://doi.org/10.1038/nrn3212-c2 Google Scholar

Ziauddeen, H., Farooqi, I. S. & Fletcher, P. C. (2012b). Obesity and the brain: how convincing is the addiction model? Nature Reviews Neuroscience, 13(4), 279–286. https://doi.org/10.1038/nrn3212 Google Scholar

Zohar, J. & Insel, T. R. (1987). Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology. Biological Psychiatry, 22(6), 667–687.Google Scholar

References

Albertella, L., Le Pelley, M. E., Yücel, M. & Copeland, J. (2018). Age moderates the association between frequent cannabis use and negative schizotypy over time. Addictive Behaviors, 87, 183–189.Google Scholar

Bersani, G., Orlandi, V., Gherardelli, S. & Pancheri, P. (2002). Cannabis and neurological soft signs in schizophrenia: absence of relationship and influence on psychopathology. Psychopathology, 35(5), 289–295.Google Scholar

Bickel, W. K., Jarmolowicz, D. P., Mueller, E. T. & Gatchalian, K. M. (2011). The behavioral economics and neuroeconomics of reinforcer pathologies: implications for etiology and treatment of addiction. Current Psychiatry Reports, 13(5), 406.Google Scholar

Bovasso, G. B. (2001). Cannabis abuse as a risk factor for depressive symptoms. American Journal of Psychiatry, 158(12), 2033–2037.Google Scholar

Brikmanis, K., Petersen, A. & Doran, N. (2017). Do personality traits related to affect regulation predict other tobacco product use among young adult non-daily smokers? Addictive Behaviors, 75, 79–84.Google Scholar

Bruijnzeel, A. W. & Markou, A. (2003). Characterization of the effects of bupropion on the reinforcing properties of nicotine and food in rats. Synapse, 50(1), 20–28.Google Scholar

Cano, M. Á., de Dios, M. A., Correa-Fernández, V., et al. (2017). Depressive symptom domains and alcohol use severity among Hispanic emerging adults: examining moderating effects of gender. Addictive Behaviors, 72, 72–78.Google Scholar

Carleton, R. N., Thibodeau, M. A., Teale, M. J., et al. (2013). The center for epidemiologic studies depression scale: a review with a theoretical and empirical examination of item content and factor structure. PLoS ONE, 8(3), e58067.Google Scholar

Carroll, K. M., Nich, C., Frankforter, T. L., et al. (2018). Accounting for the uncounted: physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder. Drug and Alcohol Dependence, 192, 264–270.Google Scholar

Carton, L., Pignon, B., Baguet, A., et al. (2018). Influence of comorbid alcohol use disorders on the clinical patterns of major depressive disorder: a general population-based study. Drug and Alcohol Dependence, 187, 40–47.Google Scholar

Chuang, C. W. I., Chan, C. & Leventhal, A. M. (2016). Adolescent emotional pathology and lifetime history of alcohol or drug use with and without comorbid tobacco use. Journal of Dual Diagnosis, 12(1), 27–35.Google Scholar

Cho, J., Stone, M. D. & Leventhal, A. M. (2019). Anhedonia as a phenotypic marker of familial transmission of polysubstance use trajectories across midadolescence. Psychology of Addictive Behaviors, 33(1), 15–25.Google Scholar

Cobb, N. K., Byron, M. J., Abrams, D. B. & Shields, P. G. (2010). Novel nicotine delivery systems and public health: the rise of the “e-cigarette”. American Journal of Public Health, 100(12), 2340–2342.Google Scholar

Cohen, A. S., Najolia, G. M., Brown, L. A. & Minor, K. S. (2011). The state-trait disjunction of anhedonia in schizophrenia: potential affective, cognitive and social-based mechanisms. Clinical Psychology Review, 31(3), 440–448.Google Scholar

Cook, J. W., Lanza, S. T., Chu, W., Baker, T. B. & Piper, M. E. (2017). Anhedonia: its dynamic relations with craving, negative affect, and treatment during a quit smoking attempt. Nicotine & Tobacco Research, 19(6), 703–709.Google Scholar

Cook, J. W., Piper, M. E., Leventhal, A. M., et al. (2015). Anhedonia as a component of the tobacco withdrawal syndrome. Journal of Abnormal Psychology, 124(1), 215.Google Scholar

Creamer, M. R., Perry, C. L., Harrell, M. B. & Diamond, P. M. (2015). Trends in multiple tobacco product use among high school students. Tobacco Regulatory Science, 1(3), 204–214.Google Scholar

Crits-Christoph, P., Wadden, S., Gaines, A., et al. (2018). Symptoms of anhedonia, not depression, predict the outcome of treatment of cocaine dependence. Journal of Substance Abuse Treatment, 92, 46–50.Google Scholar

Cryan, J. F., Dalvi, A., Jin, , et al. (2001). Use of dopamine-β-hydroxylase-deficient mice to determine the role of norepinephrine in the mechanism of action of antidepressant drugs. Journal of Pharmacology and Experimental Therapeutics, 298(2), 651–657.Google Scholar

Cryan, J. F., O'Leary, O. F., Jin, S. H., et al. (2004). Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. Proceedings of the National Academy of Sciences, 101(21), 8186–8191.Google Scholar

Curtin, S. C., Tejada-Vera, B. & Warmer, M. (2017). Drug overdose deaths among adolescents aged 15–19 in the United States: 1999-2015. NCHS Data Brief, 282, 1–8.Google Scholar

Daughters, S. B., Magidson, J. F., Anand, D., et al. (2018). The effect of a behavioral activation treatment for substance use on post‐treatment abstinence: a randomized controlled trial. Addiction, 113(3), 535–544.Google Scholar

D’Souza, M. S. & Markou, A. (2010). Neural substrates of psychostimulant withdrawal-induced anhedonia. In Behavioral Neuroscience of Drug Addiction. Berlin, Heidelberg: Springer, pp. 119–178.Google Scholar

Davis, C. & Woodside, D. B. (2002). Sensitivity to the rewarding effects of food and exercise in the eating disorders. Comprehensive Psychiatry, 43(3), 189–194.Google Scholar

Deng, Y., Chang, L., Yang, M., Huo, M. & Zhou, R. (2016). Gender differences in emotional response: inconsistency between experience and expressivity. PLoS ONE, 11(6), e0158666.Google Scholar

Dervaux, A., Laqueille, X., Bourdel, M. C., Olié, J. P. & Krebs, M. O. (2010). Impulsivity and sensation seeking in alcohol abusing patients with schizophrenia. Frontiers in Psychiatry, 1, 135.Google Scholar

Dorard, G., Berthoz, S., Phan, O., Corcos, M. & Bungener, C. (2008). Affect dysregulation in cannabis abusers. European Child & Adolescent Psychiatry, 17(5), 274–282.Google Scholar

Dumas, P., Saoud, M., Bouafia, S., et al. (2002). Cannabis use correlates with schizotypal personality traits in healthy students. Psychiatry Research, 109(1), 27–35.Google Scholar

Dutra, L., Stathopoulou, G., Basden, S. L., et al. (2008). A meta-analytic review of psychosocial interventions for substance use disorders. American Journal of Psychiatry, 165(2), 179–187.Google Scholar

Eiber, R., Berlin, I., de Brettes, B., Foulon, C. & Guelfi, J. D. (2002). Hedonic response to sucrose solutions and the fear of weight gain in patients with eating disorders. Psychiatry Research, 113(1–2), 173–180.Google Scholar

Erwin, M. C., Charak, R., Durham, T. A., et al. (2017). The 7-factor hybrid model of DSM-5 PTSD symptoms and alcohol consumption and consequences in a national sample of trauma-exposed veterans. Journal of Anxiety Disorders, 51, 14–21.Google Scholar

Fawcett, J., Clark, D. C., Scheftner, W. A. & Gibbons, R. D. (1983). Assessing anhedonia in psychiatric patients: the pleasure scale. Archives of General Psychiatry, 40(1), 79–84.Google Scholar

Feingold, D., Rehm, J. & Lev-Ran, S. (2017). Cannabis use and the course and outcome of major depressive disorder: a population based longitudinal study. Psychiatry Research, 251, 225–234.Google Scholar

Fiore, M. C., Jaen, C. R., Baker, T. B., et al. (2008). Treating Tobacco Use and Dependence: 2008 Update. Rockville, MD: US Department of Health and Human Services.Google Scholar

Fiorito, E. R. & Simons, R. F. (1994). Emotional imagery and physical anhedonia. Psychophysiology, 31(5), 513–521.Google Scholar

Franken, I. H., Zijlstra, C. & Muris, P. (2006). Are nonpharmacological induced rewards related to anhedonia? A study among skydivers. Progress in Neuro-psychopharmacology and Biological Psychiatry, 30(2), 297–300.Google Scholar

Gard, D. E., Gard, M. G., Kring, A. M. & John, O. P. (2006). Anticipatory and consummatory components of the experience of pleasure: a scale development study. Journal of Research in Personality, 40(6), 1086–1102.Google Scholar

Garfield, J. B., Cotton, S. M., Allen, N. B., et al. (2017). Evidence that anhedonia is a symptom of opioid dependence associated with recent use. Drug and Alcohol Dependence, 177, 29–38.Google Scholar

Garfield, J. B., Lubman, D. I. & Yücel, M. (2014). Anhedonia in substance use disorders: a systematic review of its nature, course and clinical correlates. Australian & New Zealand Journal of Psychiatry, 48(1), 36–51.Google Scholar

Garland, E. L., Froeliger, B. & Howard, M. O. (2014). Effects of Mindfulness-Oriented Recovery Enhancement on reward responsiveness and opioid cue-reactivity. Psychopharmacology, 231(16), 3229–3238.Google Scholar

Garland, E. L., Froeliger, B. & Howard, M. O. (2015). Neurophysiological evidence for remediation of reward processing deficits in chronic pain and opioid misuse following treatment with Mindfulness-Oriented Recovery Enhancement: exploratory ERP findings from a pilot RCT. Journal of Behavioral Medicine, 38(2), 327–336.Google Scholar

Geschwind, N., Peeters, F., Drukker, M., van Os, J. & Wichers, M. (2011). Mindfulness training increases momentary positive emotions and reward experience in adults vulnerable to depression: a randomized controlled trial. Journal of Consulting and Clinical Psychology, 79(5), 618.Google Scholar

Guillot, C. R., Halliday, T. M., Kirkpatrick, M. G., Pang, R. D. & Leventhal, A. M. (2017). Anhedonia and abstinence as predictors of the subjective pleasantness of positive, negative, and smoking-related pictures. Nicotine & Tobacco Research, 19(6), 743–749.Google Scholar

Hall, W. & Lynskey, M. (2016). Evaluating the public health impacts of legalizing recreational cannabis use in the United States. Addiction, 111(10), 1764–1773.Google Scholar

Harvey, P. O., Pruessner, J., Czechowska, Y. & Lepage, M. (2007). Individual differences in trait anhedonia: a structural and functional magnetic resonance imaging study in non-clinical subjects. Molecular Psychiatry, 12(8), 767.Google Scholar

Haslam, A. K., Correa-Fernández, V., Hoover, D. S., et al. (2018). Anhedonia and smoking cessation among Spanish-speaking Mexican-Americans. Health Psychology, 37(9), 814.Google Scholar

Hatzigiakoumis, D. S., Martinotti, G., Di Giannantonio, M. & Janiri, L. (2011). Anhedonia and substance dependence: clinical correlates and treatment options. Frontiers in Psychiatry, 2, 10.Google Scholar

Heirene, R. M., Shearer, D., Roderique-Davies, G. & Mellalieu, S. D. (2016). Addiction in extreme sports: an exploration of withdrawal states in rock climbers. Journal of Behavioral Addictions, 5(2), 332–341.Google Scholar

Higgins, S. T., Silverman, K. & Heil, S. H. (Eds.) (2007). Contingency Management in Substance Abuse Treatment. Guilford Press.Google Scholar

Hughes, J. R., Budney, A. J., Muellers, S. R., et al. (2017). Does tobacco abstinence decrease reward sensitivity? A human laboratory test. Nicotine & Tobacco Research, 19(6), 677–685.Google Scholar

Huhn, A. S., Meyer, R. E., Harris, J. D., et al. (2016). Evidence of anhedonia and differential reward processing in prefrontal cortex among post-withdrawal patients with prescription opiate dependence. Brain Research Bulletin, 123, 102–109.Google Scholar

Huys, Q. J., Pizzagalli, D. A., Bogdan, R. & Dayan, P. (2013). Mapping anhedonia onto reinforcement learning: a behavioural meta-analysis. Biology of Mood & Anxiety Disorders, 3(1), 12.Google Scholar

Janiri, L., Martinotti, G., Dario, T., et al. (2005). Anhedonia and substance-related symptoms in detoxified substance-dependent subjects: a correlation study. Neuropsychobiology, 52(1), 37–44.Google Scholar

Johnson, K. A., Bonn-Miller, M. O., Leyro, T. M. & Zvolensky, M. J. (2009). Anxious arousal and anhedonic depression symptoms and the frequency of current marijuana use: testing the mediating role of marijuana-use coping motives among active users. Journal of Studies on Alcohol and Drugs, 70(4), 543–550.Google Scholar

Kahler, C. W., Spillane, N. S., Day, A., et al. (2014). Positive psychotherapy for smoking cessation: treatment development, feasibility, and preliminary results. The Journal of Positive Psychology, 9(1), 19–29.Google Scholar

Kahler, C. W., Spillane, N. S., Day, A. M., et al. (2015). Positive psychotherapy for smoking cessation: a pilot randomized controlled trial. Nicotine & Tobacco Research, 17(11), 1385–1392.Google Scholar

Kelley, A. E. & Berridge, K. C. (2002). The neuroscience of natural rewards: relevance to addictive drugs. Journal of Neuroscience, 22(9), 3306–3311.Google Scholar

Kirkpatrick, M. G., Goldenson, N. I., Kapadia, N., et al. (2016). Emotional traits predict individual differences in amphetamine-induced positive mood in healthy volunteers. Psychopharmacology, 233(1), 89–97.Google Scholar

Koob, G. F. & Le Moal, M. (2001). Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology, 24(2), 97.Google Scholar

Krupitsky, E. M., Burakov, A. M., Didenko, T. Y., et al. (2002). Effects of citalopram treatment of protracted withdrawal (syndrome of anhedonia) in patients with heroin addiction. Addictive Disorders & Their Treatment, 1(1), 29–33.Google Scholar

Krupitsky, E., Zvartau, E., Blokhina, E., et al. (2016). Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant. The American Journal of Drug and Alcohol Abuse, 42(5), 614–620.Google Scholar

Lawn, W., Freeman, T. P., Pope, R. A., et al. (2016). Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis ‘amotivational’ hypotheses. Psychopharmacology, 233(19–20), 3537–3552.Google Scholar

Lee, Y. O., Hebert, C. J., Nonnemaker, J. M. & Kim, A. E. (2015). Youth tobacco product use in the United States. Pediatrics, 135(3), 409–415.Google Scholar

Leibenluft, E., Fiero, P. L., Bartko, J. J., Moul, D. E. & Rosenthal, N. E. (1993). Depressive symptoms and the self-reported use of alcohol, caffeine, and carbohydrates in normal volunteers and four groups of psychiatric outpatients. American Journal of Psychiatry, 150, 294–294.Google Scholar

Lejuez, C. W., Hopko, D. R. & Hopko, S. D. (2001). A brief behavioral activation treatment for depression: treatment manual. Behavior Modification, 25(2), 255–286.Google Scholar

Leventhal, A. M. & Zvolensky, M. J. (2015). Anxiety, depression, and cigarette smoking: a transdiagnostic vulnerability framework to understanding emotion–smoking comorbidity. Psychological Bulletin, 141(1), 176.Google Scholar

Leventhal, A. M., Brightman, M., Ameringer, K. J., et al. (2010). Anhedonia associated with stimulant use and dependence in a population-based sample of American adults. Experimental and Clinical Psychopharmacology, 18(6), 562.Google Scholar

Leventhal, A. M., Chasson, G. S., Tapia, E., Miller, E. K. & Pettit, J. W. (2006). Measuring hedonic capacity in depression: a psychometric analysis of three anhedonia scales. Journal of Clinical Psychology, 62(12), 1545–1558.Google Scholar

Leventhal, A. M., Cho, J., Stone, M. D., et al. (2017). Associations between anhedonia and marijuana use escalation across mid‐adolescence. Addiction, 112(12), 2182–2190.Google Scholar

Leventhal, A. M., Piper, M. E., Japuntich, S. J., Baker, T. B. & Cook, J. W. (2014). Anhedonia, depressed mood, and smoking cessation outcome. Journal of Consulting and Clinical Psychology, 82(1), 122.Google Scholar

Leventhal, A. M., Ramsey, S. E., Brown, R. A., LaChance, H. R. & Kahler, C. W. (2008). Dimensions of depressive symptoms and smoking cessation. Nicotine & Tobacco Research, 10(3), 507–517.Google Scholar

Leventhal, A. M., Strong, D. R., Sussman, S., et al. (2016). Psychiatric comorbidity in adolescent electronic and conventional cigarette use. Journal of Psychiatric Research, 73, 71–78.Google Scholar

Lichlyter, B., Purdon, S. & Tibbo, P. (2011). Predictors of psychosis severity in individuals with primary stimulant addictions. Addictive Behaviors, 36(1–2), 137–139.Google Scholar

Liverant, G. I., Sloan, D. M., Pizzagalli, D. A., et al. (2014). Associations among smoking, anhedonia, and reward learning in depression. Behavior Therapy, 45(5), 651–663.Google Scholar

Liu, C. H. & Tronick, E. (2014). Prevalence and predictors of maternal postpartum depressed mood and anhedonia by race and ethnicity. Epidemiology and Psychiatric Sciences, 23(2), 201–209.Google Scholar

Lubman, D. I., Garfield, J. B., Gwini, S. M., et al. (2018). Dynamic associations between opioid use and anhedonia: a longitudinal study in opioid dependence. Journal of Psychopharmacology, 32(9), 957–964.Google Scholar

Luby, J. L., Agrawal, A., Belden, A., et al. (2018). Developmental trajectories of the orbitofrontal cortex and anhedonia in middle childhood and risk for substance use in adolescence in a longitudinal sample of depressed and healthy preschoolers. American Journal of Psychiatry, 175(10), 1010–1021.Google Scholar

MacPherson, L., Tull, M. T., Matusiewicz, A. K., et al. (2010). Randomized controlled trial of behavioral activation smoking cessation treatment for smokers with elevated depressive symptoms. Journal of Consulting and Clinical Psychology, 78(1), 55.Google Scholar

Marra, D., Warot, D., Payan, C., et al. (1998). Anhedonia and relapse in alcoholism. Psychiatry Research, 80(2), 187–196.Google Scholar

Martinotti, G., Cloninger, C. R. & Janiri, L. (2008a). Temperament and character inventory dimensions and anhedonia in detoxified substance-dependent subjects. American Journal of Drug and Alcohol Abuse, 34(2), 177–183. doi:10.1080/00952990701877078Google Scholar

Martinotti, G., Di Nicola, M., Reina, D., et al. (2008b). Alcohol protracted withdrawal syndrome: the role of anhedonia. Substance Use & Misuse, 43(3–4), 271–284.Google Scholar

Martinotti, G., Andreoli, S., Reina, D., et al. (2011). Acetyl-l-carnitine in the treatment of anhedonia, melancholic and negative symptoms in alcohol dependent subjects. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 35(4), 953–958.Google Scholar

Mathew, A. R., Cook, J. W., Japuntich, S. J. & Leventhal, A. M. (2015). Post‐traumatic stress disorder symptoms, underlying affective vulnerabilities, and smoking for affect regulation. The American Journal on Addictions, 24(1), 39–46.Google Scholar

McClure, E. A., Vandrey, R. G., Johnson, M. W. & Stitzer, M. L. (2012). Effects of varenicline on abstinence and smoking reward following a programmed lapse. Nicotine & Tobacco Research, 15(1), 139–148.Google Scholar

McGregor, C., Srisurapanont, M., Jittiwutikarn, J., et al. (2005). The nature, time course and severity of methamphetamine withdrawal. Addiction, 100(9), 1320–1329.Google Scholar

Meehl, P. E. (1975). Hedonic capacity: some conjectures. Bulletin of the Menninger Clinic, 39(4), 295–307.Google Scholar

Meshesha, L. Z., Pickover, A. M., Teeters, J. B. & Murphy, J. G. (2017). A longitudinal behavioral economic analysis of non-medical prescription opioid use among college students. The Psychological Record, 67(2), 241–251.Google Scholar

Miotto, P., Preti, A. & Frezza, M. (2001). Heroin and schizophrenia: subjective responses to abused drugs in dually diagnosed patients. Journal of Clinical Psychopharmacology, 21(1), 111–113.Google Scholar

Morie, K. P., De Sanctis, P., Garavan, H. & Foxe, J. J. (2014). Executive dysfunction and reward dysregulation: a high-density electrical mapping study in cocaine abusers. Neuropharmacology, 85, 397–407.Google Scholar

Newton, T. F., Kalechstein, A. D., Duran, S., Vansluis, N. & Ling, W. (2004). Methamphetamine abstinence syndrome: preliminary findings. The American Journal on Addictions, 13(3), 248–255.Google Scholar

Noordsy, D. L., Drake, R. E., Teague, G. B., et al. (1991). Subjective experiences related to alcohol use among schizophrenics. Journal of Nervous and Mental Disease, 179(7), 410–414.Google Scholar

Nunn, J. A., Rizza, F. & Peters, E. R. (2001). The incidence of schizotypy among cannabis and alcohol users. The Journal of Nervous and Mental Disease, 189(11), 741–748.Google Scholar

Pang, R. D., Khoddam, R., Guillot, C. R. & Leventhal, A. M. (2014). Depression and anxiety symptoms moderate the relation between negative reinforcement smoking outcome expectancies and nicotine dependence. Journal of Studies on Alcohol and Drugs, 75(5), 775–780.Google Scholar

Parrish, K. H., Atherton, O. E., Quintana, A., Conger, R. D. & Robins, R. W. (2016). Reciprocal relations between internalizing symptoms and frequency of alcohol use: findings from a longitudinal study of Mexican-origin youth. Psychology of Addictive Behaviors, 30(2), 203.Google Scholar

Peechatka, A. L., Whitton, A. E., Farmer, S. L., Pizzagalli, D. A. & Janes, A. C. (2015). Cigarette craving is associated with blunted reward processing in nicotine-dependent smokers. Drug and Alcohol Dependence, 155, 202–207.Google Scholar

Peters, E. N., Bae, D., Barrington-Trimis, J. L., Jarvis, B. P. & Leventhal, A. M. (2018). Prevalence and sociodemographic correlates of adolescent use and polyuse of combustible, vaporized, and edible cannabis products. JAMA Network Open, 1(5), e182765.Google Scholar

Pettorruso, M., Martinotti, G., Fasano, A., et al. (2014). Anhedonia in Parkinson's disease patients with and without pathological gambling: a case-control study. Psychiatry Research, 215(2), 448–452.Google Scholar

Piper, M. E., Vasilenko, S. A., Cook, J. W. & Lanza, S. T. (2017). What a difference a day makes: differences in initial abstinence response during a smoking cessation attempt. Addiction, 112(2), 330–339.Google Scholar

Powers, J. M., Carroll, A. J., Veluz-Wilkins, A. K., et al. (2016). Is the effect of anhedonia on smoking cessation greater for women versus men? Nicotine & Tobacco Research, 19(1), 119–123.Google Scholar

Pozzi, G., Martinotti, G., Reina, D., et al. (2008). The assessment of post-detoxification anhedonia: influence of clinical and psychosocial variables. Substance Use & Misuse, 43(5), 722–732.Google Scholar

Rømer Thomsen, K. (2015). Measuring anhedonia: impaired ability to pursue, experience, and learn about reward. Frontiers in Psychology, 6, 1409.Google Scholar

Roys, M., Weed, K., Carrigan, M. & MacKillop, J. (2016). Associations between nicotine dependence, anhedonia, urgency and smoking motives. Addictive Behaviors, 62, 145–151.Google Scholar

Schlaepfer, T. E., Cohen, M. X., Frick, C., et al. K (2008). Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. Neuropsychopharmacology, 33(2), 368.Google Scholar

Schmitz, J. M., Mooney, M. E., Moeller, F. G., et al. (2008). Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platform. Drug and Alcohol Dependence, 94(1–3), 142–150.Google Scholar

Seligman, M. E., Rashid, T. & Parks, A. C. (2006). Positive psychotherapy. American Psychologist, 61(8), 774.Google Scholar

Seney, M. L. & Sibille, E. (2014). Sex differences in mood disorders: perspectives from humans and rodent models. Biology of Sex Differences, 5(1), 17.Google Scholar

Seth, P., Rudd, R. A., Noonan, R. K. & Haegerich, T. M. (2018). Quantifying the epidemic of prescription opioid overdose deaths. American Journal of Public Health, 108(4), 500–502.Google Scholar

Snaith, P. (1993). Anhedonia: a neglected symptom of psychopathology. Psychological Medicine, 23(4), 957–966.Google Scholar

Snaith, R. P., Hamilton, M., Morley, S., et al. (1995). A scale for the assessment of hedonic tone the Snaith–Hamilton Pleasure Scale. The British Journal of Psychiatry, 167(1), 99–103.Google Scholar

Stevens, A., Peschk, I. & Schwarz, J. (2007). Implicit learning, executive function and hedonic activity in chronic polydrug abusers, currently abstinent polydrug abusers and controls. Addiction, 102(6), 937–946.Google Scholar

Stone, M. D., Audrain-McGovern, J. & Leventhal, A. M. (2017). Association of anhedonia with adolescent smoking susceptibility and initiation. Nicotine & Tobacco Research, 19(6), 738–742.Google Scholar

Sussman, N. & DeJong, S. M. (2018). Ethical considerations for mental health clinicians working with adolescents in the digital age. Current Psychiatry Reports, 20(12), 113.Google Scholar

Thomas, E. A. & Garland, E. L. (2017). Mindfulness is associated with increased hedonic capacity among chronic pain patients receiving extended opioid pharmacotherapy. The Clinical Journal of Pain, 33(2), 166.Google Scholar

Tomarken, A. J., Dichter, G. S., Freid, C., Addington, S. & Shelton, R. C. (2004). Assessing the effects of bupropion SR on mood dimensions of depression. Journal of Affective Disorders, 78(3), 235–241.Google Scholar

Treadway, M. T. & Zald, D. H. (2011). Reconsidering anhedonia in depression: lessons from translational neuroscience. Neuroscience & Biobehavioral Reviews, 35(3), 537–555.Google Scholar

Tremblay, L. K., Naranjo, C. A., Cardenas, L., Herrmann, N. & Busto, U. E. (2002). Probing brain reward system function in major depressive disorder: altered response to dextroamphetamine. Archives of General Psychiatry, 59(5), 409–416.Google Scholar

Tremblay, L. K., Naranjo, C. A., Graham, S. J., et al. (2005). Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe. Archives of General Psychiatry, 62(11), 1228–1236.Google Scholar

van Roekel, E., Bennik, E. C., Bastiaansen, J. A., et al. (2016). Depressive symptoms and the experience of pleasure in daily life: an exploration of associations in early and late adolescence. Journal of Abnormal Child Psychology, 44(5), 999–1009.Google Scholar

Vivolo-Kantor, A. M., Seth, P., Gladden, R. M., et al. (2018). Vital signs: trends in emergency department visits for suspected opioid overdoses – United States, July 2016–September 2017. Morbidity and Mortality Weekly Report, 67(9), 279.Google Scholar

Voce, A., McKetin, R., Burns, R., Castle, D. & Calabria, B. (2018). The relationship between illicit amphetamine use and psychiatric symptom profiles in schizophrenia and affective psychoses. Psychiatry Research, 265, 19–24.Google Scholar

Wardle, M. C., Vincent, J. N., Suchting, R., et al. (2017). Anhedonia is associated with poorer outcomes in contingency management for cocaine use disorder. Journal of Substance Abuse Treatment, 72, 32–39.Google Scholar

Wise, R. A. (2008). Dopamine and reward: the anhedonia hypothesis 30 years on. Neurotoxicity Research, 14(2–3), 169–183.Google Scholar

Witkiewitz, K., Bowen, S., Harrop, E. N., et al. (2014). Mindfulness-based treatment to prevent addictive behavior relapse: theoretical models and hypothesized mechanisms of change. Substance Use & Misuse, 49(5), 513–524.Google Scholar

References

American Psychiatric Association [APA] (2013). Diagnostic and Statistical Manual of Mental Disorders (5th edition). Arlington, VA: American Psychiatric Association.Google Scholar

Avena, N. M. (2011). Food and addiction: implications and relevance to eating disorders and obesity. Current Drug Abuse Reviews, 4(3), 131–132.Google Scholar

Avena, N. M. & Bocarsly, M. E. (2012). Dysregulation of brain reward systems in eating disorders: Neurochemical information from animal models of binge eating, bulimia nervosa, and anorexia nervosa. Neuropharmacology, 63(1), 87–96.Google Scholar

Avena, N. M. & Gold, M. S. (2011). Food and addiction – sugars, fats and hedonic overeating. Addiction, 106(7), 1214–1215. doi:10.1111/j.1360-0443.2011.03373.xGoogle Scholar

Avena, N. M., Gold, J. A., Kroll, C. & Gold, M. S. (2012). Further developments in the neurobiology of food and addiction: update on the state of the science. Nutrition, 28(4), 341–343. doi:10.1016/j.nut.2011.11.002Google Scholar

Bass, C., Van Nevel, J. & Swart, J. (2014). A comparison between dialectical behavior therapy, mode deactivation therapy, cognitive behavioral therapy, and acceptance and commitment therapy in the treatment of adolescents. The International Journal of Behavioral Consultation and Therapy, 9(2), 4.Google Scholar

Bellg, A. J., Borrelli, B., Resnick, B., et al. (2004). Enhancing treatment fidelity in health behavior change studies: best practices and recommendations from the NIH Behavior Change Consortium. Health Psychology, 23(5), 443–451. doi:10.1037/0278-6133.23.5.443Google Scholar

Black, D. S. (2012). Mindfulness and substance use intervention. Substance Use & Misuse, 47(3), 199–201. doi:10.3109/10826084.2011.635461Google Scholar

Black, D. S. (2014). Mindfulness-based interventions: an antidote to suffering in the context of substance use, misuse, and addiction. Substance Use & Misuse, 49(5), 487–491. doi:10.3109/10826084.2014.860749Google Scholar

Blaszczynski, A., Maccallum, F. & Joukhador, J. (2001). A comparative evaluation of imaginal desensitisation and group cognitive therapy in the treatment of pathological gambling. In Coman, G. (Ed.), Lessons of the Past: Proceedings of the 10th Conference of the National Association for Gambling Studies. Victoria, Australia: National Association for Gambling Studies, pp. 40–49.Google Scholar

Borrelli, B. (2011). The assessment, monitoring, and enhancement of treatment fidelity in public health clinical trials. Journal of Public Health Dentistry, 71, S52–S63.Google Scholar

Bowen, S., Chawla, N., Collins, S. E., et al. (2009). Mindfulness-based relapse prevention for substance use disorders: a pilot efficacy trial. Substance Abuse, 30(4), 295–305. doi:10.1080/08897070903250084Google Scholar

Breitenstein, S. M., Gross, D., Garvey, C. A., et al. (2010). Implementation fidelity in community-based interventions. Research in Nursing & Health, 33(2), 164–173. doi:10.1002/nur.20373Google Scholar

Brewer, J. A. (2017). The Craving Mind : From Cigarettes to Smartphones to Love – Why We Get Hooked and How We Can Break Bad Habits. New Haven: Yale University Press.Google Scholar

Brewer, J. A., Elwafi, H. M. & Davis, J. H. (2013). Craving to quit: psychological models and neurobiological mechanisms of mindfulness training as treatment for addictions. Psychology of Addictive Behaviors, 27(2), 366–379. doi:10.1037/a0028490Google Scholar

Carroll, C., Patterson, M., Wood, S., et al. (2007). A conceptual framework for implementation fidelity. Implementation Science, 2, 40. doi:10.1186/1748-5908-2-40Google Scholar

Christensen, D. R., Dowling, N. A., Jackson, A. C., et al. (2013). A proof of concept for using brief dialectical behavior therapy as a treatment for problem gambling. Behaviour Change, 30, 117–137.Google Scholar

Criscitelli, K. & Avena, N. M. (2016). The neurobiological and behavioral overlaps of nicotine and food addiction. Preventive Medicine, 92, 82–89. doi:10.1016/j.ypmed.2016.08.009Google Scholar

de Lisle, S. M., Dowling, N. A. & Allen, J. S. (2011). Mindfulness-based cognitive therapy for problem gambling. Clinical Case Studies, 10, 210–228.Google Scholar

Garland, E. L. & Howard, M. O. (2018). Mindfulness-based treatment of addiction: current state of the field and envisioning the next wave of research. Addiction Science & Clinical Practice, 13(1), 14. doi:10.1186/s13722-018-0115-3Google Scholar

Garland, E. L., Froeliger, B. & Howard, M. O. (2014a). Mindfulness training targets neurocognitive mechanisms of addiction at the attention-appraisal-emotion interface. Front Psychiatry, 4, 173. doi:10.3389/fpsyt.2013.00173Google Scholar

Garland, E., Gaylord, S. & Park, J. (2009). The role of mindfulness in positive reappraisal. Explore (NY), 5(1), 37–44. doi:10.1016/j.explore.2008.10.001Google Scholar

Garland, E. L., Manusov, E. G., Froeliger, B., et al. (2014b). Mindfulness-oriented recovery enhancement for chronic pain and prescription opioid misuse: results from an early-stage randomized controlled trial. Journal of Consulting and Clinical Psychology, 82(3), 448–459. doi:10.1037/a0035798Google Scholar

Godfrey, K., Gallo, M. & Afari, L. . (2015). Mindfulness-based interventions for binge eating: A systematic review and meta-analysis. Journal of Behavioral Medicine, 38(2), 348–362.Google Scholar

Gould, L. F., Dariotis, J. K., Greenberg, M. T. & Mendelson, T. (2016). Assessing fidelity of implementation (FOI) for school-based mindfulness and yoga interventions: A systematic review. Mindfulness (NY), 7(1), 5–33. doi:10.1007/s12671-015-0395-6Google Scholar

Grant, S., Colaiaco, B., Motala, A., et al. (2017). Mindfulness-based relapse prevention for substance use disorders: A systematic review and meta-analysis. Journal of Addiction Medicine, 11(5), 386–396.Google Scholar

Greeson, J., Garland, E. L. & Black, D. S. (2014). Mindfulness: A transtherapeutic approach for transdiagnostic mental processes. In Amanda Ie, C. T. N. & Langer, E. J. (Eds.), The Wiley Blackwell Handbook of Mindfulness (1st edition). John Wiley & Sons, Ltd.Google Scholar

Kabat-Zinn, J. (1982). An outpatient program in behavioral medicine for chronic pain patients based on the practice of mindfulness meditation: Theoretical considerations and preliminary results. General Hospital Psychiatry, 4(1), 33–47. https://doi.org/10.1016/0163-8343(82)90026-3 Google Scholar

Kabat-Zinn, J. (2003). Mindfulness-based interventions in context: Past, present, and future. Clinical Psychology: Science and Practice, 10, 144–156.Google Scholar

Kabat-Zinn, J. (2013). Full Catastrophe Living : Using the Wisdom of Your Body and Mind to Face Stress, Pain, and Illness – Revised and Updated Edition. New York: Bantam Books.Google Scholar

Katterman, S. N., Kleinman, B. M., Hood, M. M., Nackers, L. M. & Corsica, J. A. (2014). Mindfulness meditation as an intervention for binge eating, emotional eating, and weight loss: A systematic review. Eating Behaviors, 15(2), 197–204.Google Scholar

Kechter, A., Amaro, H. & Black, D. S. (2019). Reporting of treatment fidelity in mindfulness-based intervention trials: A review and new tool using NIH behavior change consortium guidelines. Mindfulness, 10(2), 215–233.Google Scholar

Kelly, T., Yang, W., Chen, C. S., Reynolds, K. & He, J. (2008). Global burden of obesity in 2005 and projections to 2030. International Journal of Obesity, 32(9), 1431–1437. doi:10.1038/ijo.2008.102Google Scholar

Kiecolt-Glaser, J. K. (2010). Stress, food, and inflammation: Psychoneuroimmunology and nutrition at the cutting edge. Psychosomatic Medicine, 72(4), 365–369. doi:10.1097/PSY.0b013e3181dbf489Google Scholar

Kristeller, J. L. & Wolever, R. Q. (2011). Mindfulness-based eating awareness training for treating binge eating disorder: The conceptual foundation. Eating Disorders, 19(1), 49–61. doi:10.1080/10640266.2011.533605Google Scholar

Kristeller, J., Wolever, R. Q. & Sheets, V. (2014). Mindfulness-based eating awareness training (MB-EAT) for binge eating: A randomized clinical trial. Mindfulness. http://dx.doi.org/10.1007/s12671-012-0179-1 Google Scholar

Lazarus, R. S. & Folkman, S. . (1984). Stress, Appraisal, and Coping. New York: Springer.Google Scholar

Leventhal, A. M. & Zvolensky, M. J. (2015). Anxiety, depression, and cigarette smoking: A transdiagnostic vulnerability framework to understanding emotion-smoking comorbidity. Psychological Bulletin, 141(1), 176–212. doi:10.1037/bul0000003Google Scholar

Li, W., Garland, E. L. & Howard, M. O. (2018). Therapeutic mechanisms of Mindfulness-Oriented Recovery Enhancement for internet gaming disorder: Reducing craving and addictive behavior by targeting cognitive processes. Journal of Addictive Diseases, 37, 5–13. doi:10.1080/10550887.2018.1442617Google Scholar

Li, W., Howard, M. O., Garland, E. L., McGovern, P. & Lazar, M. (2017). Mindfulness treatment for substance misuse: A systematic review and meta-analysis. Journal of Substance Abuse Treatment, 75, 62–96.Google Scholar

Lindsay, E. K. & Creswell, J. D. (2017). Mechanisms of mindfulness training: Monitor and Acceptance Theory (MAT). Clinical Psychology Review, 51, 48–59. doi:10.1016/j.cpr.2016.10.011Google Scholar

Maynard, B. R., Wilson, A. N., Labuzienski, E. & Whiting, S. W. (2018). Mindfulness-based approaches in the treatment of disordered gambling: A systematic review and meta-analysis. Research on Social Work Practice, 28(3), 348–362.Google Scholar

Murray, S., Kroll, C. & Avena, N. M. (2015). Food and addiction among the ageing population. Ageing Research Reviews, 20, 79–85. doi:10.1016/j.arr.2014.10.002Google Scholar

Murray, S., Tulloch, A., Gold, M. S. & Avena, N. M. (2014). Hormonal and neural mechanisms of food reward, eating behaviour and obesity. Nature Reviews Endocrinology, 10(9), 540–552. doi:10.1038/nrendo.2014.91Google Scholar

O'Reilly, G., Cook, L., Spruijt‐Metz, D. & Black, D. (2014). Mindfulness‐based interventions for obesity‐related eating behaviours: A literature review. Obesity Reviews, 15(6), 453–461.Google Scholar

Resnick, B., Bellg, A. J., Borrelli, B., et al. (2005). Examples of implementation and evaluation of treatment fidelity in the BCC studies: Where we are and where we need to go. Annals of Behavioral Medicine, 29 (Supplement), 46–54. doi:10.1207/s15324796abm2902s_8Google Scholar

SAMHSA (2017). Behavioral Health Treatments and Services. Retrieved from https://www.samhsa.gov/treatment Google Scholar

Segal, Z. V., Williams, M. & Teasdale, J. (2018). Mindfulness-Based Cognitive Therapy for Depression. Guilford Publications.Google Scholar

Sinha, R. (2008). Chronic stress, drug use, and vulnerability to addiction. Annals of the New York Academy of Sciences, 1141, 105–130.Google Scholar

Sussman, S. (2017). Substance and Behavioral Addictions: Concepts, Causes, and Cures. Cambridge, Great Britain: Cambridge University Press.Google Scholar

Sussman, S. & Black, D. S. (2008). Substitute addiction: A concern for researchers and practitioners. Journal of Drug Education, 38(2), 167–180. doi:10.2190/DE.38.2.eGoogle Scholar

Sussman, S., Reynaud, M., Aubin, H. J. & Leventhal, A. M. (2011). Drug addiction, love, and the higher power. Evaluation & the Health Professions, 34(3), 362–370. doi:10.1177/0163278711401002Google Scholar

Van Gordon, W., Shonin, E., Dunn, T. J., et al. (2017). Meditation awareness training for the treatment of workaholism: A controlled trial. Journal of Behavioral Addictions, 6(2), 212–220. doi:10.1556/2006.6.2017.021Google Scholar

Van Gordon, W., Shonin, E. & Griffiths, M. D. (2016). Meditation awareness training for the treatment of sex addiction: A case study. Journal of Behavioral Addictions, 5(2), 363–372. doi:10.1556/2006.5.2016.034Google Scholar

Volkow, N. D., Wang, G. & Baler, R. D. (2011). Reward, dopamine, and the control of food intake: Implications for obesity. Trends in Cognitive Sciences, 15(1), 37–46.Google Scholar

Warlow, S. M., et al. (2020). Sensitization of incentive salience and the transition to addiction. In Sussman, S. (Ed.) The Cambridge Handbook of Substance and Behavioral Addictions. Cambridge, UK: Cambridge University Press, pp. 23–37.Google Scholar

Witkiewitz, K. Bowen, S., Harrop, E. N., et al. (2014). Mindfulness-based treatment to prevent addictive behavior relapse: Theoretical models and hypothesized mechanisms of change. Substance Use & Misuse, 49(5), 513–524.Google Scholar

Witkiewitz, K. & Marlatt, G. A. (2005). Emphasis on interpersonal factors in a dynamic model of relapse. American Psychologist, 60(4), 341–342. doi:10.1037/0003-066X.60.4.341Google Scholar

Yau, Y. H. C., Gottlieb, C. D., Krasna, L. C. & Potenza, M. N. (2014). Food addiction – Chapter 7: Evidence, evaluation, and treatment. In Behavioral Addictions, pp. 143–184.Google Scholar

References

American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders (5th edition). Arlington: American Psychiatric Association.Google Scholar

American Psychiatric Association (2018). Position Statement on Inquiries about Diagnosis and Treatment of Mental Disorders in Connection with Professional Credentialing and Licensing.Google Scholar

Americans with Disabilities Act, 42 U.S.C. sections 12101, et seq., 12102(1)(A), 12114, 12210, 12211, 12214.Google Scholar

Azim, A. (2018). Note: Common sense; Rethinking the new Common Rule’s weak protections for human subjects. Vanderbilt Law Review, 71, 1704–1736.Google Scholar

Belmont Report (1979). National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. www.hhs.gov/ohrp/sites/default/files/the-belmont-report-508c_Final.pdf.Google Scholar

Bollas, C. & Sundelson, D. (1995) The New Informants: The Betrayal of Confidentiality in Psychoanalysis and Psychotherapy. Northvale, N.J.: Jason Aronson, Inc.Google Scholar

Bower v. Bower, 758 So.2d 405 (Miss. 2000).Google Scholar

California Business and Professions Code sections 740-742, 2241.5.Google Scholar

California Civil Code sections 43.92, 51, 51.5, 56.10(c)(19), 56.104, 56.35.Google Scholar

California Confidentiality of Medical Information Act, Civil Code sections 56.10(c)(19), 56.104, 56.35.Google Scholar

California Constitution, Article I, sections 1 and 13.Google Scholar

California Evidence Code sections 990-1007. Physician-patient privilege.Google Scholar

California Evidence Code sections 995, 1015.Google Scholar

California Evidence Code sections 1010-1027. Psychotherapist-patient privilege.Google Scholar

California Health and Safety Code sections 11165.4, 11480-11481, 11812, 11845.5, 24170-24179.5, 111515-111545, 123100-123149.5.Google Scholar

California Insurance Code sections 791.01-791.22. California Insurance Information And Privacy Protection Act.Google Scholar

California Penal Code sections 1203.067(b)(3), 3500, 3521-3523.Google Scholar

California Welfare and Institutions Code section 5328-5330. Lanterman, Petris, Short Act confidentiality provisions.Google Scholar

Centers for Disease Control and Prevention (2016), Guideline for Prescribing Opioids for Chronic Pain. www.cdc.gov/drugoverdose/pdf/Guidelines_Factsheet-a.pdf.Google Scholar

Cox v. Miller, 296 F.3d 89 (2d Cir. 2002).Google Scholar

Hason v. Medical Board of California, 279 F.3d 1167 (9th Cir. 2002).Google Scholar

Hedegaard, H., Minino, A. & Warner, M. (2018). Drug Overdose Deaths in the United States, 1999–2017. National Center for Health Statistics Data Brief No. 329, Nov. 2018. www.cdc.gov/nchs/products/databriefs/db329.htm.Google Scholar

In Re: Menna, 11 Cal.4th 975 (1995).Google Scholar

Jaffee v. Redmond, 116 S.Ct. 1923 (1996).Google Scholar

Lewis v. Superior Court, 3 Cal.5th 561 (2017).Google Scholar

Medical Board of California (2010). Guidelines for Prescribing Controlled Substances for Pain.Google Scholar

Medical Board of California (2018). Authorization for Release of Alcohol and Drug Abuse Information.Google Scholar

National Alliance for Model State Drug Laws (2014) Prescription Drug Abuse, Addiction and Diversion, Part 1. www.namsdl.org/library/884CB2C5-1372-636C-DD54DCC00FD31313/.Google Scholar

People v. Ignacio Garcia, 2 Cal.5th 792 (2017).Google Scholar

People v. Gonzales, 56 Cal.4th 353, 371-372 (2013).Google Scholar

Petersen, A., Peters, S. C., Richard, M. H. & Whites, A. (2018). State legislative responses to the opioid crisis: Leading examples. Journal of Health & Life Sciences Law, Feb. 2018, 11, 30.Google Scholar

Powell v. Texas, 392 U.S. 514 (1968).Google Scholar

Robinson v. California, 370 U.S. 660 (1962).Google Scholar

Roe v. Wade, 410 U.S. 113, 93 S.Ct. 705 (1973).Google Scholar

SAMHSA (2017). Substance Abuse Confidentiality Regulations, Frequently Asked Questions (FAQs regarding the Substance Abuse Confidentiality Regulations). September 15, 2017. www.samhsa.gov/about-us/who-we-are/laws-regulations/confidentiality-regulations.htm.Google Scholar

Secretary’s Advisory Committee on Human Research Protection (SACHRP) (2017). Attachment B to December 12, 2017, SACHRP Letter to the HHS Secretary Recommendations on the Interpretation and Application of Exemption §_.104(d)(4), the “HIPAA Exemption”. www.hhs.gov/ohrp/sachrp-committee/recommendations/attachment-b-december-12-2017/index.html.Google Scholar

Seth, P., Scholl, L., Rudd, R. & Bacon, S. (2018). Overdose deaths involving opioids, cocaine, and psychostimulants in United States, 2015–2016. Centers for Disease Control and Prevention, Morbidity, Mortality Weekly Report, March 30, 2018, 67(12), 349–358. www.cdc.gov/mmur/volume/67/wr/mm6712al.htm.Google Scholar

Slater, M. (2018) Note: Is Powell still valid? The Supreme Court’s changing stance on cruel and unusual punishment. Virginia Law Review, 104, 547–588.Google Scholar

SUPPORT ACT (Public Law No. 115-271).Google Scholar

Surgeon General of the United States (1999). Mental Health – A Report of the Surgeon General, Chapter 7, pp. 440–441. https://profiles.nlm.nih.gov/ps/access/NNBBHS.pdf.Google Scholar

Tarasoff v. Regents of the University of California, 17 Cal.3d 425 (1976).Google Scholar

Unger, D. (2014). Student note: Minding your meds: Balancing the needs for patient privacy and law enforcement in prescription drug monitoring programs. West Virginia Law Review, 117, 345–388.Google Scholar

United States Constitution, Fourth Amendment, Eighth Amendment.Google Scholar

United States Sentencing Guidelines (2004) Section 5K2.13.Google Scholar

U.S. v. Brooks, 628 F.3d 79 (6th Cir. 2011).Google Scholar

U.S. v. Caro, 309 F.3d 1348 (11th Cir. 2002).Google Scholar

U.S. v. Carucci, 33 F.Supp.2d 302 (S.D.N.Y. 1999).Google Scholar

U.S. v. Davis, 182 Fed.Appx. 741 (9th Cir. 2006).Google Scholar

U.S. v. Lighthall, 389 F.3d 791 (8th Cir. 2004).Google Scholar

U.S. v. Liu, 267 F.Supp.2d 371 (E.D.N.Y. 2003).Google Scholar

U.S. v. Miller, 178 Fed.Appx. 70 (2d Cir. 2006).Google Scholar

U.S. v. Long, 185 F.Supp.2d 30 (D.D.C. 2001).Google Scholar

U.S. v. Romualdi, 101 F.3d 971 (3d Cir. 1996).Google Scholar

U.S. v. Sadolsky, 234 F.3d 938 (6th Cir. 2000).Google Scholar

Venezia v. U.S., 884 F.Supp. 919 (D.N.J. 1995) affd. without opin., 77 F.3d 465 (3d Cir. 1995).Google Scholar

Webb v. Smart Document Solutions, LLC, 499 F.3d 1078, 1081 (9th Cir. 2007).Google Scholar

Whalen v. Roe, 429 U.S. 589, 97 S.Ct. 869 (1977).Google Scholar

21 C.F.R. Parts 50 and 56.Google Scholar

21 U.S.C. sections 822-824.Google Scholar

42 C.F.R. Part 2.Google Scholar

42 U.S.C. section 280g-3.Google Scholar

42 U.S.C. section 290dd-2.Google Scholar

42 U.S.C. section 300gg-22.Google Scholar

42 U.S.C. sections 1320d, et seq.Google Scholar

42 U.S.C section 12132.Google Scholar

45 C.F.R. Part 46.Google Scholar

45 C.F.R. Parts 160 and 164.Google Scholar

45 C.F.R. sections 164.508 and 164.512.Google Scholar

82 Federal Register 6053, Confidentiality of Substance Use Disorder Patient Records (2017).Google Scholar

Book contents

Part V - Ongoing and Future Research Directions

Summary

Access options

References

References

References

References

References

References

References

References

References

References

References

References

Save book to Kindle

Save book to Dropbox

Save book to Google Drive